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Abstract 
There are conflicting reports from Europe and North America regarding trends in the incidence 
of primary brain tumour, whereas the incidence of primary brain tumours in Australia is 
currently unknown. 
We aimed to determine primary brain tumour incidence in Australia with age-, sex-, and benign-
versus-malignant histology-specific analyses. A multicenter study was performed in the state of 
New South Wales (NSW) and the Australian Capital Territory (ACT), representing a combined 
population of >7 million with >97% rate of population retention for medical care. 
We retrospectively sourced pathology databases servicing neurosurgical centres in NSW and 
ACT for histologically confirmed primary brain tumours diagnosed from January 2000 through 
December 2008. Data were weighted for patient outflow and data completeness. Incidence rates 
were age standardised and trends analysed using joinpoint analysis. 
A weighted total of 7651 primary brain tumours were analysed. The overall US-standardised 
incidence of primary brain tumours was 11.3 cases 100 000 person-years (+0.13; 95% 
confidence interval, 9.8-12.3) during the study period with no significant linear increase. A 
significant increase in primary malignant brain tumours from 2000 to 2008 was observed; this 
appears to be largely due to an increase in malignant tumour incidence in the >65-year age 
group. 
A significant increasing incidence in glioblastoma multiforme (GBM) was observed in the study 
period (annual percentage change, 2.5; 95% confidence interval, 0.4-4.6, n=2275), particularly 
after 2006. In GBM patients in the >65-year group, significantly increasing incidence for men 
and women combined (APC, 3.0; 95% CI, 0.5-5.6) and men only (APC, 2.9; 95% CI, 0.1-5.8) 
were seen. Rising trends in incidence were also seen in meningioma for total male population 
(APC, 5.3; 95% CI, 2.6-8.1, n=515) and males aged 20-64 years (APC, 6.3; 95% CI, 3.8-8.8). 
Significantly decreasing incidence trends were observed for Schwannoma for the total study 
population (APC, -3.5; 95% CI, -7.2 - -0.2, n=492), significant in women (APC, -5.3; 95% CI, -
9.9 - -0.5) but not men. 
This collection represents the best estimate of primary brain tumour incidence in Australia. 
Whether the observed increase in malignant primary brain tumours, particularly in persons aged 
>65 years, is due to improved detection, diagnosis, and care delivery or a true change in 
incidence remains undetermined. 
An important trend observed from this study, using benign tumour data collection, was an 
increasing trend in meningioma and a decreasing trend in Schwannoma in the years 2000 to 
2008. This is data for which we have no direct comparison in Australia. 
Our registries may observe an increase in malignant tumours in the next few years that they are 
not detecting now due to late ascertainment. We recommend a direct, uniform and centralized 
approach to monitoring primary brain tumour incidence, including the introduction of non-
malignant tumour data collection. 
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In his thesis "Temporal Trends in Incidence of Primary Brain Tumours in the Australian Capital Territory and New South Wales 2000 to 2008", Dr. Dobes clearly demonstrates a compilation of his extensive background study and independent research relative to the epidemiology of brain tumors in the ACT and NSW with comparative data from other nations. The study ams and hypothesis are clearly identified and a study design established for identification of index cases of primary brain tumor. The thesis confirms in detail his diligent attempts to "capture" these cases through retrospective mining of a medical database Of the ACT and NSW population. Thn rawnplwrity anH mngmtuH.. nf tfiig nnHwtalrii^ g is clearly articulated 
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From this review I have complete confidence that Dr. Dobes has accomplished the independent research, made a substantial contribution to learning, and demonstrated the relevance of his research towards better definition of the epidemiology of primary brain tumors in Australia. I am unreserved in my opinion that this work fulfills the thesis requirements for the degree of Master of Philosophy. 
This is a detailed study of the incidence of primary brain tumours in Australian 
Capital Territory and New South Wales. The author summarized the world-wide literature on 
the incidence of primary brain tumours. This has also highlighted the lack of recent accurate 
data in Australia. 
The method of data collection is exhaustive and well described. 
The results of the current study are well described. It is particularly interesting to note 
the significant increase in incidence of GBM and a rising trend in the incidence in 
meningioma. 
Many factors could have influence the results of the current study. The author 
discussed in length the various confounding factors. The author presented sound arguments in 
supporting their assertion of an increasing incidence in GBM. 
The author's conclusion of a direct, uniform and centralized approach in monitoring 
primary brain tumour incidence in Australia is a logical conclusion from his current study. 
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Preface 
Primary brain tumours are an important cause of untimely death in our community, with few 
risk factors identified to date. Although Australian reports have shown little change in the 
overall number of new malignant brain tumours per year, overseas studies are showing increases 
in specific types of brain tumours. We believe this trend may occur here in the next 5-10 years. 
Of particular concern to the community is the reported increase in malignant brain tumours that 
can be fatal in a matter of months, despite best possible treatment. Unique to the brain, unlike 
other areas of the human body, are slow-growing benign tumours that have potential deleterious 
effects due to growth in an unyielding enclosed space, i.e., the skull. 
Studies, particularly from US and European countries, have focussed on subtype analysis of 
both benign and malignant brain tumours, and indeed, the US passed a law in 2004 for 
mandatory reporting of all benign brain tumours. 
The current study was commenced in 2008 to address a potential deficit in reliable brain tumour 
subtype incidence trends in Australian literature. The primary source at that point (and still to 
this day) of brain tumour data is from state-based cancer registries. Few independent studies 
have been performed and the Australian literature is scanty at best. 
Registry data have reported a stable malignant brain tumour incidence trend, with projections to 
2011 remaining at a constant rate. No data on subtypes or benign tumours are available. In 
reviewing the existing literature, Australia appears to have a real deficit in brain tumour 
reporting, and it was the aim of this study to set a reliable baseline incidence rate based on brain 
tumour subtypes with a view for future expansion to a national framework. By following these 
trends, we may then be able to identify potential risk factors for developing this disease. 
Ethical approval was obtained from the ACT Health Human Research Ethics Committee, the 
NSW Population & Health Services Research Ethics Committee (with lead HREC approval by 
the NSW Cancer Institute), and the Sydney Adventist Hospital Human Research Ethics 
Committee to examine the number of new cases per year at the source of definitive diagnosis -
i.e. at microscopic analysis in the ACT and NSW regions. 
Chapter 1. Introduction 
The current study is an ecological multicentre retrospective analysis of histopathological data 
obtained directly from the source of diagnosis. No associations with risk factors for the 
development of brain tumours were analysed but the study may be viewed as a pilot for future 
expansion to a national framework. It has sought to identify the feasibility of such an expansion 
and addresses a number of perceived deficits in current brain tumour data collection in 
Australia. 
This section describes the current state of literature on the incidence of primary brain tumours 
both in Australia and overseas, most notably from European and US literature. 
It also discusses factors that have influenced the incidence rate over time, particularly the 
introduction of modern imaging techniques and increased clinical awareness of brain tumours. 
Further discussion regarding coding and classification changes are explored in more depth later 
in the thesis. A brief overview of brain tumours and their subtypes is confined to the appendix. 
1.1 Incidence and Descriptive Epidemiology of Primary Brain Tumours 
1.1.1 O v e r v i e w 
The incidence of brain tumours is reported to be rising worldwide1 and yet our database 
searches have so far yielded only limited data published from Australian sources. The most 
extensive reports about brain tumour incidence to date have come from American4'712 and 
European2-13'14 sources. 
The recently published 2010 Statistical Report of the Central Brain Tumour Registry of the 
United States (CBTRUS) provides a primary central nervous system (CNS) tumour age-
adjusted incidence of 18.71 cases per 100,000 population in 2006.10 According to its 2002-2003 
Statistical Report,7 the incidence was 13.4 cases per 100,000 population in 1995. Given that 
CBTRUS reports CNS tumour incidence age-adjusted to the 2000 US Standard population and 
that the time period of these reports is well embedded within the MRI era of the US, the 
observed increase in incidence of approximately 35 - 40% in less than a decade is not likely to 
be adequately explained by an "ageing population" or by "better diagnosis." If the change is in 
part due to the effects of delayed reporting or "late ascertainment"15 from the 15-19 cooperating 
state registries used by CBTRUS, it follows that the latest 2010 incidence is also likely to be an 
underestimation. 
Trends in incidence rates for Brain 
(ICD10C71). Australia. 1982-2004 
Figure 1.1. Trends in incidence for Malignant neoplasm of brain (ICD10 
C71), Australia 1982-2004. Australian Institute of Health and Welfare 
(AIHW) Australian Cancer Incidence and Mortality (ACIM) book version 1 
2007. 
Figure 1.1 shows incidence data calculated by the Australian Institute of Health and Welfare 
(AIHW) for Malignant neoplasm of brain (International Classification of Diseases, ICD10 C71) 
over the period 1982-2004. The incidence represented in the graph above is age-standardised 
using 2001 Australian census data as the standard population. Surprisingly, little change in the 
brain tumour incidence rate over 22 years is seen in Australia despite changes in reporting, 
classification and population demographics. 
In the 1970s and 1980s, increased incidence of brain tumours was reported internationally and 
correlated with use of new imaging technology (CT and M R I ) 1 1 , 1 6 - 1 7 and associated clinical 
awareness of brain tumours. 2 However, during the mid to late 1990s, when use of CT and MRI 
technology became widespread in Australia, no such trend in AIHW data is observed. Indeed, a 
decrease in incidence is observed (particularly for females). Further, changes in brain tumour 
pathology classification changes also occurred during the reported period 1982-2004 and yet, 
again, no significant trends are demonstrated in the AIHW data depicted in Figure 1.1. 
Notably, incidence data (e.g. AIHW data) have tended to include only malignant neoplasms of 
brain (ICD10 C71), and thus excluded meningioma, pituitary and pineal tumours, acoustic 
neuroma, and previously, low-grade astrocytoma. 1 8 ' 1 9 Exclusion of these tumours produces a 
tendency to underestimate incidence as well as undervaluing the importance of benign brain 
tumours. Australia is unique when compared to the US in that there is legislated total coverage 
of malignant brain tumour data collection, whereas the US uses "sample methodology" for its 
incidence estimates. 
In Australia, a small number of descriptive epidemiologic studies on primary central nervous 
system (CNS) tumours were published in series from Melbourne, Tasmania and Adelaide20 
from the early 1990s. One Victorian study20 of 4,577 tumours showed age- standardised 
incidence rates for malignant CNS tumours of 5-0 cases per 100,000 person-years males and 3-4 
cases per 100,000 person-years females but reported no significant trends during the period 
1986-1988 regarding specific histological subtypes. Another Victorian study21 analysed 3,575 
cases of primary benign and malignant brain tumours over the period 1982-1990 with no clear 
trend in incidence, while a third Victorian study reported a 14% non-significant increase in 
childhood malignant brain tumours over two decades 1970-1989.24 The Tasmanian study2 
analysed 1,752 cases from two registries during the period 1978-1992 and reported increasing 
age-standardised primary brain cancer incidence rates in males (16.3 to 26.2 cases per 100,000 
person-years) and females (9.7 to 18.0 cases per 100,000 person-years) aged 75+, most 
prominent in cases of glioblastoma multiforme (GBM). The Adelaide study23 was a short study 
of a low sample population, showing an increased risk of glioma in women who reported 
working with cathode-ray tubes. 
Our literature searches have to date yielded no comparable Australian studies published 
subsequently. 
1.1.2 Overseas Literature 
Descriptive epidemiology relies largely on population-based cancer registries, which record 
cases according to the International Classification of Diseases for Oncology (ICD-O), which 
corresponds closely to the WHO Classification of Tumours of the Central Nervous System. 
Often, incidence data include only malignant neoplasms and thus exclude most meningiomas 
and, previously, also low-grade astrocytomas.19 
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Figure 1.2. Global incidence rates of nervous system tumours, adjusted to the World Standard Population 
(all ages; cases per 100,000 persons per year). Rates tend to be higher in highly developed countries.19 
As seen in Figure 1.2, age-adjusted brain tumour incidence rates tend to be higher in highly 
developed countries. This likely reflects more diligent monitoring/reporting practice and health 
care delivery but an underlying organic cause needs to be considered as well. 
In western Europe, North America, and Australia, there are about 6.0 -11.0 new cases of 
primary intra-cranial tumours (including meningiomas) cases per 100,000 population per year in 
men and 4.0 -11.0 new cases in women. 19, 25-27 Europe and North America provide the most 
comprehensive data to date and are explored in greater detail below. 
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Figure 1.3. Incidence rates of astrocytic brain tumours in various countries and world regions adjusted to 
the World Standard Population (all ages; cases per 100,000 person- years).1 
Australian rates are approximations based on NSW Central Cancer Registry data (these are not part of the 
original figure).28 
A population-based study of primary brain tumours in Kumamoto prefecture suggests that, in 
Japan, gliomas are about half as frequent as in the US but that childhood tumours are at similar 
rates to Western countries.2 9"3 3 As seen in Figure 1.3, Asian populations generally show lower 
incidence rates of astrocytic tumours that Caucasians. 1 9 ' 2 6 
China describes age-standardised rates (adjusted to the world standard population) of 4.2 (in 
2000) and 4.4 cases per 100,000 person-years (in 2005) in males, and 3.1 (2000) and 3.3 cases 
per 100,000 person-years (2005) in females. 3 4 Although not specified, these data were collected 
by tumour site (ICD-10, C70-72) and likely include spinal and metastatic disease, while 
excluding pituitary and pineal tumours. No further comparable Chinese studies are available in 
our search of English literature. 
New Zealand has published incidence rates of intra-cranial neoplasm with particular focus on 
socioeconomic factors and race. One early study discussed a substantial difference in brain 
tumour incidence rates in non-Maori vs. Maori populations over a 40 year period, 3 5 but a recent 
study has suggested no difference. 3 6 The latest study quotes an age-adjusted incidence rate of 
high grade glioma of -4.0 cases per 100,000 person-years and the authors suggest an improved 
capture rate of Maori tumours explains their observations. 
Between 1995 and 2009,439 males and 383 females had primary intra-cranial tumours in 
Kuwait with only a statistically significant declining trend described for medulloblastoma. The 
study included all primary intra-cranial neoplasms including malignant and non-malignant 
entities as well as metastatic disease. 3 7 
In the 1980s and 1990s, there was considerable worldwide interest in brain tumour incidence 
with many authors attributing increasing trends to improved imaging technology and better 
clinical diagnosis, 2 ' 1 2 ' 3 8 but some studies reported increases irrespective of these changes. 3 9. A 
reported increase of approximately 1-2% per year in the incidence or brain tumours, 3 5 ' 4 
particularly in the elderly, 1 1 ' 2 2 ' 4 1 but also in children was seen. 
There is now renewed interest in brain tumour incidence, particularly in more developed 
countries, and much of the current presentation will focus on the more pertinent contemporary 
studies. 
United States of America 
The largest collection of brain tumour incidence data comes from multiple databases compiled 
by the Central Brain Tumour Registry of the United States (CBTRUS), established in 1992. 
From that time, only malignant cases of brain tumours were reported, but in January 2004, with 
the passage of the Benign Brain Tumour Cancer Registries Amendment Act (Public Law 107-
260), all cancer surveillance registries expanded their primary brain tumour collection to include 
tumours of benign and uncertain behaviour. 
CBTRUS contains data collected from the National Program of Cancer Registries (NPCR) and 
states belonging to the National Cancer Institutes Surveillance, Epidemiology and End Results 
(SEER) program. Initially, data from 12 state registries across the US were included in the 
2002-3 report, covering data from 1995-1999. In the latest 2010 report, 47 population-based 
cancer registries were included. 
Tables 1.1 and 1.2 show reported incidence rates for sequential CBTRUS reports for all 
primary CNS tumours, as well as for selected histologies. These trends, although appearing to 
be increasing each year, need to be interpreted with caution in view of the number of 
participating registries with each report. That is, in the earlier reports, fewer registries were 
available to contribute data than in the later reports. As such, incidence rates are not directly 
comparable between reports. Changes in incidence within and between years have been 
attributed by CBTRUS mainly to better surveillance and delayed reporting (late 
ascertainment). 1 0 ' 1 5 
Diagnosis 
Year 
CBTRUS Report 
2002-2003 2004-2005 2005-2006 2007-2008 2010 
1995 13.4 
1996 14 
1997 14.2 13.5 
1998 14.5 13.9 14.2 
1999 14 14.1 14.5 
2000 14.2 14.8 15.2 
2001 14.7 15.3 15.9 
2002 15.2 16.2 
2003 17 
2004 18.2 
2005 
2006 18.71 
Table 1.1. Age-adjusted incidence of primary CNS tumours in the sequential reports of CBTRUS. 
Adapted from Khurana et al.4 
Incidence is the number of cases per 100,000 population age-adjusted to the US population 2000 
standard. 
The CBTRUS data series is an internationally recognised resource for brain tumour incidence 
data. They have a comprehensive coverage of all types of primary brain tumours from an 
increasing number of participating registries. 
Most US studies have been published from the CBTRUS/SEER data s e r i e s , 4 ' 1 5 , 1 7 ' 1 8 ' 4 4 - 4 6 but a 
few have come from individual population-based registries. 5 Most recently however, studies 
rely more heavily on CBTRUS data and use it as the gold standard. A few of the more widely 
cited US studies from the last 10-20 years include the following. 
Hoffman and colleagues demonstrated only modest overall increases in brain tumour incidence 
rates in a study of CBTRUS data spanning the period 1985-1999.4 However, the authors 
reported increasing incidence in both microscopically-confirmed and non-confirmed 
meningiomas and nerve sheath tumours. An observation suggesting that the increases were less 
likely to be due to improvements in diagnosis and highlighting the importance of continued 
collection of meningioma and nerve sheath tumour (benign brain tumour) data to explain the 
trends 4 
A similar study published in the same year (2006) from many of the same authors, analysed the 
incidence of vestibular Schwannoma (a nerve sheath tumour of the eighth cranial nerve) from 
the CBTRUS and Los Angeles cancer databases. They demonstrated increasing incidence of 
both nerve sheath tumours overall and of vestibular Schwannoma, again, suggesting continuing 
monitoring of these tumours to be important.46 
McCarthy and colleagues have recently (2008) described increasing trends in oligodendroglial 
tumour incidence corresponding to decreases in astrocytic tumour incidence over the same 
period (1992-2004). The suggestion from the authors is that misclassification and improvements 
in molecular diagnostics and treatment have lead to the observed change.1 
Table 1.2 below shows compiled data from sequential CBTRUS reports to give the reader an 
idea of incidence rates cases per 100,000 persons per year. The latest report was released at the 
end of 2010 and includes data for the years 2004-6. 
Tumour 
CBTRUS Report 
2002-2003 
1995-1999 data 
2004-2005 
1997-2001 data 
2005-2006 
1998-2002 data 
2007-2008 
2000-4 data 
2010 
2004-6 data 
Total Glioblastoma 3.24 3.01 3.05 3.09 3.17 
Meningioma 3.86 4.18 4.52 5.35 6.29 
Nerve Sheath 1.05 1.11 1.17 1.46 1.61 
Pituitary 0.92 0.82 0.92 1.37 2.40 
Total 14.02 14.10 14.80 16.52 18.71 
Male Glioblastoma 4.02 3.75 3.86 3.94 3.97 
Meningioma 2.46 2.57 2.75 3.17 3.76 
Nerve Sheath 1.07 1.12 1.19 1.48 1.63 
Pituitary 1 . 0 0 0.85 0.94 1.37 2.31 
Total 14.22 13.92 14.50 15.77 17.44 
Female Glioblastoma 2.59 2.40 2.39 2.38 2.51 
Meningioma 5.04 5.56 6.01 7.19 8.44 
Nerve Sheath 1.04 1.11 1.17 1.45 1.60 
Pituitary 0.88 0.82 0.93 1.42 2.56 
Total 13.86 14.27 15.07 17.19 19.88 
Table 1.2. Age-adjusted incidence of selected primary CNS tumours in the sequential reports of 
CBTRUS by gender. Adapted from Khurana et al.43 Rates are expressed in cases per 100,000 person-
years. 
The current study has used CBTRUS data as its primary point of comparison to US incidence 
rates and many of the quoted rates have been standardised to the 2000 US standard population 
for ease of comparison. Methodology used has also been modelled on the most recent 
publications from the CBTRUS database.4,18,46 
Europe 
Europe is unique in its brain tumour data collection with a number of countries having 
mandatory collection of both malignant and non-malignant tumours for their entire population, 
some from birth. Denmark, Finland, Norway, and Sweden have well developed brain tumour 
registries that include notifications for all residents from two independent sources, clinicians 
and pathologists, ensuring a high completeness of coverage. These registries also cover cases 
without microscopic or radiological confirmation and tumours detected at autopsy.1 
Two studies from the four Nordic countries mentioned showed a stable, even declining 
incidence of adult intracerebral tumours over the period 1969-98 and 1974-2003. Increases in 
incidence were observed in the 1970s and 1980s, coinciding with improved diagnostic methods, 
and largely confined to the elderly. 1 6 ' 5 1 Meningioma incidence from the same four countries 
from 1968-1997 showed a significant increase, more strongly in women than men aged 35-59. 
The increase coincides with the introduction of CT imaging technology but is accompanied by a 
decrease in post-mortem diagnoses. The authors suggest a hormonal influence for the observed 
increase (e.g. use of hormone replacement therapy in the period). 5 2 
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Figure 1.4. Incidence per 100,000 persons per year of nervous system tumours in Europe, adjusted to the 
European Standard Population. Cancer in the European Union (1995), IARC, 1999. 1 9 
England Wales Scotland Northern Ireland UK 
Numbers Males 2092 159 196 81 2528 
Females 1529 136 165 37 1867 
Persons 3.621 295 361 118 4395 
Age standardised rdes ' Males 8.3 10.1 7.6 10.4 814 
Females 5.3 7.6 5.2 4.4 1 4 
Persons 6.8 8.8 6.3 7.2 6.8 
9 5 % confidence intervals Males |8.0 to 8.7) (8.5 to 11.7) (6.5 to 8.6) (8.1 to 12.7) (8.1 to 8.7) 
Femdes (5.1 to 5.6) (6.4 to 8.9) ( 4 4 to 6.0) (3.0 to 5.8) (5.2 to 5.7) 
Persons (6.5 to 7.0) (7.8 to 9.8) ( 5 6 to 6.9) (5.9 to 8.5) (6.6 to 7.0) 
"Direcly age standardised (European) rale per 100000 population at ride 
Source: www.crwicerresearchUK.org 
Table 1.3. Brain and central nervous system tumours: UK incidence 1999. Taken from McKinney 2004. 4 7 
Figure 1.4 and Table 1.3 show summary brain tumour incidence rates for Europe and the 
UK.19,47 From the map, it can be seen that incidence rates are subject to geographical variation, 
a finding confirmed by a number of other European studies, even within a similar area (Table 
1.3).19'47'53 
In Austria, a recent change in brain tumour collection occurred with the setting up of the 
Austrian Brain Tumour Registry that was set up under the auspices of the Austrian Society of 
Neuropathology for the registration of both malignant and non-malignant tumours. The template 
used was based on the 2004 US experience and published (2009) incidence rates are comparable 
to the CBTRUS database with overall age-adjusted rates of 18.1 cases per 100,000 person-years 
that were higher in females (18.6/100,000) than males (17.8/100,000).54 
Studies from Europe have now turned their focus to risk association to attempt to explain rising 
brain tumour incidence trends with particular focus on mobile phone technology.4 ' 5 " This is 
of course beyond the scope of the current study, and beyond reach in Australian, but I mention it 
to describe current trends in brain tumour incidence reporting internationally (the US appears to 
also be following suit60). 
A future direction for Australia may involve setting up similar nation-wide databases and risk 
association studies. 
1.1.3 Australian Cancer Registry data 
In Australia, CNS tumour incidence data is collected by population-based cancer registries, 
some of which include non-malignant tumours, while others restrict data collection to malignant 
disease.20 Further, some registries collect both malignant brain tumour data as well as tumours 
with malignant behaviour but a non-malignant WHO grading. An important distinction. This is 
a feature of the NSW and ACT cancer registries and is explored in further detail below as a 
point of divergence from the current study's definition. 
Few independent studies or reviews on brain tumour incidence have been published from 
Australia recently, but a review by Giles in 1995 gives a good historic picture of malignant 
brain tumour incidence. Giles quotes age-standardised incidence rates at that time of 6.6 and 4.9 
cases per 100,000 person-years in males and females respectively. Incidence rates 1982-1991 by 
histological type are shown in Table 1.4 below. 
MALES FEMALES 
Number Rate Number Rate 
Glioblastoma multiforme 662 2.80 462 1.83 
Astrocytoma 372 1.73 274 1.29 
Medulloblastoma 51 0.31 21 0.12 
Oligodendroglioma 33 0.14 21 0.09 
Ependymoma 30 0.15 29 0.16 
Other glioma 106 0.46 86 0.38 
Meningioma 302 1.27 665 2.69 
Nerve sheath tumour SO 0.35 83 0.35 
Other specified type 41 0.20 46 0.21 
Unspecified type 10 0.05 2 0.01 
Not microscopically confirmed 363 1.47 379 1.28 
TOTAL 2052 8.91 2068 8.40 
Table 1.4. CNS tumour incidence by histological type: age-standardised rates per 100,000 population, 
Victoria, Australia 1982-1991. Source, Victorian Cancer Registry. Taken from Giles 1995. 
Since 1972, public health legislation in NSW requires that all new cases of malignant brain 
tumours are notified. From 1986 to 2004, the NSW Central Cancer Registry (CCR) was based at 
the NSW Cancer Council and received notifications under the authority of the Public Health Act 
of 1991. Since 2004, it has been based at the NSW Cancer Institute. 
The NSW CCR collects notifications of malignant neoplasms from public and private hospitals, 
departments of radiation oncology, nursing homes, pathology laboratories, outpatient 
departments and day procedure centres. Notifications are also received from other state- and 
territory-based cancer registries. 
NSW is the most populous state of Australia with 6,888,014 residents in 2007. According to the 
Australian Bureau of Statistics publication of the Estimated Resident Population in June 2006 
for NSW, the population increased by 70,832 people between 2006 and 2007. 6 2 
From the latest NSW CCR publication, the Australian standardised (to the Australian 2001 
population) incidence rates for brain cancer in 2007 were 8.3 and 5.2 cases per 100,000 person-
years respectively in males and females, with an 84-86% histological verification rate. In 2009 
and longer term (up to 2021), the estimated incidence rates are estimated to remain at 2007 
levels with 8.0 cases per 100,000 person-years in males and 5.4 in females. 6 3 Between 1998 and 
2007, incidence rates of brain cancer showed no statistically significant change in males and 
females (see Figure 1.5). 6 2 
Figure 1.5. Age-standardised incidence rates for brain cancer by gender in NSW 1972-2007.62 
Figures 1.6a) and 1.6b) show comparative age-standardised incidence rates in males and 
females for brain cancer for the years 1998-2002 between NSW and other registries from 
Australia and overseas.28 
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Figures 1.6a) and 1.6b). Age standardised incidence rates in males and females for brain cancer 1998-
2002.64 
The data presented above from the NSW CCR summarise the current state of malignant brain 
tumour collection in Australia over the years 1972-2007. No significant changes have been 
reported in the years 1998-2007. 
We view the Australian Registries as the gold standard in Australia for brain tumour collection. 
Their collection encompasses tumours of malignant and uncertain behaviour and notifications 
are received from multiple different sources in fully identified format, allowing accurate control 
for representation and migration (something beyond the scope of the current study's resources). 
11 
No benign brain tumours are included in the NSW CCR data however. This is the main point of 
divergence between the current study and the established collection of the registry. 
1.2 Risk Factors Associated with the Development of CNS Tumours 
Risk factors associated with the development of brain tumours analysed in the international 
literature have included an ageing population, 3 9 constitutional factors (female hormones, 
genetic predispositions 6 6 , 6 7), environmental exposures (ionizing radiation, mobile phone 
technology, 1 6 , 4 3 ' 5 5 " 5 9 - 6 8 7 1 radiotherapy in children ) and various others (see Table 1.5 below). 
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Table 1.5. Summary of environmental risk factors for brain tumours investigated in epidemiological 
studies. Taken from McKinney 2004. 4 7 
To examine these factors specifically at this time is beyond the scope of the proposed study, but 
they are important factors to bear in mind, particularly given increasing public concern over 
mobile phone usage 16,43,55-59, 69-71,73 and "electropollution". 74 
1.3 Aims and Hypothesis 
• Measure a better estimate of brain tumour burden in the ACT and NSW populations to 
provide essential information to policy makers; 
• Establish a baseline incidence rate for any future monitoring of changes in incidence, 
because this may allow early intervention in the context of potential environmental 
causes; 
• Collect and present reliable data on age-adjusted, histologically specific, sex-
differentiated incidence data on both benign and malignant brain tumours; 
• Determine a better estimate of age-adjusted incidence, trends and annual percentage 
change for selected histologies of brain tumours in the ACT and NSW over the period 
1994-2008. 
o Specifically, test the hypothesis that the age-adjusted incidence rate of 
astrocytoma, acoustic neuroma and meningioma in the ACT and NSW is 
increasing; 
• Identify any gaps in current collection of data that would assist further investigation of 
brain cancer in the ACT and NSW; and 
• Facilitate dissemination of data for public education and ongoing research purposes. 
1.4 Ethical Approval 
Ethical approval was granted for the study by the following bodies; 
• ACT Health Human Research Ethics Committee 
• NSW Population & Health Services Research Ethics Committee with lead HREC 
approval by the NSW Cancer Institute 
• Sydney Adventist Hospital Human Research Ethics Committee 
Approval was granted by the NSW Population & Health Services Research Ethics Committee 
for a multicentre study into the incidence of primary brain tumours for the years 1994-2008 at 
the following sites in NSW; 
• John Hunter Hospital 
• Royal North Shore Hospital 
• Prince of Wales Hospital 
• Wollongong Hospital 
• St Vincent's Hospital Darlinghurst 
• Concord Repatriation General Hospital 
• Liverpool Hospital 
• Royal Prince Alfred Hospital 
• Nepean Hospital 
• Westmead Hospital 
• The Children's Hospital at Westmead 
• Sydney Adventist Hospital 
• Douglass Hanly Moir Pathology, Macquarie Park, Sydney 
• Dalcross Private Hospital 
Data collection was approved for the following parameters 
• All primary brain tumours (malignant and benign) including cranial nerve tumours 
• In the time period January 1994 to December 2008 
• Histological description (e.g. ICD-O-3, SNOMed III) 
• Topographical location (e.g. ICD-O-3, ICD 10) 
• Date of diagnosis 
• All age groups 
• Both male and female 
• Year of birth 
• Postcode 
The approval process for this project extended from July 2008 until February 2009, with the 
ACT Health Human Research Ethics Committee granting approval on the 21 July 2008 and the 
NSW Cancer Institute HREC granting approval on th 17 February 2009 (see Appendix 6.8 for 
approval letters). 
Please consider the length of a 64-page NSW Health On-line National Ethics Application Form 
(NEAF) and 19-page Site Specific Assessment Form (SSA) at www.neaf.gov.au. Now consider 
21 such forms (both NEAF and SSA) needing to be completed online, sent to the 21 
participating sites for signatures and then sent in triplicate to the NSW Cancer Insitute HREC 
for approval. Furthermore, separate private hospital ethical approval (e.g. Sydney Adventist 
Hospital) was also required. This was a time consuming task and seemed out of proportion to 
the simple nature of the study. 
Unfortunately, approval for the use of fully identified data was not granted - a significant issue 
for ensuring an accurate case capture rate. Without the use of identifiers, data were not able to 
be analysed across multiple different collection centres, and representations of the one patient to 
a number of different centres would thus presumably be included in the analysis. This would 
lead to an over-estimation of the incidence rate. 
Moreover, when approached to complete a data match for the study, our Cancer Registries were 
too short staffed, and the authors were referred to a private data matching service. Data 
matching is the accessing of fully identified Cancer Registry data and performing a cross match 
with an independent study's results. The fee for the private data matching service was beyond 
the budget of the current study. Again, this is a significant issue for ensuring an accurate case 
capture rate. Without the aid of a data matching service, we have no yardstick by which to 
compare our data. 
Although the above point would regardless be true of all benign brain tumours since these data 
are not currently collected, data matching for malignant tumours would provide a good 
indication of our data quality. 
Overall, ethics approval proved a very time consuming process. This process would benefit 
from review, particularly if future studies similar to the current one are to be performed. 
In the end, complete data sets for all participating centres from mid-1999 to December 31 2008 
were obtained. 
1.5 Sampling 
The study population was defined as all histologically confirmed primary brain tumours from 
patients with listed ACT or NSW postcodes. 
The ACT/NSW region was used as the sample population because of its low rate of outward 
migration based on cross-border patient flows from the Australian Institute of Health and 
Welfare Hospital Separation data. 
Initial analysis of ACT data in isolation highlighted this issue, where cross border flows 
between the ACT and NSW were highly significant, resulting in poor case coverage. 
Additionally, it was found that The Canberra Hospital (ACT) incidence rates were heavily 
affected by operating rates and service delivery (see 1.5.2 Migration Effect below). 
Later in the study, our data collection encompassed the largest stereotactic radiosurgery centre 
in the ACT/NSW region - the Prince of Wales Cancer Centre. This centre treats meningiomas, 
pituitary adenomas and vestibular Schwannomas either as the primary treatment option or as an 
adjuvant to surgical treatment. 
Stereotactic radiosurgery is often employed for brain tumours where the risk of surgery 
outweighs the benefit such as in skull base tumours or tumours in eloquent areas of the brain. 
Capture of this data has added to the completeness of our data set, particularly in terms of the 
benign brain tumours listed above. 
1.5.1 Coverage 
Fifteen pathology units servicing all 25 neurosurgical hospitals in the ACT and NSW regions of 
Australia provided data on all incident primary brain tumours diagnosed in the period 1994 to 
2008. 
Capture of brain tumours at this level allowed greater diagnostic accuracy. 
Cancer Registries and previous independent studies have included non-operative brain tumour 
diagnoses as well as tumours diagnosed at autopsy.7 5 Although this approach yields large 
sample sizes, the current study aimed to provide a greater acuity in assessment of histological 
subtypes that is lost upon inclusion of tumours diagnosed solely on imaging technology, 
conservative (i.e. non-operative) treatment or clinical decision making. 
Importantly, pathology data is the primary point of diagnosis, and provides the most up to date 
information on histology, topography and time of diagnosis. 
Other sources have argued that the timing of diagnosis should be based upon the date of first 
clinical diagnosis. 5 3 ' 7 5 This approach is justified in those tumours that are either inoperable or 
slow growing and thus allows capture of a greater number of tumours, particularly those that are 
followed with a "wait-and-watch" approach. However, notification systems employed by 
Registries in this regard are subject to significant reporting delay and require resources beyond 
the scope of the current study. 
The European Network of Cancer Registries has developed a hierarchy regarding the date of 
diagnosis.7 6 In order of declining priority; 
1. Date of first histological or cytological confirmation of this malignancy (with the 
exception of histology or cytology at autopsy). This date should be, in the following 
order: 
a. date when the specimen was taken (biopsy) 
b. date of receipt by the pathologist 
c. date of the pathology report. 
2. Date of admission to the hospital because of this malignancy. 
3. When evaluated at an outpatient clinic only: date of first consultation at the outpatient 
clinic because of this malignancy. 
4. Date of diagnosis, other than 1, 2 or 3. 
5. Date of death, if no information is available other than the fact that the patient has died 
because of a malignancy. 
6. Date of death, if the malignancy is discovered at autopsy. 
Coverage of brain tumours diagnosed in the ACT/NSW region has been assumed to be 
complete in the study period, but capture of brain tumours diagnosed at smaller private 
pathology units cannot be excluded. 
1.5.2 Migration effect 
Migration of patients between states for health care can have an undue effect on the incidence 
rate, particularly when no control for outward migration exists (as in the current study). The 
Australian Cancer Registries have an agreement where fully identified data is shared between 
states and territories in order to control and quantify this migration. 
Within Australia there is no direct quarterly measure of interstate migration, unlike that of 
natural increase and net overseas migration. Instead, quarterly estimates of interstate migration 
are modelled using Medicare change of address data. This model is reviewed and updated every 
five years using data from the latest Census of Population and Housing. 7 7 Statistics published by 
the Australian Bureau of Statistics record the number of interstate arrivals and departures. In the 
period March 2000 to September 2008, the median population for arrivals into NSW was 21849 
persons and 4751 persons for the ACT, while the median population for departures was 28048 
persons and 4752 persons. 7 8 , 7 9 Population flows into and out-of the ACT/NSW region have thus 
remained relatively stable over the study period. 
Unfortunately, as noted, the lack of ethical approval for the use of identified data and the 
reluctance for data matching by our local registries, have made full control for migration an 
insurmountable issue in light our resource capabilities. Consequently, an average weighting of 
3.21%, calculated from both public and private Australian hospital separation data (2006-7), 
was applied to the data to account for patient outflow from the study region.80 Inflows were 
controlled for by manual exclusion of postcode of residence. To account for completeness of 
data as well as migration effect an overall average weighting of 5.00% was used. 
To highlight the issue, a preliminary analysis of incidence trends using data only from The 
Canberra Hospital was performed while awaiting NSW ethical approval and data. The data was 
of top quality owing to dedicated staff and all codes were cross-checked by professional coders 
at The Canberra Hospital. A pictorial representation of our methods is shown below (Figure 
1.7) where all tumours operated within the ACT were refined by exclusion of irrelevant 
diagnoses, recurrence of a tumour in the same patient, and patients residing in an area outside 
the ACT. 
n 
the Australian Capital Territory in the years 1997-2008 with refinement of numbers based on diagnosis, 
recurrence and postcode. Final number = 427. 
A crude incidence rate of -11.0 - 12.0 cases per 100,000 person-years was calculated over the 
years 1997-2008. The analysis was limited by the low number of tumours (n=427). A decrease 
in the age-standardised incidence rate of primary brain tumours is observed in the years 1998-
2000 (Figure 1.8). This trend over time however was biased by migration out of the territory 
reflected by operating rates over the time period (Figure 1.9). This reflected the strong 
influence of health service delivery on The Canberra Hospital neurosurgical service in terms of 
access to health care and referrals to other centres outside the ACT. 
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Figure 1.8. Incidence of all primary brain tumours in the ACT, adjusted to the Australian Standard 
Population as at census 2006 by 5 year age groupings, per 100,000 person-years, 1997-2008 
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Figure 1.9. Number of operations by year for all (ACT and other Australian states) primary brain 
tumours at The Canberra Hospital by number in the period 1997-2008. 
Further analysis was suspended until receipt of NSW data, which, as discussed above, has a 
very low outward migration rate for health care. Moreover, the ACT and NSW region is a very 
homogenous population covering multiple ethnicities, backgrounds and exposures, and thus an 
ideal area to analyse the trends in brain tumour incidence. 
1.5.3 Inclusion and Exclusion criteria 
The primary aim of the current study was to establish an accurate collection of all primary intra-
cranial tumours in the ACT and NSW region by examining trends over time by age, sex and 
histological subtype. Perhaps the most widely used system for brain tumour classification is the 
World Health Organisation (WHO) classification system. The histological grade defined under 
this system is a means of predicting the biological behaviour of a neoplasm, with tumour grade 
having clinical implications for treatment choice. 
According to the WHO Classification of Tumours of the Nervous System (4 t h Edition 2007), 8 1 
tumours of the central nervous system may be classified into the following major histological 
subgroups: 
• Tumours of neuroepithelial tissue 
• Tumours of the cranial and paraspinal nerves 
• Tumours of the meninges 
• Tumours of the sellar region 
• Lymphomas and haematopoietic neoplasms 
• Germ cell tumours 
• Metastatic tumours 
We have defined our collection of brain tumours according to the WHO Classification of 
Central Nervous System Tumours 4 t h edition (2007)8 with the exclusion of extra-cranial, germ 
cell and metastatic tumours. The use of this system allows greater comparison of rates in 
international literature. 
Grade III and IV tumours demonstrate histological evidence of malignancy, including nuclear 
atypia, brisk mitotic activity and necrosis, with invariably fatal outcomes. Grade I lesions are 
generally considered tumours of low proliferative potential and the possibility of cure with 
surgical resection alone. Lesions designated grade II are typically infiltrative in nature, and 
despite low proliferative activity, often recur. Some grade II tumours tend to progress to higher 
grade tumours, for example, low-grade diffuse astrocytomas that transform to anaplastic 
astrocytoma and glioblastoma.8 These tumours are thus assigned an uncertain or borderline 
behaviour code (/3), despite being grade II classification. This is the basis of brain tumour 
collection by the Australian Cancer Registries, who collect all malignant and borderline tumours 
for "brain" (ICD code C71). Collection of these tumours is mandated by Australian law and 
published rates are thus considered only in terms of "malignant" tumours, with no collection of 
benign or non-malignant tumours. 
Unlike the Australian Cancer Registries however, we have defined malignant brain tumours as 
WHO Grade III and IV. Grade II tumours are considered a separate entity in the current study 
that despite having the potential to progress to malignancy, are considered non-malignant at the 
time of diagnosis. Combining both borderline and malignant brain tumours into the one 
incidence rate creates difficulty in comparison of published rates in the literature, as well as 
being less meaningful clinically. This is particularly true considering no recent published data 
exists on histological subtypes or benign tumours in Australia. 
Registry data also includes collection of systemic lymphoma, metastatic, extracerebral, soft 
tissue and germ cell tumours (see Table 1.6).62 Collection of this data was beyond the scope of 
the current project - spinal, metastatic tumours and lymphoma have origins outside the central 
nervous system. Interestingly, there are multiple diagnoses not traditionally considered either 
brain tumours or malignant tumours in the list, and may explain the higher numbers of tumours 
observed by the registry compared to the current study (see Chapter 2). 
C7I Brail (ICD-O-2 €71} 1 Tumours of sieuraepHhelnl tissue 6680. 9360-9362.9364.93BO-9506,9520-9523 
Iruii codes I.I QOTBS 9380-9384,9391-9460,9480, 9481 
1.11 Astrocytic tumour? 9384,9400-9421,9424.9440-9442,9481 
1.12 CMjgodendragm tinurs and nwad 
gfiomas 
9382.9450-9451 
1.13 Epei Kjyuial tumours 9383.9391-9394 
1.14 Gbornas of inoertain origin 9380.9381.9422.9423.9430,9460,9480 
1.2 EmbryonaJ tumours 9470-9473.9490.9500-9504 
1.21 Medullcblastorm 9470-9472,9364, 9473 £>tc C7I6, C7I7) 
1.22 Other embryonal tLmom 9490.9500-9504,9364.9473 (othersites torn C716. 
C7I7) 
1.31 Choroid pleas tumours 9390 
IJ2 Neutral & mind nemral ^ oj 
tunaunc 
8680,9491,9505, 9506, 9520-9S23 
1.33 OHactory tumours 9520-9523 (steCJOOj) 
1.34 Hneal parenoymal tumours 9360-9362.9364,9473 (site C7S3) 
2 Tumours of cranial nerves 9540-9570 
3.1 Menrfgunia 9530-9535, 9537.9538 
32 Soft tissue 8800-9044. 9120-9142.9150.9536,9539. 9160-9251 
13 Melanoma 8720-8790 
4.1 Gemnoma 9060,9064 
42 Other germ eel 9020-9072,9080-9085, 91001 9101 
5J Rtutary tumours B140-6381 (ateC75l) 
5.2 Craniopharyngioma 9350 
6 Other specified tunour 8050-86501 B693-, 071ft 9270-93319320-9371, 
9580-9581 
7 Lfrnspeofiec tumour 8000-8045 
9 Other; very odd else 
C7I bail (ICD-O-2 C7I) Qiobtasrtoma 9440-9442 
franVlC Astrocytoma 
Other gliomas 
No histolopal confirmation 
9384.9400-9421,9430,9424 
9470-9473,9450-9460.9391-9394,9380-9383, 9390-
9394,9480 
999.0,800 
Table 1.6. Histology codes collected by the NSW CCR classified using IARC histological groupings.62 
Of the mesenchymal brain tumours, only haemangioma and haemangiopericytoma were 
included in the study. Pituitary, craniopharyngeal duct and pineal tumours, as well as primary 
central nervous system lymphoma and cranial nerve tumours were included in the analysis. 
Atypical teratoid/rhabdoid tumours were also included in the study - being the main differential 
diagnosis of medulloblastoma. 
Tumours in patients from overseas or other Australian states and territories were excluded from 
the analysis. This exclusion was based on listed postcode from the pathology report that was not 
verified as a patient's place of residence. 
To capture the tumours described above, pre-existing search engines at each site or specifically 
written search programs were employed to capture related diagnoses (see Tables 1.7 and 1.8). 
Methods varied from site to site depending on available technology with a broad margin of 
irrelevant diagnoses initially being included. These were then refined at the co-ordinating centre 
(The Canberra Hospital) by a limited number of investigators to maximise consistency of 
methods. 
C70.0 Cerebral meninges 
C70.1 Spinal meninges 
C70.9 Meninges unspecified 
C71.0 Cerebrum 
C71.1 Frontal lobe 
C71.2 Temporal lobe 
C71.3 Parietal lobe 
C71.4 Occipital lobe 
C71.5 Cerebral ventricle 
C71.6 Cerebellum 
C71.7 Brainstem 
C71.8 Overlapping lesion of brain 
C71.9 Brain unspecified 
C72.0 Spinal cord 
C72.1 Cauda equina 
C72.2 Olfactory nerve 
C72.3 Optic nerve 
C72.4 Acoustic nerve 
C72.5 Other and unspecified cranial nerves 
C72.8 Overlapping lesion of brain and other parts of central nervous system 
C72.9 Central nervous system, unspecified 
C75.1 Pituitary gland 
C75.2 Craniopharyngeal duct 
C75.3 Pineal gland 
Table 1.7. Topography Codes for Brain Tumours (ICD 10 Malignant Codes). 
M 9421/1 Pilocytic astrocytoma 
M 9425/3 Pilomyxoid astrocytoma 
M 9424/3 Pleomorphic xanthoastrocytoma 
M 9384/1 Subependymal giant cell astrocytoma (Tuberous sclerosis) 
M 9400/3 Diffuse Astrocytoma 
M 9420/3 Fibrillary astrocytoma 
M 9411/3 Gemistocytic astrocytoma 
M 9410/3 Protoplasmic astrocytoma 
M 9401/3 Anaplastic astrocytoma 
M 9440/3 Glioblastoma 
M 9441/3 Giant cell glioblastoma 
M 9442/3 Gliosarcoma 
M 9381/3 Gliomatosis cerebri 
M 9450/3 Oligodendroglioma 
M 9451/3 Anaplastic oligodendroglioma 
M 9382/3 Oligo-astrocytoma 
M 9382/3 Anaplastic oligo-astrocytoma 
M 9383/1 Subependymoma 
M 9394/1 Myxopapillary ependymoma 
M 9391/3 Ependymoma 
M 9391/3 Cellular Ependymoma 
M 9393/3 Papillary Ependymoma 
M 9391/3 Clear cell Ependymoma 
M 9391/3 Tanycytic Ependymoma 
M 9392/3 Anaplastic ependymoma 
M 9390/0 Choroid plexus papilloma 
M 9390/1 Atypical choroid plexus papilloma 
M 9390/3 Choroid plexus carcinoma 
M 9430/3 Astroblastoma 
M 9444/1 Chordoid glioma of the 3rd Ventricle 
M 9431/1 Angiocentric glioma 
M 9493/0 Dysplastic gangliocytoma of cerebellum (Lhermitte-Duclos) 
M 9412/1 Desmoplastic infantile astrocytoma /ganglioglioma 
M 9413/0 Dysembryoplastic neuroepithelial tumour 
M 9492/0 Gangliocytoma 
M 9505/1 Ganglioglioma 
M 9505/3 Anaplastic ganglioglioma 
M 9506/1 Central neurocytoma 
M 9506/1 Cerebellar neurolipocytoma 
M 9509/1 Papillary glioneuronal tumour 
M 9509/1 Rosette-forming glioneuronal tumour of the fourth ventricle 
M 9361/1 Pineocytoma 
M 9362/3 Pineal parenchymal tumour of intermediate differentiation 
M 9362/3 Pineoblastoma 
M 9395/3 Papillary tumour of the pineal region 
M 9470/3 Medulloblastoma 
M 9471/3 Desmoplastic nodular medulloblastoma 
M 9471/3 Medulloblastoma with extensive nodularity 
M 9474/3 Anaplastic medulloblastoma 
M 9474/3 Large cell medulloblastoma 
M 9473/3 CNS primitive neuroectodermal tumours (PNETs) 
M 9500/3 CNS Neuroblastoma 
M 9490/3 Ganglioneuroblastoma 
M 9501/3 Medulloepithelioma 
M 9392/3 Ependymoblastoma 
M 9560/0 Schwannoma (Neurilemoma, Neurinoma) 
M 9560/0 Cellular Schwannoma 
M 9560/0 Plexiform Schwannoma 
M 9560/0 Melanotic Schwannoma 
M 9540/0 Neurofibroma 
M 9550/0 Plexiform 
M 9571/0 Perineurioma, NOS 
M 9571/3 Malignant perineurioma 
M 9540/3 Epithelioid MPNST 
M 9540/3 MPNST with mesenchymal differentiation 
M 9540/3 Melanotic MPNST 
M 9540/3 MPNST with glandular differentiation 
M 9530/0 Meningioma 
M 9531/0 Meningothelial meningioma 
M 9532/0 Fibrous (fibroblastic) meningioma 
M 9537/0 Transitional (mixed) meningioma 
M 9533/0 Psammomatous meningioma 
M 9534/0 Angiomatous meningioma 
M 9530/0 Microcystic meningioma 
M 9530/0 Secretory meningioma 
M 9530/0 Lymphoplasmacyte-rich meningioma 
M 9530/0 Metaplastic meningioma 
M 9538/1 Clear cell meningioma 
M 9538/1 Chordoid meningioma 
M 9539/1 Atypical meningioma 
M 9538/3 Papillary meningioma 
M 9538/3 Rhabdoid meningioma 
M 9530/3 Anaplastic (malignant) meningioma 
M 9120/0 Haemangioma 
M 9133/1 Epithelioid haemangioendothelioma 
M 9150/1 Hemangiopericytoma 
M 9150/3 Anaplastic hemangiopericytoma 
M 9364/3 Ewing sarcoma - PNET 
M 9161/1 Haemangioblastoma 
M 9590/3 Primary CNS lymphoma 
M 9350/1 Craniopharyngioma 
M 9351/1 Adamantinomatous Craniopharyngioma 
M 9352/1 Papillary Craniopharyngioma 
M 9582/0 Granular cell tumour 
M 9432/1 Pituicytoma 
M 9400/1 Astrocytoma low-grade, NOS 
M 9400/3 Astrocytoma high-grade, NOS 
M 9380/1 Glioma low-grade, NOS 
M 9380/3 Glioma high-grade, NOS 
M 8272/3 Pituitary carcinoma 
M 8140/0 Adenoma, NOS 
Table 1.8. Example of Morphology Codes for Brain Tumours (ICD-O, SNOMed III). 
Discrepancies in data completeness were followed up with the collecting institution and 
if further specific searches did not yield more complete data, the records were excluded 
from the analysis. 
1.5.4 Recurrence/representation 
If not done manually, a random number was assigned to the names of patients to control for 
repeat presentations to the same hospital/hospital network. Data quality was to be assessed 
through data matching of fully identified data with Cancer Registry data. However, ethical 
approval for this undertaking was not granted and due to staff shortage issues, the registries 
were unable to match data for all malignant tumours. 
This was a significant issue for quality assurance, particularly because there is no mandatory 
reporting of benign tumours in Australia. Data matching of malignant data may have given at 
least some indication of the quality of benign tumour data. No control for repeat presentations 
of one patient to multiple hospitals (not in the same network) was performed. This gives rise to 
the potential for overestimation of the incidence rate. 
1.6 Database Background, Design and Search Method 
Thirteen sites participated in the current study. Most sites employed on-site search engines to 
identify cases through SNOMED morphology and topography codes. Extraction and translation 
of data to an excel spreadsheet for the larger centres (RPAH, RNSH, STVH, POW) was 
computerised. A number of the smaller centres however, required a very labour-intensive 
method of manual translation from individual pathology reports (after computerised 
identification of cases). The following provides an overview of the methods employed at each 
site including the period of data received and primary search method. 
Collecting Centre Database (year) Search Method Translation 
to Excel 
The Canberra Hospital (public and private) 1996 - 2009 (mid) Text diagnosis** Manual 
Sydney Adventist Hospital 2008 - 2009 (mid) Text diagnosis** Manual 
St Vincent's Hospital (public and private) 1994 - 2009 (mid) 
Postcodes by manual 
extraction 
SNOMED* Manual 
Prince of Wales Hospital (public and 
private) including St George Hospital 
(public and private) 
1999 - 2008 SNOMED* Computerised 
Children's Hospital at Westmead 1997 - 2008 Text diagnosis** Manual 
John Hunter Hospital 1994 - 2008 SNOMED* Computerised 
Wollongong Hospital 2000 - 2008 SNOMED* Manual 
Nepean Hospital 1994 - 2008 
Two databases 
Postcodes by manual 
extraction 
SNOMED* Manual 
Royal North Shore Hospital 1975 - 2009 (mid) SNOMED* Computerised 
Including North Shore Private, Royal North Shore 
Hospital (public), Dalcross Private Hospital, Clinical 
Cancer Registry, Royal North Shore Pathology 
Meeting data collection, Dr Janice Brewer private 
records 
Multiple databases 
sourced and 
amalgamated 
Westmead Hospital (public and private) 1996 - 2008 SNOMED* Manual 
Douglass Hanly Moir Pathology 1987 - 2009 (mid) 
Four separate databases 
SNOMED* Manual 
Royal Prince Alfred Hospital database 
including Concord Repatriation General 
Hospital and Liverpool Hospital 
1994 - 2008 SNOMED* 
Specific search 
program written on-
site 
Computerised 
Prince of Wales Cancer Centre 1970 - 2008 Text diagnosis** Computerised 
Table 1.9. Database information including collecting site, years of data coverage, search method and 
method of translation to excel. 
*SNOMED topography (T) and morphology (M) code search. T-A* (brain), TBI* (pituitary), T-B2* 
(pineal), T-91* (pituitary), M-91* M-93* M-94*, M-95* codes were used over two versions of 
SNOMED (international 3.5, and II). * means a wildcard search 
**Text diagnosis using keywords; glioma, brain, tumour, pituitary, astrocytoma, cancer, CNS, 
Schwannoma, vestibular Schwannoma, acoustic neuroma, adenoma, meningioma, ependymoma, 
haemangioblastoma, medulloblastoma, neuroblastoma, oligodendroglioma, oligoastrocytoma and pineal 
The data range of the current study was limited by data received from the Prince of Wales 
Hospital, which provided data from mid-1999 to end-2008. This centre contributed 
approximately 15% of all tumours to the current collection (see Chapter 3), and so analysis of 
trends prior to the year 2000 would have been unreliable, with a large margin for error. 
1.7 Effect of Individual Hospital Coding Practice on Capture Rate 
Databases are used by hospitals to generate statistics for quality care and resource management 
but coding practice varies between hospitals depending on the training and experience of coders. 
The majority of hospital coding practice follows the International Classification of Diseases 
(ICD) coding system that has been in its 10th edition (ICD-10) since 1994. Since 1996, yearly 
updates to the ICD-10 have been published, and the time to widespread use of updates varies 
between hospitals. Additionally, because of the vast list of available codes (topographical and 
morphological) and multiple different methods of coding the same tumour, standard practice 
varies between institutions. 
Routine search methods can thus lead to variability of capture rate of brain tumours. For this 
reason, we employed an on-site data collector familiar with the system after discussion with on-
site pathologists to work out the optimal search method to maximise capture rate of brain 
tumours. For example, topographical vs. morphological vs. text diagnosis search method. 
Specifically, brain tumours fall into the ICD-O (oncology) coding system that is currently in its 
3rd edition (ICD-O-3). Examples of important corrections to the early edition of ICD-O-3 
include re-classification of pilocytic astrocytoma from a malignant entity (/3 behaviour) to a 
borderline/uncertain tumour (/I behaviour). Rhabdoid meningiomas were reclassified in the 
same year (2001) from /1 to /3 behaviour code. The ICD system is related but distinct from the 
Systematized Nomenclature of Medicine (SNOMED) employed by most pathology units in the 
ACT/NSW region. The SNOMED system has a greater number of tumour codes and is thought 
to be more specific to histological diagnosis than the ICD system. We have thus employed the 
SNOMED coding system for the present study and converted each code to its equivalent WHO 
2007 code. For the purposes of the current study however, the differences between the three 
systems are minimal. 
Widespread use of a particular coding system or use of an updated code varies between 
hospitals and was thus an important issue to clarify prior to commencing a search to ensure near 
complete capture rates. In terms of the current study, specific searches were needed to capture 
pituitary and pineal tumours, which, depending on the site, could have potentially been missed 
if only the "brain" or "pituitary/pineal" topography code was used. 
These coding issues are significant for maintenance of accurate databases but coding changes 
for brain tumours in the years 2000-2008 are minimal, and the present study has remained 
relatively unaffected by coding changes. Further, we have re-coded all tumours according to the 
latest WHO classification for morphology and ICD classification for topography to avoid this 
issue. The issue is worth highlighting to make the reader aware that caution is needed when 
interpreting the data. We cannot guarantee complete capture rates and coding issues are a large 
contributor to missed tumours. We have attempted to minimise this error through tailoring our 
searches to the on-site capabilities of the databases. 
1.8 Central Database Management (The Canberra Hospital) 
This section outlines the methods used to combine, sort, code, clean and analyse the dataset. 
Strict methodology is important when handling large volumes of data to minimise error and 
maximise consistency. 
1.8.1 Combining Data 
De-identified data were received at the central site (The Canberra Hospital) via electronic 
transfer of an Excel spreadsheet. All diagnoses were coded to SNOMED morphology and ICD 
10 topography coding systems (see Tables 1.7 and 1.8) by a limited number of investigators to 
maximise consistency of coding practice. Professional coders at The Canberra Hospital were 
employed to cross-check the coding method. 
1.8.2 Cleaning Data 
-12,200 records were received to the central site. Data were cleaned by individual Excel 
spreadsheet by site prior to amalgamating all relevant data into one spreadsheet. A pictorial 
representation of the cleaning and weighting process is provided below (Figure 1.10). 
14000 
As mentioned previously, each collection site employed a different search method to extract 
records from the local database and so the quality of data also varied between sites. If a record 
was ambiguous or incomplete, a further check with the site was performed for additional 
information based on a unique code for that entry. If the additional search did not yield adequate 
information, the entry was discarded. Common examples included topographical site of 
meningioma (intra-cranial versus extra-cranial), not-otherwise-specified (NOS) codes, date of 
birth, and postcode. 
Commonly encountered irrelevant diagnoses included lymphoma, metastatic disease, extra-
cerebral tumours, abscess and infection (n ~ 1800). Patients with recorded postcodes from 
overseas or outside of the ACT/NSW region (n « 450) were excluded from the analysis. 
Figure 1.11. Distribution of postcodes for patients excluded from the analysis (n = 450 total). 
49 records were excluded from the analysis based on incomplete data fields. The incomplete 
fields included lack of date of diagnosis, date of birth, gender, unspecified site and uncertain 
diagnosis, the most common of which was lack of date of diagnosis. 
Recurrence of a tumour in a patient was defined as the same histological subtype of brain 
tumour occurring in that patient two months or more after initial resection. If two entries were 
found for the one patient within two months of each other, with the same histological diagnosis, 
the entries were assumed to be the same tumour and only the earliest record was included for 
analysis (n = 1350 excluded). If the two entries were greater than two months apart and of the 
same histological diagnosis, the later entry was excluded as being a recurrence of the first 
tumour (n ~ 1100). 
This definition is still under debate and applies only for malignant tumour collection in the 
United States, with some suggesting the need for a longer timeframe (e.g. four months or one 
year) for recurrence. 8 4 This issue is related but also distinct from the Rule of Multiple Primaries 
(see below). 
1.8.3 Data Reporting Rules 
Coding rules are an important aspect of data collection in incidence determination. Although 
affecting only a small proportion of the whole, the rules deserve special mention due to the 
potential bias that variation amongst definitions might cause. This is particularly true in relation 
to brain tumours. In the early 20 t h Century, neurosurgeon Harvey Cushing made the observation 
that some brain tumours are malignant because of their histology, and some are malignant 
because of their location. Despite advances in technology and treatment, this observation still 
holds true, with slow growing tumours in eloquent (i.e. vital to normal functioning) and 
difficult-to-access areas of the brain still having significant consequences for the patient. Brain 
tumours, whether benign or malignant, can cause devastating effects through mass effect, 
oedema, haemorrhage, or seizures, resulting in a similar clinical outcome. 
No current world standard of coding rules has been published. 
On January 1, 2004, a standard collection for all non-malignant and malignant brain and central 
nervous system tumours in the United States according to the following sites was developed. 8 5 
Of note, anatomically, the tentorium cerebelli is a dural structure that separates the cerebellum 
from the cerebrum. The hypothalamus, pallium and thalamus are classified as infratentorial 
structures but yet are anatomically located superior to the tentorium and incisura tentorii 
(opening of the tentorium that transmits the cerebral peduncles)! 
Cerebral Meninges 
ICD-O-3 Term 
C70.0 Cerebral meninges 
C70.1 Spinal meninges 
C70.9 Meninges, NOS 
Brain 
Supratentorial Infratentorial 
C71.0 Cerebrum X 
Basal ganglia X 
Central white matter X 
Cerebral cortex X 
Cerebral hemisphere X 
Corpus striatum X 
Globus pallidus X 
Hypothalamus X 
Insula X 
Internal capsule X 
Island of Reil X 
Operculum X 
Pallium X 
Putamen X 
Rhinencephalon 
Supratentorial brain, NOS 
Thalamus 
C71.1 Frontal lobe 
C71.2 Temporal lobe 
Hippocampus 
Uncus 
C71.3 Parietal lobe 
C71.4 Occipital lobe 
C71.5 Ventricle, NOS* 
Cerebral ventricle 
Choroid plexus, NOS* 
Choroid plexus of lateral ventricle 
Choroid plexus of third ventricle 
Ependyma* 
Lateral ventricle, NOS 
Third ventricle, NOS 
C71.6 Cerebellum, NOS 
Cerebellopontine angle 
Vermis of cerebellum 
C71.7 Brain stem 
Cerebral peduncle 
Basis pedunculi 
Choroid plexus of fourth ventricle 
Fourth ventricle, NOS 
Infratentorial brain, NOS 
Medulla oblongata 
Midbrain 
Olive 
Pons 
Pyramid 
C71.8 Overlapping lesion of brain 
Corpus callosum 
Tapetum 
C71.9 Brain, NOS* 
Intra-cranial site* 
Cranial fossa, NOS* 
Anterior cranial fossa 
Middle cranial fossa 
Posterior cranial fossa 
Suprasellar 
Spinal Cord and Other Central Nervous System 
C72.0 Spinal cord 
C72.1 Cauda equina 
C72.2 Olfactory nerve 
C72.3 Optic nerve 
C72.4 Acoustic nerve 
C72.5 Cranial nerve, NOS 
C72.8 Overlapping lesion of brain and central nervous system 
C72.9 Nervous system, NOS 
Table 1.10. Topographic sites used for coding based on clinical information supplied on pathology forms 
in the current study. Taken from SEER coding advice.8 5 
The impetus for this definition was the Benign Brain Tumour Cancer Registries Amendment 
Act (Public Law 107, 260) and has been used in the current study (Table 1.10). 
The following section details some of the more penitent rules for coding of benign, borderline 
and malignant brain and CNS tumours applicable to the current study. For further details, the 
National Program of Cancer Registries (NPCR) 8 6 and SEER Websites8 5, the 2009 Facility 
Oncology Registry Data Standards publication,87 the 2004 Centres for Disease Control and 
Prevention publication84 and the 2007 National Cancer Institute Surveillance Epidemiology and 
End Results Program publication,88 the 2002 North America Association of Central Cancer 
Registries publication89 should be referred to. 
As mentioned, on January 1, 2004, all cancer registrars in the United States were mandated by 
Public Law 107, 260, the Benign Brain Tumour Cancer Registries Amendment Act to collect 
benign brain and central nervous system tumours. 
The reason for reporting benign and borderline brain and CNS tumours are: 
• Benign and borderline CNS tumours cause disruption in normal function similar to that 
caused by malignant CNS tumours. 
• Location of a CNS tumour is as important as tumour behaviour (benign or malignant) 
for morbidity and mortality. 
Benign Tumour Rules 
1. Pilocytic astrocytoma changed from malignant behaviour (/3) to borderline behaviour (/I) 
when the 3 r d edition of the ICD-0 was published. Registrars in the United States were 
instructed to continue to assign the code with malignant behaviour. However, we have 
instead coded these tumours as non-malignant tumours, an important point of divergence 
from US practice. 
2. Where a diagnosis of Schwannoma has been made in an intra-cranial site with no further 
detail, the tumour was coded to "C72.5 Cranial nerve, NOS". The site of intra-cranial 
Schwannoma (9560/0) can be difficult to determine and not always available from 
pathology reports. If the site was indeterminate, the tumour was excluded from the analysis. 
3. A benign meningioma with the site listed as skull should be coded to the cerebral meninges. 
The meninges are between the skull and the intra-cranial tissues. A meningioma would 
originate in the meninges and can invade the skull. Meningioma arising strictly from bone is 
rare. 
4. Orbital meningiomas were excluded from the study if not involving the sphenoid bone. 
5. Classification of meningioma subtypes is still relatively difficult to define at the histological 
level. Where doubt existed regarding subtype, the tumour was first coded to the highest 
grade, and then to the diagnosis of the highest M code (see Table 1.8). 
6. Chondroma (9220/0) is a benign tumour of cartilage cells. These tumours are not currently 
reportable tumours in the United States and have not been included in the current study. 
7. Chordoma is a malignant tumour arising from the embryonic notochord, and 
chondrosarcoma (9220/3) is a malignant tumour of cartilage cells. Although these tumours 
are reportable in the United States (if their site is intra-cranial) they have not been included 
in the current study. 
Malignant Brain Tumour Rules 
1. Where doubt regarding diagnosis exists, tumours were coded to the highest grade. 
2. Where the text diagnosis is given as St Anne Mayo Grade II Astrocytoma, the tumour 
was classified as "Astrocytoma, Not Otherwise Specified". 
3. Where the text diagnosis is given as Grade 4 (of 4) Glioma, the tumour was classified as 
"9440/3 Glioblastoma, NOS". 
4. Where the topography code for a tumour was "not-otherwise-specified" and no further 
information regarding its intra- or extra-cerebral location was found, the entry was 
excluded from the analysis. 
5. A high grade glioma or astrocytoma, if not otherwise specified, was coded to "M 
9380/3 Glioma high-grade, NOS" and "M 9400/3 Astrocytoma high-grade, NOS" 
respectively. Similarly with low grade glioma and astrocytoma. 
Rules for Multiple Primaries 
For large scale cancer registries, determining whether multiple tumours in the same patient are 
two separate entities or a recurrence of the first tumour is a significant issue. The problem is 
compounded by the volume of notifications from multiple different sources received by the 
registries. 
Multiple primary tumours may be considered generally as either synchronous, in which the 
cancers occur at the same time (the SEER definition is within 2 months); and (2) metachronous, 
in which the cancers follow in sequence (more than 2 months apart) (see Figure 1.12).8 9 
Birth Synchronous Metachronous 
(favored for research) 
Death 
Figure 1.12. Pictorial represntation of synchronous and metachronous tumours. Taken from Howe 
2003.89 
There are many viewpoints on the issue of multiple primaries and the clinical significance is not 
always appreciated. This is particularly true of brain and CNS tumours, where tumours can be 
particularly difficult to classify based on histology, creating ambiguity in the definition of 
"separate entities". Further, the timing interval of two months is not always relevant from a 
clinical standpoint. In the current study, we have been relatively conservative in our approach 
to defining multiple primary tumours as this field is still under development. We believe that it 
is a pertinent issue that will need to be addressed in the future, but the relative paucity of 
diagnostic information available to us from analysing only pathology records (sometimes 
including only biopsy results) has lead us to take a more conservative approach to diagnosing 
multiple primary tumours of the brain. 
Rules84'89 
1. Differences in histological subtype are considered by United States Registries according 
to the first three digits of ICD/SNOMED code (see Tables 1.7 and 1.8). If multiple 
tumours occur at the same site, and the first three digits are the same, they are 
considered the same tumour, and one entry is completed. For example, choroid plexus 
carcinoma (M9390) and an ependymoma (M9391). If the first three digits are different, 
the tumours are considered different, and separate entries are completed. For example 
astrocytoma (M9400) and a gemistocytic astrocytoma (M9411). We have not used this 
definition in the current study and instead coded only the more specific diagnosis. 
Exceptions to this rule are if the multiple tumours are of a completely separate tissue of 
origin, for example, grade 4 malignant glioma + meningioma. Although this would tend 
to underestimate our incidence rate, we have been able to use this definition in the 
current study due to our low rate of non-specific codes. Additionally, it was thought that 
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a more conservative approach to incidence determination was more desirable than 
overestimation. 
2. Laterality was used for multiple non-malignant tumours to determine if the tumours 
were two separate primary tumours but not malignant tumours. 
3. If a non-malignant tumour of the same histology and at the same site demonstrated a 
recurrence, it was counted as the same tumour regardless of timeframe (e.g. 2 months, 2 
years, 20 years). If the same situation is encountered for a malignant tumour, the current 
United States practice is to code this as a second primary and complete an additional 
entry. Again, we have opted not to follow this practice so as not to overestimate the 
incidence rate. 
4. A tumour is considered of a different site based on the first three digits of the ICD-0 
codes outline above (Table 1.7). For example, multiple tumours occurring in "C71.0 
Cerebrum" and "C71.2 Temporal Lobe" are the same tumour, and only one entry is 
completed. Multiple tumours occurring in "C70.0-C70.9 Meninges" and "C71.0 
Cerebrum" are considered two different tumours, and two separate entries are 
completed. 
1.9 Statistical Methods 
A multicentre retrospective analysis of histologically confirmed primary benign and malignant 
brain tumours was conducted over the years 2000-2008. -12,200 records from all 13 pathology 
departments servicing all 22 (23 if including the Mater Hospital) tertiary referral centres in the 
ACT/NSW region were collected. Non operative cases were collected from the region's largest 
stereotactic radiosurgery centre. Data were cleaned and analysed according to current 
international coding and statistical practice. 
1.9.1 Hardware/Software 
Descriptive information was tabulated and analysed for total numbers of tumours by age group, 
gender and histology using the following computer programs; 
• Microsoft Excel 2007 version 12.0 
• SPSS software version 17.0. 
• Joinpoint Regression90 
1.9.2 Standardisation 
Age-specific rates are calculated by dividing the number of cases occurring in each specified 
age group by the corresponding population in the same age group expressed as a rate per 
100,000 population. Rates are adjusted for age to aid comparisons between populations that 
differ in age structure. In the current study direct standardisation is used, in which the age-
specific rates are multiplied against a constant population (the 2006 Census population, 2000 
US standard population and WHO World standard 2000-2025 populations). Population data 
were obtained from the Australian Bureau of Statistics Census 2006 data. 
1.9.3 Age Specific Groupings 
All tumours were analysed in accordance with international literature for ease of comparison of 
rates in three major age groupings; 0-19 years, 20-64 years, and 65 years and above.4 
1.9.4 Recurrence of Tumours 
Recurrence of tumours was controlled for at the collection stage by data collectors as previously 
described. These tumours were removed from the final analysis, with only the earliest date of 
diagnosis being included. 
1.9.5 Weighting of Data 
Incidence rates were age standardised using the direct method and weighted against age, gender, 
year and postcode. An average weighting of 3.21%, calculated from both public and private 
Australian hospital separation data (2006-7),91 was applied to the data to account for patient 
outflow from the study region. Inflows were controlled for by manual exclusion of postcode of 
residence. To account for completeness of data as well as migration effect an overall average 
weighting of 5.00% was used. 
1.9.6 Analysis of Significance - Joinpoint Regression 
Log-linear Poisson regression, in which the logarithmic incidence rate (dependent variable) was 
calculated as an exponential function over time (independent variable) and the data (assumed to 
have a Poisson distribution), was used to statistically compare trends over time4'92. Trends were 
expressed as annual percentage change (APC) over the 9-year period, with corresponding two-
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sided 95% confidence intervals (CI) using up to two joinpoints with log-linear modelling for 
average annual percentage change calculation (AAPC). Trends were also analysed in the same 
fashion over the period 2001-2006. 
Joinpoint Regression software version 3.3.1 was obtained from the ACT Cancer Registry and 
used to identify any sharp changes in the incidence over the time period studied. Joinpoints 
correspond to the point in time of a change in trend where several different lines come to a 
juncture. The software fits the simplest joinpoint model that the data will allow using a series of 
permutation tests4 using the Monte Carlo Permutation method for significance testing.92 
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Abstract 
There are conflicting reports from Europe and North America regarding trends in the incidence 
of primary brain tumour, whereas the incidence of primary brain tumours in Australia is 
currently unknown. We aimed to determine the incidence in Australia with age-, sex-, and 
benign-versus-malignant histology-specific analyses. A multicenter study was performed in the 
state of New South Wales (NSW) and the Australian Capital Territory (ACT), which has a 
combined population of >7 million with >97% rate of population retention for medical care. We 
retrospectively mined pathology databases servicing neurosurgical centres in NSW and ACT for 
histologically confirmed primary brain tumours diagnosed from January 2000 through 
December 2008. Data were weighted for patient outflow and data completeness. Incidence rates 
were age standardised and trends analysed using joinpoint analysis. A weighted total of 7651 
primary brain tumours were analysed. The overall US-standardised incidence of primary brain 
tumours was 11.3 cases 100 000 person-years (±0.13; 95% confidence interval, 9.8-12.3) 
during the study period with no significant linear increase. A significant increase in primary 
malignant brain tumours from 2000 to 2008 was observed; this appears to be largely due to an 
increase in malignant tumour incidence in the >65-year age group. This collection represents the 
most contemporary data on primary brain tumour incidence in Australia. Whether the observed 
increase in malignant primary brain tumours, particularly in persons aged >65 years, is due to 
improved detection, diagnosis, and care delivery or a true change in incidence remains 
undetermined. We recommend a direct, uniform, and centralized approach to monitoring 
primary brain tumour incidence that can be independent of multiple interstate cancer registries. 
Keywords: Australia, brain tumour, incidence, primary neoplasm. 
Introduction 
In the 1970s and 1980s, an increased incidence of brain tumours was reported internationally 
and correlated with the emergence of imaging technologies, such as computed tomography (CT) 
and magnetic resonance imaging (MRI),11'16,17 and wider clinical awareness of brain tumours.2 
In Australia, a small number of descriptive epidemiologic studies of primary central nervous 
system (CNS) tumours were published in series from Melbourne, Tasmania, and Adelaide20"23 
from the early 1990s. One Victorian study20 of 4577 tumours reported age standardised 
incidence rates of malignant CNS tumours of 5.0 cases per 100 000 males and 3.4 cases per 100 
000 females but reported no significant trends during the period 1986-1988 regarding specific 
histological subtypes. The other Victorian study21 analysed 3575 cases of primary benign and 
malignant brain tumours over the period 1982-1990, with no clear trend in incidence. The 
Tasmanian study22 analysed 1752 cases from 2 registries during the period 1978-1992 and 
reported increasing age-standardised primary brain cancer incidence rates in males (from 16.3 to 
26.2 cases per 100 000 person-years) and females (from 9.7 to 18.0 cases per 100 000 person-
years) aged >75 years, most prominently in cases of glioblastoma multiforme (GBM). The 
Adelaide study23 was a short study of a low sample population, showing an increased risk of 
glioma among women who reported working with cathode-ray tubes. During the early 1990s, 
when use of CT and MRI technology became widespread in Australia, no change in national 
brain cancer incidence was observed by the Australian Institute of Health and Welfare 
(AIHW). In fact, a decrease was observed, particularly for females. Despite changes in brain 
tumour pathology classification that occurred during the AIHW report canvassing period of 
1982-2004,94 again no significant trends were demonstrated in the AIHW data (Figure 2.1). 
Figure 2.1. Incidence data calculated by the Australian Institute of Health and Welfare (AIHW) for 
"Malignant neoplasm of brain" (International Classification of Diseases, 10th Revision, C71) over the 
period 1982-2004.9 3 
The incidence represented in the graph above is age standardised using 2001 Australian census data as the 
standard population. According to the AIHW graph, little change in the brain tumour incidence has been 
seen in Australia over 22 years, despite changes in reporting, classification, and population demographics 
during this time. 
A number of reports regarding primary brain tumour incidence are derived from North 
American 4 , 7 " 1 0 ' 1 7 and European 2 ' 1 6 sources. One of the most comprehensive is the 2007-2008 
Statistical Report of the Central Brain Tumour Registry of the United States (CBTRUS) 1 0 which 
provides a primary CNS tumour age-adjusted incidence of 18.2 cases per 100 000 people in 
2004. According to the 2002-2003 Statistical Report of CBTRUS, 7 the incidence was 13.4 cases 
per 100 000 people in 1995. Given that CBTRUS reports CNS tumour incidence age-adjusted to 
the 2000 US standard population and that the period of these reports is well embedded in the 
MRI era in the United States, the observed increase in incidence of -36% in <1 decade is not 
likely to be adequately explained by an "aging population" or by "better diagnosis." However, 
the change may in part be due to variations in methodologies used by sources contributing to the 
CBTRUS database and to delayed tumour reporting or "late ascertainment"1 5 from its 15-19 
cooperating state registries. Given the limited data regarding the primary brain tumour incidence 
from Australasian sources, our goal was to determine the incidence in Australia with age-, sex-, 
and benign versus malignant histology-specific analyses and trends. 
Materials and Methods 
Database 
A retrospective multicenter analysis was performed from January 2009 through August 2010 of 
all 13 pathology databases servicing the 24 neurosurgical centres, including all major teaching 
hospitals, in the ACT and NSW recording tumours diagnosed during the period from 2000 
through 2008. The population of NSW and ACT increased from 6.8 to 7.3 million people from 
2000 to 2008. Ethics approval was granted by the NSW Cancer Institute for the collection of de-
identified data from all nominated centres (see Acknowledgements). Databases were queried 
based on the Systematized Nomenclature of Medicine, International Classification of Diseases, 
10th Edition (ICD-10), or text diagnoses using either specifically written search programs or 
pre-existing database search engines by a nominated data collector at the site. The use of fully 
identifiable data at the site allowed for control of repeated presentations to that institution prior 
to de-identification. Data were initially collected for the years 1994-2008, with complete data 
from all centres available from mid-1999. 
Inclusion and Exclusion Criteria 
Approximately 12 000 records were analysed for the period of diagnosis (2000-2008), with 
exclusion of records based on diagnosis, topography, and completeness, yielding a total of 7251 
records for final analysis. All tumours were microscopically confirmed. Systemic lymphoma 
and metastatic, extracerebral, and germ cell tumours (n = 1800) were excluded from the 
analysis. Tumours in patients from overseas or other Australian states and territories were also 
excluded from the analysis (n = 450). Discrepancies in data completeness were followed up 
with the collecting institution, and if further specific searches did not yield more complete data, 
the records were excluded from the analysis (n = 50). A large number of re-entrant and 
recurrence data were excluded (n = 2450), the majority (56%) of which came from the 
conglomeration of 4 databases at the 1 centre. The analysis included pituitary, craniopharyngeal 
duct, and pineal tumours; haemangioma; hemangiopericytoma; primary central nervous system 
lymphoma; and cranial nerve tumours (Supplemental Appendix 1). 
Coding and Grading 
ICD-10 and SNOMED classification systems were used to code all records at the central site by 
a limited number of professional coders to maximize consistency of coding. Reporting and 
coding rules were followed according to the 2004 guidelines of the Centres for Disease Control 
and Prevention,95 with the important exception that pilocytic astrocytoma was coded as a benign 
rather than a malignant tumour. Tumours were graded according to the 2007 World Health 
Organization (WHO) Classification of Tumours publication82 and assigned topography 
according to the Surveillance, Epidemiology, and End Results (SEER) program coding advice. 
The initial—but not any re-presenting—diagnosis of each patient was used for our analysis. If 2 
separate entries for the same patient differed in tumour grade, the higher grade of tumour was 
used, provided that the entries occurred within 8 weeks of each other. If the time difference in 
entries was greater than this period, the initial diagnosis and grade were used. 
Population Selection and Standardisation 
The ACT and NSW populations were used to benefit from the relatively low outward migration 
rate. Cross-border flows were estimated using 2008 Australian Hospital Statistics data for public 
and private hospitals 1 and an overall weighting for patient outflow, inflow, and data 
completeness of 5% was used. Population data were obtained from the Australian Bureau of 
Statistics Census 2006. Incidence rates were age adjusted using the direct method and were 
standardised to the 2001 Australian Standard and 2006 Australian Census population in 5-year 
age groupings. Incidence rates were also standardised to the 2000 US Standard Population and 
2000 World Standard Population using the direct method of analysis. Unless otherwise 
specified, reporting of incidence rates has been limited to US-standardised rates for ease of 
comparison with existing literature. 
Statistical Analysis 
Descriptive information was tabulated for total numbers of tumours by age group, sex, and 
histology in both Microsoft Excel, version 2007, and SPSS software, version 17.0. Log-linear 
Poisson regression in which the logarithmic incidence rate (dependent variable) was calculated 
as an exponential function over time (independent variable) and in which the data were assumed 
to have a Poisson distribution was used to statistically compare trends over time.4'97 Trends 
were expressed as annual percentage change (APC) over the 9-year period, with corresponding 
2-sided 95% confidence intervals (CIs) using up to 2 joinpoints with log-linear modelling for 
average annual percentage change calculation (AAPC). Joinpoint Regression software, version 
3.3.1, was obtained from the ACT Cancer Registry and was used to identify any sharp changes 
in the incidence during the time period studied. Joinpoints correspond to the point in time of a 
change in trend in which several different lines come to a juncture. The software fits the 
simplest joinpoint model that the data will allow using a series of permutation tests4 using the 
Monte Carlo Permutation method for significance testing.9 7 Incidence rates are expressed as 
mean ± standard deviation. 
Results 
Description of the Data 
The final weighted data set included 7651 primary brain tumours, with a total of 698-935 
tumours per year from 2000-2008. Persons aged 0-19 years represented ~6% of all tumours, 
whereas the majority (63%) of tumours were represented in persons aged 20-64 years, with the 
remaining 30% represented by persons >65 years. Relatively equal proportions of tumours were 
represented among male and female patients (49% and 51%, respectively). Fifty-eight percent 
of tumours were benign (WHO grade I or II), whereas 42% were malignant (WHO grade III or 
IV), with minimal (cumulative 3.1%) representation in the data of nonspecific codes (Table 
2.1). Elderly adults (age, >65 years) recorded the largest proportion of malignant tumours 
(52%), whereas children (age, 0-19 years) and adults (age, 20-65 years) demonstrated a 
preponderance of benign tumours, with only 34% and 38% being malignant, respectively 
(Figure 2.2a)). 
Morphology Frequency, no. Percentage 
Astrocytoma high-grade, NOS 74 1.0 
Astrocytoma low-grade, NOS 82 1.1 
Glioma high-grade, NOS 62 0.8 
Glioma low-grade, NOS 11 0.2 
Table 2.1. Frequency and percentage of total of nonspecific (NOS) codes 
Incidence Trends 
This study found an overall US-standardised incidence rate for primary brain tumours of 11.3 
cases per 100 000 person-years (±0.13; 95% CI, 9.8-12.3 cases per 100 000 person-years during 
the study period, with no significant linear increase observed (Figure 2.2b)). An overall crude 
rate of 11.8 cases per 100 000 person-years (range, 10.1-12.7 cases per 100 000 person-years) 
was calculated for the study period. Rates were slightly higher among males but more variable 
in females (11.7 + 0.26 cases per 100 000 person-years [95% CI, 10.0- 12.6 cases per 100 000 
person-years] and 11.4 + 0.25 cases per 100 000 person-years [95% CI, 10.0-13.0 cases per 100 
000 person-years, respectively), but again with no obvious linear increase and well below latest 
reported US rates (Figure 2.2c)). No significant trends were demonstrated for benign tumours 
when analysed by sex and age groupings. Of note, an overall significant increase in primary 
malignant brain tumours was observed over the study period from 2000 to 2008 (APC, 3.9; 
95%CI, 2.4- 5.4) (Figure 2.3a)), particularly since 2004 (overall AAPC, 3.9; 95% CI, 2.6-5.2). 
Of note, data since 2004 have not yet been published by the AIHW, and only preliminary data 
from the NSW Cancer Registry are available (see below). This overall increasing trend in 
malignant tumours was consistent for both males (APC, 2.3; 95% CI, 0.4-4.2) and females 
(APC, 2.3; 95% CI, 0.3- 4.3)—again, particularly since 2004 (AAPC for males, 2.3 [95% CI, 
0 . 7 - 3 . 9 ] ; A A P C for f ema les , 2 .3 [ 9 5 % CI . 0 . 6 - 4 . 0 ] ) (F igure 2 .3b)) . Dr iv ing this inc rease is the 
increase in ma l ignan t t u m o u r s in the >65 -yea r age g r o u p ( A P C , 1.54; 9 5 % CI, 0 . 1 - 3 . 0 ) ( F i g u r e 
2.3c)) , wi th no s igni f icant d i f f e r ence by sex (Tab le 2.2). 
Subgroup No. of cases APC (95% CI) 
All persons 
Brain tumours 
Benign tumours 
Malignant tumours 
Malignant tumours 
Males 
Females 
Persons aged >65 years 
Malignant tumours 
Men 
Women 
7651 
4445 
3206 
1907 
1299 
1223 
693 
530 
1.2 
1.7 
3.9b 
2.3 
2.3b 
1.54b 
2.6 
0.6 
20.6 to 3.0 
21.4 to 4.9 
2.4 to 5.4 
0.4 to 4.2 
0.3 to 4.3 
0.1 to 3.0 
22.7 to 8.2 
22.1 to 3.4 
Table 2.2. Overall incidence rate trends, by annual percentage change (APC), for primary brain tumours 
from the Australian Capital Territory and New South Wales populations3 
CI indicates confidence intervals. 
aAll models use exponential Poisson regression and were adjusted for age group. 
bDenotes significance of the APC. Note that APC values are statistically significant from the value 0. 
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Figure 2.2b) Incidences of all primary brain tumours, by calendar year, from the Australian Capital 
Territory (ACT) and New South Wales (NSW) populations. Rates are age standardised to the 2001 
Australian Standard, the 2000 US standard, and 2000 World standard populations. To avoid congestion, 
confidence intervals are displayed for the US-standardised trend only. 
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Figure 2.2c) US-standardised incidence rates, by sex, of all primary brain tumours from the ACT and 
NSW populations by calendar year. Confidence intervals are displayed. The latest (2008) Central Brain 
Tumour Registry of the United States incidence of 18.2 cases per 100 000 person-years is shown.10 
Figure 2.3a) US-standardised brain tumour incidence rates by WHO grade, by calendar year, from the 
Australian Capital Territory (ACT) and New South Wales (NSW) populations. Confidence intervals are 
displayed. Benign, World Health Organization (WHO) grades I and II; malignant, WHO grades III and 
IV. 
Figure 2.3b) US-standardised malignant brain tumour incidence rates, by sex and calendar year, from the 
ACT and NSW populations. 
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Figure 2.3c) Malignant brain tumour incidence rates, by age grouping and calendar year, from the ACT and NSW populations. 
Discussion 
An overall increase in age-adjusted incidence rates of primary malignant brain tumours was 
observed in the ACT and NSW during the period 2000-2008, particularly among persons aged 
>65 years. One hundred percent of tumours were histologically confirmed, with data collected 
from 13 pathology units (i.e., directly from the source of histological diagnosis), servicing an 
area of >7-million persons with minimal outward migration for health services. Similar 
increases in the primary brain tumour incidence in the elderly population have been reported 
elsewhere around the world, 3 , 1 6 but to our knowledge, no comparable study has been conducted 
in Australasia. 
For comparison purposes, local cancer registry data were obtained from yearly cancer incidence 
reports from November, 2006 to December, 2 0 0 9 , 2 8 , 6 2 ' 6 4 ' 9 8 - 1 0 0 with numbers prior to 2004 for 
the ACT being average annual numbers. Case numbers were adjusted for percentage of 
histological verification (mean, -85%) on the basis of published rates to aid comparison. 
Overall raw numbers from the current study are less than the combined ACT and NSW Cancer 
Registry numbers, particularly in the earlier years of the study period (Figure 2.4)). The 
difference in raw numbers between the 2 sets may reflect a different definition of "malignant" 
brain tumours. More notable, however, is an upward trend in raw tumour numbers seen in both 
data sets, but most marked in our study, particularly in the latest years of 2007 and 2008. This 
observed increase in malignant tumours noted by us is curious, considering that no such reports 
have been issued by the Australian cancer registries. Possible explanations for the discrepancy 
in raw numbers between our data set and those of the registries include differences in diagnostic 
and histological definitions and data lag time or "late ascertainment" by the NSW Cancer 
Registry.15 
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Figure 2.4a) Comparison of case numbers for total malignant brain tumours, Australian Capital Territory 
(ACT) and New South Wales (NSW), 2000-2008, by sex between the current study and the combined 
data from the NSW Central Cancer Registry (CCR) 
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Figure 2.4b) Comparison of case numbers for male malignant brain tumours, Australian Capital Territory 
(ACT) and New South Wales (NSW), 2000-2008, by sex between the current study and the combined 
data from the NSW Central Cancer Registry ( C C R ) 2 8 ' 6 2 ' 6 4 ' 1 0 0 and the ACT Cancer Registry 1 0 , 1 6 ' 9 8 - 9 9 
Figure 2.4c) Comparison of case numbers for female malignant brain tumours, Australian Capital 
Territory (ACT) and New South Wales (NSW), 2000-2008, by sex between the current study and the 
combined data from the NSW Central Cancer Registry ( C C R ) 2 8 ' 6 2 ' 6 4 1 1 0 0 and the ACT Cancer Registry.10' 16,98,99 6 3 
Case numbers have been adjusted according to published histological verification rates per year and by 
sex (mean, -85%) to aid comparison. The Australian Institute of Health and Welfare mentioned 
previously is the Australian Government body monitoring brain tumour data collection across the whole 
nation, whereas the aforementioned sources are state based. For comparison purposes, we have included 
all World Health Organization grade II tumours with/3 (malignant) behaviour per current collection 
practices of Australian registries, despite the ambiguity this creates in definition of tumours as 
benign/non-malignant. 
Definition of Diagnosis 
Cancer registries and previous independent studies have included non-operative brain tumour 
diagnoses as well as tumours diagnosed at autopsy. 1 0 ' 1 6 Although this approach yields large 
sample sizes, our study aimed to provide a greater acuity in assessment of histological subtypes 
that is lost upon inclusion of tumours diagnosed solely on the basis of imaging technology, 
conservative (i.e., non-operative) treatment, or clinical decision-making. Of importance, 
pathology data represent the primary point of diagnosis, and provide the most up to date 
information on histology, topography, and time of diagnosis—a definition more consistent with 
the European Network of Cancer Registries.101 Our study involved the histological confirmation 
of every tumour. Other sources have argued that the timing of diagnosis should be based on the 
date of first clinical diagnosis.10 This approach is justified for tumours that are either inoperable 
or slow growing and thus allows capture of tumours with a "wait-and-watch" approach. 
Logistically, however, this was beyond the scope of the current study but would be an 
interesting approach to adopt in the future as an additional component of primary brain tumour 
incidence. Our local Australian cancer registries quote 85% histological confirmation, and a 
15% addition in tumour numbers would no doubt enhance the current study. 
Late Ascertainment 
As previously noted by Clegg et al.,1 delayed reporting may lead to downwardly biased 
incidence trends. The study of 9 cancer registries involved in the SEER program over a 17-year 
period highlighted the importance of "late ascertainment" by comparing reported initial (after a 
standard 2-year delay) and final incidence rates. They found significant differences between 
these rates and estimated a reporting lag time of >4 years. This delay likely applies to our own 
Australian cancer registries, owing to the sheer bulk of processing required to publish incidence 
rates from multiple different sources. We believe that we have minimized the occurrence of this 
bias in our study by referring directly to the data sources themselves—namely, all relevant 
pathology units assessing primary brain tumour specimens in the chosen geographical area. Our 
results may thus be reconciled with increasing rates in later years that have perhaps not yet been 
captured by registry methods. 
Unknown Individual Subtype Trends 
Finally, we suggest suboptimal coverage and reporting of specific histological subtypes by 
current surveillance methods. Unlike the United States, there is no mandatory collection of 
benign brain tumour data in Australia, although we have attempted to collect both benign and 
malignant primary brain tumour data in a timely fashion. We have been unable to access the raw 
data of our local registries, but their public reports quote malignant brain tumour rates in terms 
of International Classification of Diseases, Oncology 3, C71 topography and morphology 
classifications. A number of reports discuss tumours not necessarily considered to be malignant 
brain tumours, such as low-grade astrocytoma, oligodendroglioma, and ependymoma. 2 8 ' 6 2 ' M ' 1 0 0 
Furthermore, the latest report from the NSW Cancer Registry included melanoma, germ cell, 
embryonal, and soft-tissue tumours in its analysis.62 This creates ambiguity in the comparison of 
rates. Finally, an unknown proportion of "unspecified" tumours are used for determination of 
the incidence by the cancer registries. Although this is an unavoidable consequence of their 
collection methods, it is a limitation we have endeavoured to minimize through direct collection 
of histological diagnoses (100% in our study's database versus an average of 85% in our local 
cancer registry databases), as evidenced by a -3% rate of non-specific histological diagnoses in 
our study (Table 2.1). 
Limitations 
The main limitations of the current study are the unavailability of identifiable data throughout 
the entire analysis and uncertainties regarding complete case capture rates. Control for re-
presentations of 1 patient to multiple different institutions was difficult in the current study 
because of the use of multiple separate databases with limited cross-communication. Ethics 
approval for data matching of identifiable data was sought but not granted due to staff 
shortages. We attempted to minimize this error, however, by controlling for repeated 
presentations to the one institution. Retrospective database mining inherently introduces an 
element of uncertainty in data quality that was compounded in the current study by the use of 
multiple different database systems and search methods. Issues around adequate coding of 
diagnoses, database technology, and diligence of data collectors contribute to this issue. The use 
of dedicated data collectors employed by the local pathology units and multiple site visits 
helped minimize this uncertainty. In view of the limitations presented, we need to be cautious in 
our approach to interpretation of the observed increase in primary malignant brain tumours. 
Additional examination of histological subtypes is currently being performed and the authors do 
not suggest an association with reported risk factors in the literature. However, because the 
observed increase in incidence is confined to malignant tumours among persons aged >65 years, 
we question whether an association between greater diagnostic capability/delivery of care 9 4 and 
tumour incidence is at play in the years 2000-2008 in Australia. 
Australia is - 1 decade behind the United States and Europe in terms of the implementation of 
certain imaging technologies, with the introduction of CT and MRI imaging occurring in the 
late 1980s to mid-1990s in the ACT and NSW. Some authors suggest that the latest reported 
increases in incidence from the United States and Europe are not adequately explained by 
advances in imaging technology or a lower clinical threshold for scanning. We believe that 
monitoring of these trends in Australia over the next 10-15 years presents an ideal opportunity 
to discover potential associated risk factors in brain tumour development through the 
establishment of a central nationwide brain tumour registry that examines both benign and 
malignant tumours in a timely fashion. Exclusion of benign tumours produces a tendency to 
underestimate incidence and an undervaluing of the importance of benign brain tumours, some 
of which can progress histologically to cancer. This raises issues of feasibility and whether such 
a collection should be combined with existing brain tumour registries or established as separate 
entity, similar to the recent experience of the Austrian Brain Tumour Registry. 5 4 
Conclusion 
To our knowledge, this collection constitutes the most contemporary data on primary brain 
tumour incidence in the Australasian region. Data were 100% histologically confirmed and were 
mined directly at the coal-face of brain tumour diagnosis from a relatively large and overall 
medically self-contained Australian subpopulation, minimizing the effect of late ascertainment 
of data and providing greater diagnostic specificity. It is unclear at this time whether the 
observed increase in malignant primary brain tumours, particularly among persons aged >65 
years, is due to improved detection, diagnosis, and delivery of care or to a true change in 
incidence. Australian Cancer Registry data have an average lag time of 4 years from collection 
to reporting, an experience shared by CBTRUS.710 Given the current importance of identifying 
risk factors for specific brain tumours,73 which we recognize is beyond the scope of a cancer 
registry, we believe that at an international level, our study supports consideration of the 
establishment of a centralized registry for each nation that (1) directly receives histologically 
confirmed primary brain tumour data from all relevant pathology units, and (2) analyses and 
reports data according to an international agreement regarding the precise definition of primary 
benign versus malignant histological subtypes suitable for collection. 
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Supplementary material containing an appendix to this paper is available online at Neuro-
Oncology (http://neuro-oncologv.oxfordjournals.org/). 
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Abstract 
Background: The incidence of primary brain tumours is currently unknown in Australia. We 
report the second part of a retrospective multicenter study in the state of New South Wales 
(NSW) and the Australian Capital Territory (ACT), a combined population of >7 million with 
>97% retention rate for medical care. 
Methods: Data from histologically-confirmed primary brain tumours diagnosed from January 
2000 through December 2008 were weighted for patient outflow and data completeness, age-
standardised and analysed using joinpoint analysis. 
Results: A significant increasing incidence in glioblastoma multiforme (GBM) was observed in 
the study period (annual percentage change, 2.5; 95% confidence interval, 0.4-4.6, n=2275), 
particularly after 2006. In GBM patients in the >65-year group, significantly increasing 
incidence for men and women combined (APC, 3.0; 95% CI, 0.5-5.6) and men only (APC, 2.9; 
95% CI, 0.1-5.8) were seen. Rising trends in incidence were also seen in meningioma for total 
male population (APC, 5.3; 95% CI, 2.6-8.1, n=515) and males aged 20-64 years (APC, 6.3; 
95% CI, 3.8-8.8). Significantly decreasing incidence trends were observed for Schwannoma for 
the total study population (APC, -3.5; 95% CI, -7.2 - -0.2, n=492), significant in women (APC, -
5.3; 95% CI, -9.9 - -0.5) but not men. 
Conclusion: This collection is the most contemporary data on primary brain tumour incidence 
in Australia. Our registries may observe an increase in malignant tumours in the next few years 
that they are not detecting now due to late ascertainment. We recommend a direct, uniform and 
centralized approach to monitoring primary brain tumour incidence, including the introduction 
of non-malignant data collection. 
Key Words: Australia, brain tumour, cancer, incidence, late ascertainment, primary neoplasm 
Introduction 
Trends in the overall incidence of primary brain tumours have been widely reported as either 
increasing, 2 ' 4 ' 1 6 ' 7 5 stable, 1 0 2 , 1 0 3 or decreasing.102 A large Danish study2 of 11,935 cases of adult 
glioma between 1943 and 1997 reported a 1.7-fold increase in incidence from 2.2 to 3.7 cases 
per 100,000 person-years. Histological confirmation was found in almost all glioma cases in the 
last 20 years of that study. The authors also examined 4845 cases of adult meningioma during 
the same period and reported a 3.9-fold increase from 0.61 to 2.42 cases per 100,000 person-
years. Surprisingly, the increasing incidence trend over time associated with glioma was seen to 
plateau after 1968, well before Denmark's introduction to computerized tomography (CT) in 
1978 and magnetic resonance imaging (MRI) in 1985. On the other hand, the authors found that 
the incidence of meningioma continued to rise throughout the years studied, possibly related to 
a lower clinical threshold for imaging older patients. A second study of 18,630 cases of adult 
primary intracranial meningioma encompassed Denmark, Finland, Norway and Sweden from 
1968 through 1997.5" Increasing trends were again noted in both males (1.4 to 1.9 cases per 
100,000 person-years) and females (2.6 to 4.5 cases per 100,000 person-years). The authors 
suggested this was due to widespread use of new imaging technologies.52 The updated study 
however, covering the same region from 1974 to 2003 and almost 60,000 patients aged 20-79 
years, showed increasing incidence rates for glioma and meningioma overall, but flattening of 
trends in the latest years 1998-2003.51 
In the United States, Inskip et al. 1 0 analysed almost 40,000 brain cancer cases over a 30 year 
period from 1977 to 2006 using the SEER database and reported stable, even decreasing, overall 
incidence rates in most age groups. During the earlier study period 1977-1991, large and 
statistically significant increases were demonstrated in persons <30 years of age and >65 years 
of age. In the later study period (1991-2006), stable incidence was reported across the board, 
with the exception of females aged 20-29 years who showed a significant increasing trend in 
frontal lobe malignancies (APC, 4.27; CI, 1.88-6.71). Interestingly, although incorporating brain 
cancer (i.e. including metastatic disease but excluding meningioma and lymphoma) and thus 
not directly comparable to the current study, the authors highlight expected delay-adjustment 
with upward revision of incidence rates, so the observed increases may in fact be 
underestimates. This phenomenon termed "late ascertainment"15 is common to many cancer 
registries and is associated with a data lag of 3-5 years that is also reflected in Australian 
registries. 
An absence of any overall trends in the incidence of brain cancers in both males and females in 
the population of England in the period 1998-2007 was recently reported.1 0 4 This stable 
incidence trend, along with the levelling off of incidence trends in four Nordic countries during 
1974-2003 has led some authors to conclude that mobile phones result in no significant 
increased risk of brain tumours. 1 However, the European study 1 was criticized for stopping 
case ascertainment in 2003,58 and for not presenting results stratified by anatomic site.105 In this 
regard, our recently published Australian study106 reported a significant increase in malignant 
tumour incidence most evident from 2006 onwards. Further, the English study that reported no 
change in overall incidence did report results stratified by anatomic site and found significantly 
increased rates of tumours of the temporal lobe in both men and women, and increased rates in 
frontal lobe tumours in men only. Such changes may not be due to chance occurrence.107 
Regardless of risk association,43'58'73 these data reflect an ongoing need for incidence trend 
monitoring of both malignant and non-malignant tumours. 
Given the limited data regarding primary brain tumour incidence from Australasian sources, our 
goal was to develop an understanding of the Australian incidence with age-, sex-, and 
pathology-specific analyses and trends. Further, because Australia lags behind the US and 
Europe by several years in terms of imaging technology and mobile phone use, we feel that now 
is an optimal time to begin data collection and pave the way for future association studies. 
Materials and Methods 
A full account of our methods has been published recently.106 
Database 
A retrospective multicenter analysis was performed from January 2009 through July 2010 of all 
13 pathology databases servicing the 24 neurosurgical centres, including all major teaching 
hospitals, in the ACT and NSW recording brain tumours diagnosed during the period from 
2000-2008. The population of NSW and ACT increased from 6.8 to 7.3 million people between 
2000 and 2008. Databases were queried with control for repeated presentations and tumoural 
recurrence to individual institutions. Data was initially collected for the years 1994-2008, with 
complete data from all centres available from mid-1999.106 
Inclusion and exclusion criteria 
Approximately 12,000 records were analysed for the period of diagnosis (2000-2008), with 
exclusion of records based on diagnosis, topography, and completeness, yielding a total of 7251 
records for final analysis. All tumours were microscopically confirmed at a single pathology 
department but no independent review was performed as this was beyond the scope of the 
current study. Systemic lymphoma, metastatic, extracerebral and germ cell tumours were 
excluded from the analysis (not presented but discussed in our previous paper), as were tumours 
in patients from overseas or other Australian states and territories. The analysis included 
pituitary, craniopharyngeal duct and pineal tumours, haemangioma, hemangiopericytoma, 
primary central nervous system (CNS) lymphoma, and cranial nerve tumours.1 
Coding and grading 
ICD-10 and SNOMED classification systems were used to code all records according 2004 
guidelines of the Centres for Disease Control and Prevention.95 Tumours were graded according 
to the 2007 World Health Organization (WHO) Classification of Tumours publication.82 The 
initial but not any re-presenting diagnosis of each patient was used for our analysis.1 0 6 
Standardisation and statistical analysis 
The ACT and NSW populations were used to benefit from the relatively low outward migration 
rate. Cross-border flows were estimated at 3.2% using 2008 Australian Hospital Statistics data 
for public and private hospitals91 and an overall weighting for patient outflow, inflow, and data 
completeness of 5% was used. Incidence rates were age-adjusted using the direct method and 
were standardised to the 2001 Australian Standard and 2006 Australian Census population in 5-
year age groupings. Incidence rates were also standardised to the 2000 US Standard Population 
and 2000 World Standard Population using the direct method of analysis. Unless otherwise 
specified, reporting of incidence rates has been limited to US-standardised rates for ease of 
comparison with existing literature. Log-linear Poisson regression was used to statistically 
compare trends over time.4' 7 ' 1 0 6 Trends were expressed as annual percentage change (APC) 
over the 9-year period, with corresponding 2-sided 95% confidence intervals (CI) using up to 2 
joinpoints with log-linear modelling for average annual percentage change calculation (AAPC). 
Trends were also analysed in the same fashion over the period 2001-2006. Joinpoint Regression 
software version 3.3.1 was used to identify any sharp changes in incidence as described 
elsewhere.1 
Results 
Incidence by pathology 
The most frequently encountered histology was a malignant tumour, glioblastoma multiforme 
(GBM; 30%, n=2275) followed by a predominantly non-malignant tumour, meningioma (24%, 
n=1865). Pituitary tumours and Schwannoma accounted for 13% (n=960) and 6% (n=492) of all 
tumours, respectively. Primary malignant tumour incidence was found to have increased by 
approximately 35% between 2000-2008 (APC, 3.9; 95% CI, 2.4-5.4) with most of this increase 
occurring after 2006 (Figures 3.1a), 3.1b), 3.1c)). 1 0 6 
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Figure 3.1a) US-standardised brain tumour incidence rates for total population by major histological 
groupings by calendar year from the Australian Capital Territory (ACT) and New South Wales(NSW) 
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Figure 3.1b) US-standardised brain tumour incidence rates for male population by major histological 
groupings by calendar year from the Australian Capital Territory (ACT) and New South Wales(NSW) 
populations. 
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Figure 3.1c) US-standardised brain tumour incidence rates for female population by major histological 
groupings by calendar year from the Australian Capital Territory (ACT) and New South Wales(NSW) 
populations. 
Confidence intervals are displayed. * denotes significance. 
Subgroup No. of cases APC (95% CI) 
Glioblastoma multiforme 
All persons 
Women 
Men 
Persons aged >65 years 
All 
Women 
Men 
Meningioma 
All persons 
Women 
Men 
Persons aged 20 to 64years 
Women 
Men 
Schwannoma 
All persons 
Women 
Men 
2275 
885 
1390 
1027 
438 
589 
1865 
1350 
515 
1227 
936 
291 
491 
258 
233 
2.5* 
2.2 
2.6 
3.0* 
3.2 
2.9* 
1.9 
0.6 
5.3* 
1.9 
0.5 
6.3* 
-3.5* 
-5.3* 
-1.0 
0.4,4.6 
-1.5,6.0 
-0.1,5.4 
0.5,5.6 
-2.9,9.6 
0.1,5.8 
-1.6,5.5 
-3.6,5.0 
2.6,8.1 
-0.9,4.9 
-3.2,4.4 
3.8, 8.8 
-7.2, -0.2 
-9.9, -0.5 
-7.9,6.3 
Table 3.1: Overall incidence rate trends, by annual percentage change (APC), for primary brain tumours 
from the Australian Capital Territory and New South Wales populations**. 
CI indicates confidence intervals. 
**A11 models use exponential Poisson regression and were adjusted for age group. 
* Denotes significance of the APC. Note that APC values are statistically significant from the value 0. 
Glioblastoma 
A weighted total of 2275 GBM (n=2197,96.5%), gliosarcoma (n=62, 2.7%) and giant cell 
glioblastoma (n=17, 0.7%) were collected during the years 2000-2008, with a 1.6:1 male:female 
predominance. A significant increase in incidence of all GBM from 3.22 to 3.96 cases per 
100,000 person-years was observed in the study period of 2000-2008 (APC, 2.5; 95% CI, 0.4-
4.6) (Figure 3.1a)). During the same period, in patients in the >65-year group, the incidence 
rates increased from 10.30 to 14.42 cases per 100,000 person-years (APC, 3.0; 95% CI, 0.5-5.6) 
for both men and women combined (Figure 3.2). This significant increase held for men (13.55 
to 18.71 cases per 100,000 person-years; APC, 2.9; 95% CI, 0.1-5.8) but not for women (7.77 to 
10.92 cases per 100,000 person-years; APC, 3.2; 95% CI, -2.9 - 9.6) (Table 3.1; Figure 3.2). 
Figure 3.2: US-standardised brain tumour incidence rates for glioblastoma multiforme (GBM) by 
calendar year from the Australian Capital Territory (ACT) and New South Wales (NSW) populations for 
total population, total population aged 65 and above, and male population aged 65 and above. 
Confidence intervals are displayed. All three trends show significant (*) increase using joinpoint analysis. 
Meningioma 
A weighted total of 1865 meningiomas were collected during the period 2000-2008, with a 
2.6:1 female:male predominance. Of these tumours, 92% were WHO Grade 1,7% WHO II, and 
1% WHO III. From 2000-2008 a significantly increasing incidence trend in meningioma in 
men, both for total male population (APC, 5.3; 95% CI, 2.6-8.1, n=515) and in males aged 20-
64 years (APC, 6.3; 95% CI, 3.8-8.8) was observed (Table 3.1; Figures 3.1b) & 3.3). Incidence 
rates ranged from 1.1 to 1.8 cases per 100,000 person-years in the period 2000-2008 for all 
meningioma, and 1.2 to 2.0 cases per 100,000 person-years for men aged 20 to 64. 
Figure 3.3: US-standardised brain tumour incidence rates for meningioma for total male population, and 
male population aged 20-64 years by calendar year from the Australian Capital Territory (ACT) and New 
South Wales (NSW) populations. 
Confidence intervals are displayed. Both trends show significant (*) increase using joinpoint analysis. 
Nerve sheath tumours 
A weighted total of 492 nerve sheath tumours were used in the analysis, with a 1.1:1 
female:male ratio. The current collection did not include extra-cerebral nerve sheath tumours, so 
the majority (76%) were labelled acoustic neuroma/vestibular Schwannoma, 12% labelled as 
cerebellar and 12% as cerebral not-otherwise specified (NOS). A significantly decreasing trend 
was observed in all Schwannomas for the period 2000-2008 (APC, -3.5; 95% CI, -7.2- -0.2), 
that was significantly present in women (APC, -5.3; 95% CI, -9.9 - -0.5) but not in men (APC, -
1.0; 95% CI, -7.9 - 6.3) (Table 3.1; Figures 3.1a), b), c) & 3.4). Part of our dataset on non-
malignant tumours included collection of non-histologically-confirmed data from the largest 
stereotactic radiosurgery (SRS) centre in the region. Even upon exclusion of the SRS data, 
analysis for both meningioma and nerve sheath tumours in the period 2000-2008 maintained the 
significant trends described above (data not shown). 
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Figure 3.4: US-standardised brain tumour incidence rates, by sex, of Schwannoma from the Australian 
Capital Territory (ACT) and New South Wales (NSW) populations, by calendar year. 
Confidence intervals are displayed. * denotes significance. 
Discussion 
The key finding of this two-part study 1 0 6 is a significant increase in primary malignant brain 
tumours, particularly GBM, occurring over the time period 2000-2008, especially evident after 
2006. 
Glioblastoma 
The recent published incidence rates (2004-2006) from the Central Brain Tumour Registry of 
the United States (CBTRUS) for GBM (3.17 +0.04 cases per 100,000 person-years)1 0 are 
similar to rates from the present study averaged over the period (-3.4 ± 0.51 cases per 100,000 
person-years). Incidence rates and trends over the period 2000-2008 from our study are also 
similar to the Danish results discussed above.2 Further, when our data were analysed using 
multiple joinpoints in the time period 2001-2006, that is, the years for which there are 
corresponding published Australian cancer registry data, no significant increase was seen (data 
not presented). Our findings are therefore also consistent with the most up-to-date data on 
malignant tumours from our local cancer registries, except that the increasing trend we report 
herein is largely due to the higher brain cancer incidence observed in the years 2007 and 2008, 
data that may not have as yet been received and/or analysed by Australian registries. Our 
relatively early access to these data via the direct analysis of local pathology databases has been 
discussed in the first part of this study. 1 0 6 
Meningioma 
Significant trends were observed for meningioma in the period 2000-2008, particularly in men. 
These trends held significance when non-histologically-confirmed tumours from the region's 
largest SRS centre were excluded (data not presented).The 2010 CBTRUS report for data from 
the period 2004-2006 quotes the incidence of male meningioma as 3.76 (95% CI, 3.70-3.83) 
cases per 100,000 person-years.1 0 This rate is higher than US standardised rates from the present 
study. Trend analysis using the same database (CBTRUS) over the years 1985-1999 reported an 
increase in overall meningioma incidence (AAPC, 1.5),4 but no significant trends by gender. 
Incidence rates from the current study are thus more akin to observed rates and increasing trends 
for meningioma in Europe during the approximate period 1970-2000 described above. 
Nerve sheath tumours 
Female nerve-sheath tumours in the 2010 CBTRUS publication quote an incidence rate of 1.60 
(95% CI, 1.57-1.64) cases per 100,000 person-years.1 0 Although these rates are higher than US 
standardised rates for vestibular Schwannoma in the present study, CBTRUS data also include 
both malignant and non-malignant nerve sheath tumours in the quoted rate. A study examining 
vestibular Schwannoma data from two sources (CBTRUS 1995-1999, and the Los Angeles 
County Cancer Surveillance Program 1995-1998) found average annual incidence rates of 0.55 
(95% CI, 0.51-0.58) and 0.80 (95% CI, 0.66-0.94) cases per 100,000 person-years respectively 
in females. 4 6 Incidence for nerve-sheath tumours was approximately 1.07 cases per 100,000 
person-years for both sources in the same study. These rates are more in keeping with the 
present study. 
A recent study from Denmark presenting 2283 cases of vestibular Schwannoma over a 42-year 
study period reported increasing incidence from 0.31 to 2.28 tumours per 100,000 person-years 
between 1976 and 2004, and stabilizing at 1.94 tumours per 100,000 person-years in 2008. 1 0 8 
The study is unique in that all cases of vestibular Schwannoma in Denmark are referred to a 
single centre for treatment, and the data have been prospectively entered into a database since 
1976. Increased clinical awareness and technological advances in MR imaging technology seem 
to have accounted for the increase in incidence and the 2008 rate is considered by those authors 
as a true incidence. Australia is only 5-10 years behind Denmark in terms of imaging 
technology, with the first MR scanner in Denmark being introduced in 1985. Our rates of 
vestibular Schwannoma are considerably less than those reported in Denmark, and show a 
decreasing trend. This may be due in part to changing clinical practice in the treatment of 
vestibular Schwannoma towards non-operative (SRS) management. 
Strengths and limitations of this study 
We are primarily concerned with histologically-confirmed primary intracerebral tumours and 
our collection excludes tumours diagnosed solely based on clinical, imaging and post-mortem 
examination. Our study has a relatively high rate of histological specificity, with a low rate of 
non-specific codes used, 1 0 6 and we believe this strength will allow more precise and timely trend 
analysis through sourcing of brain tumour incidence data at the point of definitive diagnosis, 
namely, the pathology department. We also consider it a methodological strength that a different 
definition of "malignant" tumours has been used in the present study when compared to 
established Australian practice. Our definition is based on WHO Grade III and IV tumours and 
excludes lymphoma, metastatic disease, germ cell and extracerebral tumours, whereas 
Australian registries include WHO Grade II tumours of uncertain/borderline behaviour amongst 
others in their definition. 2 8 , 6 2 , 1 0 0 , 1 0 6 Defining brain tumours in terms of the WHO 
Classification of CNS tumours allows the use of the most contemporary and widely used 
classification system in the international literature, and thus a more optimal comparison of rates 
within and between countries. 
The limitations of our study have been described in our preceding publication. 1 0 6 Briefly, the 
main limitations we encountered involved uncertainty regarding completeness of case capture 
rates due to lack of standardisation, lack of independent pathological review of diagnoses, lack 
of multiple sources of notification, the presence of cross-talk between databases and lack of 
control for re-entry of data from the one patient visiting multiple different institutions in the 
study area (an uncommon situation anecdotally). Although we have attempted to validate our 
incidence rates through direct comparison of malignant rates with our gold standard in Australia 
(i.e. the Cancer Registries), we acknowledge that there is no such comparator for non-malignant 
tumours in Australia. This implies a cautious approach when interpreting our published non-
malignant tumour rates but at the same time provides the first Australian insight into their "ball-
park" incidence rates. 
Conclusion 
The current study represents the most contemporary collection of primary brain tumours in 
Australia and underpins the importance of continued monitoring. We observed significant 
increases in incidence rates for GBM, particularly after 2006, and meningioma at rates 
comparable to recent US and European data. Incidence trends for Schwannoma, in contrast to 
the European experience, were observed to be significantly decreasing, but were akin to 
reported rates from the US. We recommend a direct, uniform and centralized approach to 
monitoring primary brain tumour incidence, as well as the introduction of non-malignant data 
collection. 
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Chapter 4. Discussion 
The current study represents the best estimate of brain tumour data in Australia, including both 
benign and malignant rates for all primary intra-cranial tumours. 
Chapter 3 describes the overall incidence trends for the period 2000-2008 analysed by age, 
gender and WHO grade (published March 2011). A significant increase in primary malignant 
brain tumours was observed; that appeared to be largely accounted for by the increase in 
malignant tumours in the 65+ age group. 
Chapter 4 presents subtype analysis of incidence data for the same period (2000-2008) with 
comparison to ACT/NSW Cancer Registry malignant tumour data (accepted for publication). 
Our results follow a very similar trend to the ACT/NSW Cancer Registry published trends for 
malignant tumours in the period 2001-2006, suggesting a sound collection methodology in this 
period. Data from 2007 and 2008 is not yet available from the Cancer Registries. 
An important trend resulting from the benign data collection in the present study was an 
increasing trend in the years 2000 - 2008 and 2001-2006 for meningioma, particularly for 
males. A significant decrease in the incidence of vestibular Schwannoma was observed in the 
same period. This is data for which we have no direct comparison in Australia. 
A number of procedures and quality checks were used to maximise data quality in the 
collection. Indicators suggest there was some bias around migration. Consequently, a weight 
was used to make adjustments using Australian Institute of Health and Welfare migration flows. 
The trends presented from the collection here establish a good estimate of rates of brain tumours 
for Australia. The process has also established a considered methodology for launching a more 
formal and routine collection. Registries may see an increase in malignant tumours in the next 
few years that they are not seeing now due to late ascertainment. 
4.1 Incidence Rates, Trends and Comparison to Australian and 
International Data 
From the results, we observe no linear increase or decrease in overall incidence trends for all 
primary brain tumours. US-standardised incidence rates varied from 9.95 to 12.47 cases per 
100,000 person years in the period 2000-2008. Table 4.1 below shows a comparison of US 
standardised incidence rates from the current study and sequential reports from the CBTRUS 
database. Incidence rates in the current study are below those reported by CBTRUS. 
Diagnosis 
Year 
CBTRUS Re port Current 
Study 2002-2003 2004-2005 2005-2006 2007-2008 2010 
1995 13.4 
1996 14 
1997 14.2 13.5 
1998 14.5 13.9 14.2 
1999 14 14.1 14.5 
2000 14.2 14.8 15.2 9.95 
2001 14.7 15.3 15.9 11.66 
2002 15.2 16.2 11.28 
2003 17 12.47 
2004 18.2 11.75 
2005 11.06 
2006 18.71 11.99 
2007 11.78 
2008 11.94 
Table 4.1. Age-adjusted incidence of primary CNS tumours in the sequential reports of CBTRUS. 
Adapted from Khurana et al.43 Rates are expressed in cases per 100,000 person-years. 
The most common type of Tumours of Neuroepithelial Tissue included glioblastoma (~57%, n 
= 2276), astrocytoma (-20%, n = 820) and oligodendroglioma (10%, n = 404) (Figure 4.1). 
Glioblastoma included all glioblastoma, gliosarcoma and giant cell glioblastoma. 
Oligodendroglioma included both classic and anaplastic variants. 
Figure 4.1. Distribution of histological subtype of all tumours of neuroepithelial tissue according to 
WHO Classification. Percentages are shown. 
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Figure 4.2. Distribution of All Primary Brain and CNS Gliomas by Histology Subtypes (n = 50,240). 
CBTRUS Statistical Report: NPCR and SEER Data from 2004 - 2006. 1 0 
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Comparing Figure 4.1 to Figure 4.2 above, the spread of tumours seen in the current study are 
very similar to the latest published CBTRUS rates.1 0 This adds weight to the quality of collected 
data and gives us an objective comparator to validate our published results while also 
suggesting that overall Australian incidence rates follow similar trends to US rates. This is 
further supported by review of Tables 4.2 and 4.3 below. 
The latest publication from the NSW Central Cancer Registry described collection of astrocytic 
tumours (n = 363), oligodendroglial tumours (n = 40) and gliomas of uncertain origin (n = 37) 
in 2007. The least frequent tumour collected was ependymal tumours (n=8). Incidence rates for 
histological subtypes have remained fairly constant since the mid-1990s for all subtypes in 
NSW and are expected to remain at 2007 levels (Figure 4.3). Quoted Australian standard 
population adjusted rates include 8.0 and 5.4 cases per 100,000 in males and females 
respectively in 2007 and 8.1 and 5.4 cases per 100,000 expected in 2021. 6 2 
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Figure 4.3. Actual and projected brain cancer incidence by sex, NSW, 1975-2011. Taken from the latest 
NSW CCR report. 6 2 
Figure 4.4 below compares NSW CCR data with other Australian Registries and selected 
international registries with similar reporting standards. Age-standardised incidence rates for 
brain cancer in NSW between 1998 and 2002 were 6.6 in males and 4.6 in females cases per 
100,000 person-years, with highest rates being recorded in Victoria (7.2 cases per 100,000 
person-years).6 2 
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Figure 4.4. Age-standardised incidence rates by histological type for brain cancer in males (1998-
2002).62 
The main point of divergence from the NSW CCR practice and comparison of rates is in 
histological subtype definition. The NSW CCR and databases listed in Figure 4.4 publish 
incidence rates by behaviour rather than WHO grade. This practice yields higher numbers but 
tumours that are considered "non-malignant" are included, thus diluting the meaning of the 
rates. For example, astrocytic tumours (comprising 75% of total brain cancers in the NSW 
collection) are a heterogenous population of tumour, with the majority (54%) being accounted 
for by glioblastoma (see Figure 4.2). Approximately 7% are anaplastic astrocytoma (WHO 
grade III) but the rest are WHO grade I and II tumours. That is, non-malignant tumours. 
As mentioned, the focus on WHO grade vs. tumour behaviour is the point of divergence. A 
number of WHO grade II tumours if left untreated, have malignant potential, hence the focus on 
these tumours. This practice has arisen from changes in brain tumour classification over time 
and is explored in more detail below Section 4.3.4 Change Over Time in Classification. 
Another example of this is ependymal and oligodendroglial tumours (approximately 6 and 7% 
of all tumours respectively, Figure 4.2). These tumours are again divided into WHO grade II 
and III but most of these types of tumours carry a malignant behaviour code. 
Our practice follows the practice of the larger international databases (i.e. CBTRUS and Nordic 
studies) for ease of comparison with published rates. 
Furthermore, our own neurosurgical and pathological background allows us to delineate more 
aggressive lesions from those that obtain curative therapy with complete resection. This is true 
of the WHO grade II lesions described above. 
Tables 4.2 and 4.3 present major histological subtype (glioblastoma, meningioma, nerve sheath 
and pituitary tumours) incidence rates by year of collection from successive CBTRUS 
publications7"10 and the current study. 
Table 4.2 below, compiled from sequential CBTRUS reports, is again presented to aid 
discussion and comparison of published incidence rates with the current study. The latest 
CBTRUS report was released at the end of 2010 and includes data for the years 2004-6. 
Tumour 
CBTRUS Report 
2002-2003 
1995-1999 data 
2004-2005 
1997-2001 data 
2005-2006 
1998-2002 data 
2007-2008 
2000-4 data 
2010 
2004-6 data 
Total Glioblastoma 3.24 3.01 3.05 3.09 3.17 
Meningioma 3.86 4.18 4.52 5.35 6.29 
Nerve Sheath 1.05 1.11 1.17 1.46 1.61 
Pituitary 0.92 0.82 0.92 1.37 2.40 
Total 14.02 14.10 14.80 16.52 18.71 
Male Glioblastoma 4.02 3.75 3.86 3.94 3.97 
Meningioma 2.46 2.57 2.75 3.17 3.76 
Nerve Sheath 1.07 1.12 1.19 1.48 1.63 
Pituitary 1 . 0 0 0.85 0.94 1.37 2.31 
Total 14.22 13.92 14.50 15.77 17.44 
Female Glioblastoma 2.59 2.40 2.39 2.38 2.51 
Meningioma 5.04 5.56 6.01 7.19 8.44 
Nerve Sheath 1.04 1.11 1.17 1.45 1.60 
Pituitary 0.88 0.82 0.93 1.42 2.56 
Total 13.86 14.27 15.07 17.19 19.88 
Table 4.2. Age-adjusted incidence of selected primary CNS tumours in the sequential reports of 
CBTRUS by gender. Adapted from Khurana et al.43 Rates are expressed in cases per 100,000 person-
years. 
Table 4.3 shows age-adjusted incidence rates by year for selected primary CNS tumours by 
gender. Significance trends and graphs are presented in the publications above (Chapter 2 and 
Chapter 3) and Appendix 6.7. The table is included for ease of comparison of rates with the 
latest CBTRUS rates (Table 4.2). 
Current Study 
Tumour 2000 2001 2002 2003 2004 2005 2006 2007 2008 
TOTAL 
Glioblastoma 3.13 3.34 3.01 3.33 2.95 3.52 3.33 3.75 3.86 
Meningioma 2.05 2.82 2.70 3.02 3.03 2.82 3.20 2.71 2.78 
Schwannoma 0.69 0.97 0.77 0.79 0.78 0.79 0.61 0.64 0.65 
Pituitary 1.43 1.48 1.39 1.59 1.68 1.17 1.66 1.36 1.26 
Total 9.95 11.66 11.28 12.47 11.75 11.06 11.99 11.78 11.94 
MALE 
Glioblastoma 4.03 4.04 3.97 4.05 4.02 4.70 3.68 4.90 4.97 
Meningioma 1.14 1.42 1.36 1.55 1.81 1.81 1.73 1.85 1.78 
Schwannoma 0.54 0.89 0.72 0.68 0.73 1.04 0.62 0.65 0.58 
Pituitary 1.42 1.59 1.99 1.60 1.91 1.15 1.79 1.70 1.50 
Total 9.96 11.42 11.85 11.96 11.96 12.08 11.21 12.59 12.34 
FEMALE 
Glioblastoma 2.27 2.72 2.18 2.67 2.02 2.40 2.98 2.71 2.79 
Meningioma 2.94 4.18 4.05 4.47 4.22 3.82 4.63 3.58 3.75 
Schwannoma 0.81 1.05 0.82 0.91 0.82 0.55 0.60 0.62 0.71 
Pituitary 1.45 1.39 0.87 1.59 1.47 1.17 1.53 1.05 1.03 
Total 9.98 11.93 10.93 13.02 11.67 10.10 12.74 11.10 11.58 
Table 4.3. Age-adjusted incidence of selected primary CNS tumours by year and gender. Rates are 
expressed in cases per 100,000 person-years. 
Similar rates are observed for glioblastoma in the current study and latest CBTRUS data, with 
the exception of higher incidence rates in males in the latest years of study in the current study 
(-4.9 cases per 100,000 person-years) in the years 2007 and 2008. This data is not yet available 
from the CBTRUS database. 
From Tables 4.2 and 4.3, we make the observation that the current study describes much lower 
rates for meningioma and nerve sheath tumours. The almost two fold increase in meningioma 
incidence, seen in US data, is thought to account for the higher overall brain tumour rates. This 
likely reflects US clinical and collection practice and can be reconciled with examination of the 
proportion of non-microscopically-confirmed tumours reported in the CBTRUS data set. 
The latest CBTRUS report describes only 57% of non-malignant tumours as histologically 
confirmed, while 39% were confirmed radiologically.10 Therefore, if we adjust the incidence 
rates presented above, similar rates of meningioma and nerve sheath tumours) are seen in the 
CBTRUS data and the current study. 
Pituitary tumours however, do not follow this simple explanation, with CBTRUS incidence 
rates being considerably smaller than our observed rates. However, similar proportions by 
gender for all four major histological subtype incidence rates presented are observed. These 
crude comparisons give us confidence in our own study methodology. 
As discussed in Chapter 3, the rates described in the current study for malignant brain tumours 
and for glioblastoma are similar to the latest published US, European and Australian Registry 
numbers (given the difference in definitions used). We thus have confidence in our own 
collection methodology. 
With this in mind, we have observed significant increasing trends in the most common type of 
non-malignant brain tumour - meningioma. In Australia, we have no direct comparator for 
meningioma rates due to lack of mandatory collection found in Europe and the United States. 
Tables 4.4 and 4.5 below compare selected histologies from historical Australian data 6 1 from 
the period 1982 through 1991 with the current study in period 2000 through 2008. It is 
important to recognise that these historical data were collected prior to the widespread use of 
imaging technology and multiple brain tumour classification changes have occurred since that 
time. Also, the study population between the two data sets is not the same (Victoria vs. 
ACT/NSW). Despite this, we observe that proportions of tumours between males and females in 
both data sets follow similar patterns; with higher rates of GBM seen in males but higher rates 
of meningioma in women, and similar rates of nerve sheath tumours between sexes. 
Tumour Males Females 
Number Rates Number Rates 
Glioblastoma multiforme 662 2.80 462 1.83 
Meningioma 302 1.27 665 2.69 
Nerve sheath tumour 80 0.35 83 0.35 
Table 4.4 . CNS tumour incidence by histological type: age-standardised rates per 100,000 population, 
Victoria, Australia, 1982 - 1991. Adapted from Giles et al.61 
Tumour Males Females 
Number Rates Number Rates 
Glioblastoma multiforme 1390 4.26 885 2.53 
Meningioma 515 1.61 1350 3.96 
Nerve sheath tumour 233 0.72 259 0.77 
Table 4.5. CNS tumour incidence by histological type: age-standardised rates per 100,000 population 
from the current study, 2000 - 2008. Rates have been averaged over the time period. 
The numbers and rates of tumours seen in the current study are higher across the board for all 
tumours in both sexes. Further, the historical study covers one extra year of data when 
compared to the current study, and so the larger numbers and rates are further accentuated when 
this is taken into consideration. There are many potential explanations, some of which are 
discussed in Section 4.3 below. The numbers and rates however, raise the question: 
"Is the observed increased incidence rate adequately explained by factors such as 
collection practice, imaging technology, clinical practice and classification 
change?" 
4.2 Demographic Features and Comparison 
Age-Specific Incidence 
The mean age of onset for all primary brain tumours is 53 years. However, the average age of 
onset for glioblastoma and meningioma, the two most common types of adult tumours (see 
Table 4.6) is about 62 years. The incidences of glioblastoma and astrocytoma peak at ages 65-
74 years and then decline, while the incidence of meningioma continues to rise with increasing 
age.10-109 
Age (yr) Most Common Histology Second Most Common Histology 
0-4 Embryonal/medulloblastoma Pilocytic astrocytoma 
5-9 Pilocytic astrocytoma Malignant glioma, NOS 
10-14 Pilocytic astrocytoma Neuronal/glial 
15-19 Pituitary Pilocytic astrocytoma 
20-34 Pituitary Meningioma 
35-44 Meningioma Pituitary 
45-54 Meningioma Glioblastoma 
55-64 Meningioma Glioblastoma 
65-74 Meningioma Glioblastoma 
75-84 Meningioma Glioblastoma 
85+ Meningioma Neoplasm, unspecified 
Table 4.6. Most common brain and CNS tumours by age. CBTRUS statistical report: NPCR and SEER 
data from 2004-6.10 
Figures 4.5 and 4.6 below have been included in the discussion to aid comparison with the 
most up to date data from the US9'10 on age-specific incidence for total population for primary 
brain tumours and selected histologies. The CBRTUS rates shown (Figures 4.5a) and 4.6a)) 
include lymphoma amongst other histologies in incidence rates for all primary brain tumours, 
but comparison of meningioma, nerve sheath and pituitary tumours follow similar ICD-O-3 
definitions to the current study. The definition of glioma in the CBTRUS data includes ICD-O-3 
codes 9380-9384, 9391-9460, and 9480. 
Incidence rates for all primary brain tumours in the 2007-8 CBRTUS report range between 4.5 
and 59.9 cases per 100,000 person-years, much higher than rates described in the current study 
that range between 2.6 to 35.1 cases per 100,000 person-years. This reflects a variable definition 
and reporting practice. 
Incidence rates for meningioma ranged between 0.1 and 29.2 cases per 100,000 person-years, 
again, much higher than the current study that found rates between 0.07 and 11.0 cases per 
100,000 person-years. Rates were higher in all age groups from the US data series, but followed 
similar increasing rates with increasing age with the exception of patients older than 85 years 
(29.18 vs. 3.03 cases per 100,000 person-years). This may reflect not only variable reporting 
practice, but also differing clinical practice. 
Rates for nerve sheath tumours were also smaller than those reported in the CBTRUS data 
series for all age groups. The CBTRUS data set however, does also include malignant 
neoplasms of the cranial and spinal nerves, likely accounting for some of the higher observed 
rates. 
Pituitary tumours followed a similar distribution in the current study when compared to the 
CBTRUS data. Incidence rates ranged between 0.13 and 4.69 cases per 100,000 person-years 
for US data and between 0.0 and 5.3 cases per 100,000 person-years for the current study with 
peak incidence in both datasets in the 55-64 year age groups. 
Figure 4.5. a) Age-specific incidence of primary brain and CNS tumours by selected histologies. 
CBTRUS Supplement -2004 data, b) Current study age-specific incidence of primary brain tumours by 
selected histologies for total population in the year 2004. 
The latest CBTRUS data reports incidence rates in the years 2004-2006 (Figure 4.6.a)). I have 
included age-specific incidence rates for all primary brain tumours and selected histologies for 
the year 2006 below (Figure 4.6.b)) as well as for our latest year 2008 (Figure 4.6.c)). The 
trends described above apply to these data and likely reflect discrepancy between reporting 
practice and health care delivery between the two countries. 
- • - A l l Primary 
Tumors 
- • - G l i o m a s * 
- X - Meningioma 
—•— Nerve Sheath 
— P i t u i t a r y 
—*— Lymphoma 
2004-2006 
Figure 4.6. a) Age-Specific Incidence of Primary Brain and CNS Tumours by Selected Histologies. 
CBTRUS Statistical Report: NPCR and SEER Data from 2004-2006.10 
2006 2008 
Figure 4.6b) and c). Current study age-specific incidence of primary brain tumours by selected 
histologies for total population in the years (b) 2006 and c) 2008). 
Sex Differences 
It is well documented that sex differences exist for certain types of tumours. Tumours of 
neuroepithelial origin are more prevalent in men (40% higher), while meningiomas are more 
prevalent in women (80% higher).45'11 
The current study reports an average incidence rate for Tumours of Neuroepithelial Origin 
between the years 2000-2008 of 7.3 cases per 100,000 person-years in males and 4.9 cases per 
100,000 person-years in females, a 49% higher rate in males. 
Average incidence rates across the years 2000-2008 for meningioma for males and females 
were 1.6 and 3.9 cases per 100,000 person-years respectively. This calculates to a 146% higher 
rate in females. 
The observed incidence rates by gender from the current study are thus proportionally akin to 
published international rates. 
4.3 Factors Influencing the Observed Incidence Rate 
Multiple factors have influenced our estimation of the incidence rate of primary brain tumours 
in the ACT and NSW region in the period 2000-2008. Some of these factors will have had more 
influence than others, but we have attempted to control for each one where possible. 
As discussed previously, inherent in our collection methodology and our definition of a primary 
brain tumour, we have introduced a certain degree of error in our estimation of the incidence 
rate (see Chapter 1.5 Sampling). Specifically, sourcing and data matching of cases limited by 
ethical constraints has proved a considerable hurdle. 
Rather than re-iterating these points, this section will discuss broader issues related to brain 
tumour diagnosis, classification and capture rates. 
4.3.1 Clinical Practice and its Influence on Incidence Rates 
Marked changes in the clinical practice and management of central nervous system tumours 
have occurred over the past 30-40 years. 
Notably, better diagnostic capability through clinician awareness and improved imaging 
technology, as well as safer anaesthetic and surgical practice, and better treatment modalities 
such as chemotherapy and radiotherapy have revolutionised brain tumour diagnosis and 
management. 1 1 1 ' 1 1 2 These improvements have presumably resulted in increased incidence rates 
based on histological diagnosis. 
At the same time, the increase in accuracy of diagnostic imaging as well as palliative care 
referrals would presumably offset some of the increase in brain tumour incidence related to 
increasing surgery rates, with some patients declining the option for surgical excision. 
A large study examining 23,766 patient discharges from 1977 to 2001 at the ACT/NSW 
region's largest neurosurgical centre did in fact demonstrate a steady increase in mean age (9.5 
years P < 0.0001) for CNS (astrocytic and oligodendroglial) tumour admissions from 1977 to 
2002 (n = 1339). There was little change in the proportion of patients not receiving surgery 
during the study period, implying the increase in mean age was for surgical treatment of CNS 
94, 113 tumours. 
The study also demonstrated a decreasing trend in burr hole biopsy and a rise in all forms of 
craniotomy, as well as decreasing mortality and complication rates.94,113 
This change in clinical practice may well account for the increase in incidence of all malignant 
primary brain tumours in patients aged 65 years and above. No studies have looked at the 
individual contributing components however. 
4.3.2 Imaging Technology 
Many studies have attributed an observed increase in incidence of brain tumours to greater 
diagnostic capabilities.11'16-17'114 Many authors hypothesised that the introduction of CT 
imaging technology in the 1970s and 1980s was a major contributing factor to the observed 
increasing incidence of brain tumours (particularly in the elderly population), and further 
influenced by the later introduction of widespread MR imaging technology use. Others 
however, argued that improved imaging technology only partially explained the observed 
increase in incidence in brain tumours, particularly in patients where malignant brain tumours 
become quickly apparent clinically (e.g. in children).115 
A retrospective review of 215 patients diagnosed with malignant brain tumour between 1985 
and 1989 by Desmeules and colleagues, excluded CT and MRI information from patients' 
medical records and suggested that the diagnosis would have been made in 80% of cases 
irrespective of imaging.116 They suggested the observed increase in brain tumour incidence rates 
observed at that time was only partly explained by the increased use of imaging technology. 
The use of CT and MRI technology became widespread in Australia during the late 1980s and 
early 1990s, only 5-10 years behind the US and Europe. 
Interestingly, as mentioned in Chapter 2, no step increase in malignant brain tumour incidence 
rates has been observed by the AIHW (Australia's gold standard) during the time period 
corresponding to CT and MR imaging introduction. The reasons for this are not entirely clear. 
Most Australian studies6,20,21 examining brain tumours incidence were published in the 1990s, a 
period presumably influenced by improved imaging diagnosis. No dramatically significant 
trends in incidence were reported in these studies and few have been published since. Instead, 
Australian brain tumour data is now almost exclusively reported by state-based registries and 
the AIHW. 
Difficulties in classification with imaging technology are many. Diagnosis of an intracranial 
lesion relies on whether the lesion is intra- or extra-axial (i.e. arising from the brain itself or 
from surrounding structures such as the meninges), the age of the patient, contrast enhancement 
characteristics and location (i.e. supra- or infra-tentorial). 
Metastatic disease is often difficult to differentiate between a primary tumour and clinical 
correlation is often needed. Contrast enhancement in a brain lesion is useful to delineate Grade I 
and IV tumours given classical imaging findings, but is poor at differentiating intermediate 
grade tumours. Meningioma is the most common extra-axial tumour, and so features high on the 
differential diagnosis list. Imaging diagnosis is not always reliable however, and differential 
diagnoses such as dural-based metastasis, solitary fibrous tumour, haemangiopericytoma, 
infection and post-operative change are amongst the differential diagnoses. Medulloblastoma 
and ependymoma are also difficult diagnoses to delineate based purely on imaging findings. 
The latest WHO Classification of Tumours of the Central Nervous System (2007) introduced 8 
new neoplasms and 4 variants.117 A recent review of the neuroimaging diagnosis of these 
entities suggests it is possible to differentiate a few of these entities based purely on imaging 
alone.118 The authors concluded however, that these entities are "uncommon and often 
indistinguishable from statistically more common entities." 
Because of these difficulties, tissue diagnosis remains the mainstay of brain tumour delineation 
and histological confirmation is a must. 
Expansion to notifications based on imaging diagnosis would increase case capture rate but the 
resources involved in such an undertaking would be immense. In addition, whether or not these 
diagnoses are clinically relevant is another consideration. For example, an asymptomatic 
meningioma diagnosed on CT or MR may be present for years with histological confirmation 
only being performed at autopsy (which is also uncommon currently in Australia). 
Assuming a clear indication for surgery, this argues that the non-malignant brain tumours such 
as meningioma in the current study are more clinically relevant than those missed through lack 
of capture via other sources of diagnosis. 
4.3.3 Collection Solely of Pathology Data 
The current study has sourced data directly from pathology departments - the site of definitive 
diagnosis. We were interested in accurate histological subtype information not found in 
Australian literature, as well as setting a baseline incidence rate for benign brain tumours, 
particularly meningioma and vestibular Schwannoma. 
The sole use of microscopically-confirmed tumours, although providing accurate diagnosis, is 
not without its shortcomings. These shortcomings relate to inadequate tissue for diagnosis (e.g. 
from biopsy rather than excision), lack of independent review by dedicated neuropathologists 
and an underestimation of the true incidence rate through incomplete capture rate. Australian 
registries also depend on the same data and would thus experience the same shortcomings, but 
these are accentuated by the additional problem of late ascertainment (of which the current is 
relatively free). 
Histological classification and grading of brain tumours has been affected by changes over time 
in techniques for operative sampling of tumours (see 4.3.4 Change Over Time in 
Classification). Samples taken at biopsy are not necessarily representative of the whole tumour, 
particularly when a single small sample is taken at needle biopsy (sampling error). The 
introduction of stereotactic biopsy has served to increase the accuracy in targeting lesions. 
However, the decision of which portion of the tumour to sample and the number of samples 
taken is sometimes only made at the time of operation and is dependent on various peri-
operative factors. Smaller tissue samples have the potential for under-grading the lesion. 1 1 9 
Further, many patients undergo adjuvant radiotherapy to shrink the tumour pre-operatively. This 
can cause difficulties in microscopic diagnosis - distinguishing between intrinsic tumour 
necrosis and radiation-induced necrosis is not always possible.1 1 
Importantly, omission of other sources of brain tumour diagnosis such as diagnostic imaging, 
radiation oncology, neurology clinics, medical oncology, autopsy reports, freestanding radiation 
therapy, MRI, gamma/cyber knife, and oncology centres, produces a tendency to underestimate 
the true incidence of brain tumours. This is particularly true of patients with slow-growing, 
inoperable, incidental or palliative brain tumours that do not undergo surgery. Patients with 
multiple co-morbidities and polypharmacy, or small meningiomas that will have minimal 
clinical significance have been missed by this study. A Nordic study 7 5 by Johannesen et al., 
2004 highlights this issue when considering microscopic confirmation and numbers of tumours 
diagnosed at autopsy. Of the 1409 patients that underwent autopsy, 358 brain tumours (3.8%) 
were diagnosed incidentally. The majority of these were tumours of meninges (232 cases), 
tumours of neuroepithelial tissue (61 cases) and tumours of the sellar region (31 cases). As 
mentioned above, capture of these tumours, although useful for completeness, have minimal 
clinical significance. 
Future studies will need to address the issue of capture rate of non-histologically confirmed 
tumours. An important question we have hoped to raise is the question; 
"How should we best capture accurate and timely brain tumour incidence rates?" 
4.3.4 Change Over Time in Classification 
Initially, our study collected data from all participating centres from the years 1994 to 2008 but 
found data completeness only from mid-1999. Although effectively halving our ability to 
examine incidence trends, this did allow us to be mostly free of brain tumour classification 
changes. After the year 2000, the majority of Australian pathologists and hospital coding 
systems were in line with the WHO and SNOMED grading systems [personal communication 
Dr Morey, St Vincent's Hospital, Department of Pathology, April 2009]. I include a historical 
discussion here on classification changes for completeness. 
Grading Systems 
Harvey Cushing, under the supervision of Percival Bailey, is generally considered the 
grandfather of modern neuropathology. Through collection of more than 2,000 cases of verified 
brain tumours, Bailey and Cushing were able to construct a classification system of gliomas 
based on histogenesis. Since then, the grading of glial tumours, astrocytoma in particular, has 
continued to be a source of debate in neuropathology. Much of the controversy surrounding the 
grading of these tumours relates to the distinction between grade II and III tumours. These 
tumours are not well differentiated on imaging alone, further clouding the issue. The essential 
aim of grading a tumour is to provide clinical guidance to neurosurgeons and oncologists 
regarding best management and prognosis. 
It is important to understand changes in brain tumour classification over time, and to recognise 
that individual pathologists will describe the same tumour in different ways depending on their 
level of expertise and education. Attempts at standardisation of method are further hampered by 
workforce shortages where pathologists do not have the resources to precisely code tumours to 
TNM (tumour, node, metastasis) coding [personal communication Dr Morey, St Vincent's 
Hospital, Department of Pathology], Four major classification systems have existed in the last 
two decades relating to brain tumours including Ringertz,120 Kernohan,121 St Anne-Mayo,122 
World Health Organisation (WHO).81 The Ringertz system is a three-tiered system, while the 
Kernohan, WHO and St Anne-Mayo schemes use four (see Table 4.7). 
Ringertz 
Kemohan 
Grade 1 
(well differentiated) 
Grade 2 
(anaplastic astrocytoma) 
Grade 3 
(glioblastoma multiforme) 
Kemohan grade! 
Kernohan grade 2 
Kemohan grades 3 & 4 
WHO 
St Anne-Mayo 
Grade 1 
Juvenile pilocytic astrocytoma 
Grade 1 
Score: 0 
Grade 2 
Astrocytoma 
variants 
• fibrillary 
• protoplasmic 
• gemistocytic 
Grade 2 
Scone: 1 
Grade 3 
Anaplastic astrocytoma 
Grade 3 
Score: 2 
Grade 4 
Glioblastoma multiforme 
variants 
• giant cell glioblastoma 
• gliosarcofna 
Grade 4 
Score: 3 or 4 
Boxes indicate overlap between the Kemohan 4-tler and Ringertz 3-tler systems. The Ringertz, Kemohan and St Anne-Mayo systems do 
not grade juvenile pilocytic astrocytoma whereas the WHO system regards this as Grade 1. 
Table 4.7. Summary of the four common histopathology-based grading schemes.1 
In 1949, Kernohan and colleagues classified glial tumours into astrocytoma, ependymoma, 
oligodendroglioma, neuroastrocytoma and medulloblastoma. The Kernohan grade defines 
progressive malignancy of astrocytomas as follows: 
• Grade 1 tumours are benign astrocytomas. 
• Grade 2 tumours are low-grade astrocytomas. 
• Grade 3 tumours are anaplastic astrocytomas. 
• Grade 4 tumours are glioblastoma multiforme. 
Reports in the 1980s noted an association between tumour necrosis, aggressive behaviour and 
decreased survival in patients with astrocytoma graded by the Ringertz system. 1 2 3 This 
prompted the formation of a new four-tiered system (St Anne-Mayo) that was based on a 
scoring system, and thus less subjective (particularly for intermediate grade tumours). 
The St. Anne-Mayo grade is used to grade astrocytomas using four morphologic criteria to 
assign a grade: nuclear atypia, mitosis, endothelial proliferation, and necrosis. The St. Anne-
Mayo grade has four categories of tumours: 
• Grade 1 tumours do not meet any of the criteria. 
• Grade 2 tumours meet one criterion, usually nuclear atypia. 
• Grade 3 tumours meet two criteria, usually nuclear atypia and mitosis. 
• Grade 4 tumours meet three or four of the criteria. 
At the other end of the spectrum (i.e. low grade tumours) however, tumours that lack the 
features of nuclear atypia, mitosis, endothelial proliferation, and necrosis, behave less 
aggressively. Accurately predicting survival time, however, is difficult for tumours graded as 
intermediate on light microscopic features. They usually show an easily recognizable increase in 
tumour cell density compared with low grade tumours and have the additional features of 
nuclear pleomorphism, mitotic figures and vascular endothelial cell proliferation but lack 
necrosis.1 1 9 'The move from a 4-tier (Kernohan) to a 3-rier (Ringertz) grading scheme was 
prompted by the lack of clear differences in survival times for patients with grade 3 versus grade 
4 tumours. The need to more accurately assess the likely biological behaviour of intermediate 
grade astrocytomas, i.e. grade 2 tumours in the 3-tier scheme, engendered the St Anne-Mayo 
features score system."119 
For example, juvenile pilocytic astrocytoma is a slow growing, often cystic astrocytoma 
occurring in children and young adults. It is difficult to apply the St Anne-Mayo grading 
scheme to this tumour because of endothelial cell proliferation, and is better classified under the 
WHO system as a Grade I tumour. Of note, the CBTRUS still codes pilocytic astrocytoma as a 
malignant tumour,1 a practice that diverges from the current study. 
The WHO grade has four categories of tumours: 
• Grade I tumours are slow-growing, non-malignant, and associated with long-term 
survival. 
• Grade II tumours are relatively slow-growing but sometimes recur as higher grade 
tumours. They can be non-malignant or malignant. 
• Grade III tumours are malignant and often recur as higher grade tumours. 
• Grade IV tumours reproduce rapidly and are very aggressive malignant tumours. 
We have used this classification system in the current study. A summary of significant changes 
in the WHO 2007 brain tumours classification are presented in Table 4.8 below. 
Grading Changes 
• Anaplastic oligoastrocytomas with necrosis: now designated glioblastoma with oligodendroglial component W H O grade IV. 
• Brain invasion by a meningioma: now an independent criterion for W H O grade II. 
• Atypical choroid plexus papilloma: criteria defined with designation of W H O grade II. 
• Pineocytoma: now classified as W H O grade I; pineal parenchymal tumor of intermediate differentiation: now W H O grade II or III; 
pineoblastoma remains W H O grade IV. 
• Gangliogliomas: classified as W H O grade I or III; grade II designation has been eliminated. 
• Cerebellar liponeurocytoma: now designated W H O grade II tumor. 
• Anaplastic hemangiopericytoma, W H O grade III: criteria established for distinguishing from hemangiopericytoma, W H O grade II. 
New Entities, Variants, Patterns of Differentiation, and Syndromes 
• Angiocentric glioma, W H O grade I 
• Pituicytoma, W H O grade I 
• Spindle cell oncocytoma of the adenohypophysis, W H O grade I 
• Papillary glioneuronal tumor, W H O grade I 
• Rosette-forming glioneuronal tumor of the fourth ventricle, W H O grade I 
• Pilomyxoid astrocytoma, W H O grade II 
• Extraventricular neurocytoma, W H O grade II 
• Fbpillary tumor of the pineal region, W H O grades IMII 
• Glioneuronal tumor with neuropil-like islands, W H O grades ll-lll 
• Small cell glioblastoma, W H O grade IV 
• Rhabdoid tumor predisposition syndrome 
Other Classification Changes 
• Medulloblastoma: variants include large cell, anaplastic, extensive nodularity, and desmoplastic/nodular; myogenic differentiation 
(previously medullomyoblastoma) and melanotic differentiation (previously melanotic medulloblastoma) are now considered mor-
phologic patterns. 
• CNS PNETs: reorganized to include CNS/supratentorial PNET (including neuroblastomas and ganglioneuroblastomas), medulloepithe-
lioma, and ependymoblastoma. 
• Giant cell glioblastoma and gliosarcoma: now classified variants of glioblastoma. 
• Hemangioblastoma: now has its own chapter as an entity, apart from von Hippel-Lindau disease. 
• Olfactory neuroblastoma and peripheral neuroblastomas: no longer included in the CNS classification. 
Table 4.8. Significant Changes in the World Health Organization (WHO) 2007 CNS Tumour 
Classification. CNS indicates central nervous system; PNET, primitive neuroectodermal tumour. Taken 
from Brat 2008.124 
As an example, in the current study, we have reported a small number of new entities described 
in the latest WHO classification of tumours of the CNS including papillary tumour of the pineal 
region, pilomyxoid astrocytoma, angiocentric glioma, pituicytoma, papillary glioneuronal 
tumours, rosette-forming glioneuronal tumour of the fourth ventricle. These are new entities not 
previously included in other studies. Of these, we described only 2 cases of pilomyxoid 
astrocytoma, 1 case of angiocentric glioma and 3 cases of papillary glioneuronal tumours in the 
current study. Encountering these tumours highlights the variable uptake of new classification 
systems, and their employment in brain tumour databases. This issue exists not only between 
population-based databases, but at the individual pathologist level, depending on level of 
expertise and education, creating variability in incidence rates (however small). 
Paediatric tumours 
Paediatric tumours have traditionally been even more difficult to classify and grade, with some 
tumours looking aggressive microscopically, but clinically behave as non-aggressive entities. A 
recent publication suggested that histological diagnosis as not being a significant prognostic 
indicator as compared to molecular markers in paediatric high grade glioma. 1 2 5 
Medulloblastoma is increasingly recognised as a heterogenous entity and the 2007 WHO 
publication recognises four variants; desmoplastic/nodular, medulloblastoma with extensive 
nodularity, anaplastic medulloblastoma and large cell medulloblastoma, on the basis of their 
histopathological features. Desmoplastic/nodular and medulloblastoma with extensive 
nodularity medulloblastomas in infants have a better outcome, while large cell and anaplastic 
medulloblastomas behave aggressively. 1 2 6 Difficulties in differentiation between 
medulloblastoma, PNET and atypical teratoid/rhabdoid tumours exist, and future molecular 
markers may help address this issue. Molecular and genetic markers are an evolving field and 
will help further delineate histological subtypes and their clinical implications. 
As mentioned, we are relatively free from brain tumour classification changes (particularly 
given that we have limited our analysis to more common entities) in the time period 2000 to 
2008 but understanding the uncertainty surrounding histological diagnosis is important to bear 
in mind when interpreting these data. 
4.3.5 Reporting Delay 
Reporting delay relates to the time between diagnosis and notification. Institutions quote 
varying durations of reporting delay and cancer statistics are continually being updated. For 
example, the current reporting delay of the National Cancer Institute (NCI) is almost 2 years -
cases diagnosed in 2007 were reported in November 2009 and released to the public in April 
2010.127 
A study by Clegg and colleagues15 examined brain tumour reporting delay in nine cancer 
registries from the SEER database. By applying joinpoint linear regression to brain tumour case 
counts from 1981-1998 that were adjusted by the registries over that period, they were able to 
quantify the impact of reporting delay on incidence rates. This has been termed late 
ascertainment, and is inherent to all institutions collecting large volumes of data from multiple 
different sources. They concluded that ignoring this reporting delay error produces downwardly 
biased trends in incidence rates, particularly in the most recent years of diagnosis. 
The current study has a lag time of approximately two years with constraints of resource and 
staffing shortage. We feel that collection of brain tumour data at the source of histological 
diagnosis however, is the most clinically appropriate method of collecting accurate and timely 
data for trend analysis. 
4.4 Feasibility for Expansion to Nation-Wide Registry 
A full summary of International, European and US registry practice is provided by Bray and 
Parkin.101'128 The authors describe issues around comparability, validity, timeliness and data 
completeness of cancer registry data. Expansion to a nation-wide reporting system for primary 
brain tumours is an enormous undertaking to say the least. We feel however, that it is both 
necessary and timely to assess potential risk factors for the development of such poorly 
differentiated and difficult to treat entities. Treatment options are few and survival poor at best. 
We suggest however, that this will not be possible without the passing of legal mandatory 
reporting practice, akin to the US experience. 
Casefinding 
There are many sources of potential casefinding including, but not limited to; 
• Disease indices 
• Surgery logs 
• Diagnostic imaging 
• Radiation oncology 
• Neurology clinics 
• Medical oncology 
• Autopsy reports 
• Pathology reports 
• Freestanding radiation therapy centres 
• Freestanding MRI centres 
• Freestanding gamma/cyber knife centres 
• Freestanding oncology centres 
• Data exchange with other central registries 
• Death clearance process 
Collection of clinical information from multiple different sources would allow verification of 
cases as well as controlling for rare but significant disorders. For example, genetic 
predispositions such and neurofibromatosis are associated with pilocytic astrocytoma, 
meningioma and optic nerve glioma, while neurofibromatosis II is associated with meningioma. 
Co-ordinating multiple notification centres and providing meaningful data would be crucial. 
There are certainly many sources of brain tumour data, all with relative advantages and 
disadvantages, but one larger question that needs to be answered is; 
"Should brain tumour data collection be based on whole population mandatory reporting, 
or just a sample of the whole?" 
Date of Diagnosis 
A further complication of involving multiple sources of notification is the impact on reporting 
method through definition of the actual date of diagnosis issue. 
The rules found in the Commission on Cancer's Facility Oncology Data Standards (FORDS),87 
Section 2: Coding Instructions, pages 89 and 90 state that it is not unusual for a patient with a 
non-malignant CNS tumour to be diagnosed in a physician's office and treated with watchful 
waiting. Several years may go by before the patient receives subsequent treatment at a health 
care facility in the form of surgery or radiation therapy or some type of systemic therapy. Also, 
non-malignant CNS tumours, especially meningiomas, often recur. The date of initial diagnosis 
should be recorded in the abstract, not the date of subsequent treatment or date of recurrence. 
Health records must be reviewed carefully to determine the initial date of diagnosis by a 
medical practitioner, regardless if the initial diagnosis was clinical or histologic. 
The report above is published by the American College of Surgeons, while the European 
recommendation is shown in Table 4.9. This issue is a source of debate but a uniform approach 
is needed. 
Rules for registration of incidence date, in 
decreasing order of priority: 
1 Date of first histological or cytological confirmation of 
this malignancy (with the exception of histology or 
cytology at autopsy). This date should be, in the following 
order: 
Date when the specimen was taken (biopsy) 
Date of receipt by the pathologist 
Date of the pathology report 
2 Date of admission to the hospital because of this 
malignancy. 
3 When evaluated at an outpatient clinic only: date of first 
consultation at the outpatient clinic because of this 
malignancy 
4 Date of diagnosis, other than 1,2 or 3 
5 Date of death, if no information is available other than 
the fact that the patient has died because of a 
malignancy 
6 Date of death, if the malignancy is discovered at autopsy 
Note: Whichever date is selected, the date of incidence should 
not be later than the date of the start of the treatment, or 
decision not to treat, or date of death. The choice of 
incidence does not determine the coding of the item 
'basis of diagnosis' 
Table 4.9. Standards recommended for the definitions of incidence given by the European network of 
cancer registries (ENCR, 1999).101 
Coding Rules 
A unified coding system is required and many of the issues were touch upon in Chapter 1.8.3 
o c QQ QC i n i 1 0 Q 
Data Reporting Rules. Well developed rules exist ' ' ' ' and the nuances would need to 
be extensively discussed prior to development of a meaningful collection. Australia has many 
potential sources for developing a template for collection of these tumours. Following suit with 
the rest of the developed world would enhance the body of knowledge of primary brain tumours 
and potentially lead to a cure. 
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Chapter 5. Conclusion 
We aimed to determine the incidence in Australia with age-, sex-, and benign-versus-malignant 
histology-specific analyses from the relatively heterogenous populations of New South Wales 
(NSW) and the Australian Capital Territory (ACT). 
The overall US-standardised incidence of primary brain tumours was 11.3 cases per 100,000 
person-years (+0.13; 95% CI, range 9.8-12.3, n = 7651) during the study period with no 
significant linear increase. A significant increase in primary malignant brain tumours from 2000 
to 2008 was observed; and appeared to be largely due to an increase in malignant tumour 
incidence in the >65-year age group. 
A significant increasing incidence in glioblastoma multiforme (GBM) was observed, 
particularly after 2006. In GBM patients in the >65-year group, significantly increasing 
incidence for men and women combined and men only were seen. Rising trends in incidence 
were also seen in meningioma for total male population and males aged 20-64 years but 
Australia has relatively non-changing low rates for meningioma compared to the US, which also 
has significant rises in overall rates, possibly explained by the large increases in meningioma 
rates. Significantly decreasing incidence trends were observed for Schwannoma for the total 
study population, significant in women but not men. 
This collection represents the most contemporary data on primary brain tumour incidence in 
Australia. Whether the observed increase in malignant primary brain tumours, particularly in 
persons aged >65 years, is due to improved detection, diagnosis, and care delivery or a true 
change in incidence remains undetermined. Our registries may observe an increase in malignant 
tumours in the next few years that they are not detecting now due to late ascertainment. 
Non-malignant tumours are currently not routinely monitored in Australia. Many international 
countries have recognised the importance of these tumours but Australia is yet to follow suit. 
The preliminary analysis presented in this thesis adds weight to the argument that collection of 
these tumours is necessary. 
We recommend a direct, uniform and centralized approach to monitoring primary brain tumour 
incidence, including the introduction of non-malignant data collection. 
Chapter 6. Appendices 
6.1 Overview of Tumours of the Central Nervous System 
Malignant brain tumours are a rare occurrence, accounting for approximately 2% of all cancer 
in adults. The greatest proportion of adult tumours are supratentorial, occurring in the cerebral 
hemispheres, and the majority (86%) arise from glial cells. Despite its relative rarity the burden 
of these tumours is considerable for the individuals, their families, and the health care system.47 
Poor survival rates lead to a disproportionate number of years of life lost (—21 years of life lost 
on average) compared to other cancers.1 
The central nervous system refers to the brain and spinal cord, whereas the peripheral nervous 
system refers to nerves exiting from the spinal cord to control the body. The central and 
peripheral nervous systems are a continuous system, giving and receiving feedback from each 
other. The current study is primarily interested in brain tumours that have originated in the brain 
parenchyma (substance) itself, termed primary brain tumours. Secondary brain tumours, which 
originate from elsewhere in the body and metastasize to the brain are the most common type of 
brain tumour. These were not included in our study. 
As mentioned previously, although primary brain tumours may be split into malignant and non-
malignant entities, the distinction in terms of clinical effect is blurred when considering intra-
cranial neoplasms. The finite volume of the intra-cranial compartment means that even benign 
tumours can have deleterious effects depending on location and size. Moreover, the anatomic 
site of brain tumours plays an important role in prognosis and treatment options. 
Histology and Location 
Corpus callosum 
astrocytoma 
oligodendroglioma 
Pineal region 
"germ cell neoplas 
Cerebellum 
•hemangioblastoma 
astrocytoma 
medulloblastoma 
Cerebral hemisphere 
astrocytoma 
"meningioma 
oligodendroglioma 
ependymoma 
Brainstem 
** astrocytoma 
* benign/borderline 
" benign or malignant 
Ventricles 
"ependymoma 
'choroid plexus papilloma 
*subependymoma 
Pituitary region 
'pituitary adenoma 
'craniopharyngioma 
"meningioma 
"germ cell neoplasm 
TB-Figure 6.1. Diagram of the central nervous system with common entities found in various locations' 
Anatomic site of brain tumours were defined as per ICD-O-3 primary site codes for (for a full 
listing, see Chapter 1.5.3); 
Meninges 
Brain 
Cranial nerves 
Pituitary and pineal gland 
C70.0 - C70.9 
C71.0 - C71.9 
C72.4 - C72.9 
C75.1 - C75.3 
Primary brain tumours are classified by light microscopy according to their predominant cell 
type and graded based upon the presence or absence of standard pathologic features. Historical 
attempts at classifying brain tumours date back to the 1830s. 1 3 0 Table 6.1 below simply 
describes the relationship between a tumour and the cell from which it formed. 
Cell/Tissue of Origin Cell/Tissue Function Tumour Type 
Astrocyte Structural/supportive Astrocytoma 
Oligodendrocyte Form myelin in the CNS Oligodendroglioma 
Lymphocyte Immune mediation Primary CNS lymphoma 
Meningothelial Surround/protect brain Meningioma 
Primitive neuronal and/or glial Structural/supportive Medulloblastoma 
Table 6.1. Examples of Primary Brain Tumours and Their Cell or Tissue of Origin. Adapted from 
Doolittle.1 
A number of classifications of brain tumours exist including the Kernohan (1950), Ringertz 
(1950), 1 2 0 St Anne-Mayo (1993), 1 2 2 the World Health Organisation (WHO) systems 1979, 1993, 
2000, 2007. These systems are important to predict response to therapy and outcome in patients 
with brain tumours. Perhaps the most widely used system is the WHO classification system, 
which divides tumours based on histological grade as a means of predicting the biological 
behaviour of the tumour. The first edition was edited by Zulch and published in 1979.132 The 
second edition (1993) reflected advances brought about by the introduction of 
immunohistochemistry into diagnostic pathology.133 The third edition incorporated genetic 
profiles and was published in the year 2000.134 
The latest WHO Classification of Tumours of the Nervous System (4th Edition 2007) includes a 
number of new entities and tumours based on epidemiological, clinical, imaging and prognostic 
factors.81 The WHO classifies brain tumours into the following major histological subgroups: 
• Tumours of Neuroepithelial Tissue 
• Tumours of the Cranial and Paraspinal Nerves 
• Tumours of the Meninges 
• Tumours of the Sellar Region 
• Lymphomas and Haematopoietic Neoplasms 
• Germ Cell Tumours 
• Metastatic Tumours 
A brief description of the major types in each category is provided in the following sections. 
6.1.1 Tumours of Neuroepithelial Tissue 
• Glioblastoma Multiforme (WHO Grade IV) ICD-0 9440/3 
Glioblastoma multiforme (GBM) is the most frequently occurring primary brain tumour and 
most malignant neoplasm, often occurring rapidly without recognizable precursor lesions. Some 
develop slowly from diffuse astrocytoma (WHO Grade II) or anaplastic astrocytoma (WHO 
Grade III). They are predominantly astrocytic in differentiation and due to their highly invasive 
nature, complete resection is rarely achieved, despite chemo- and radiotherapy. Less than half of 
patients with GBM survive more than a year (Table 6.2). This is particularly true for older 
patients. 
Brain/CNS Tumours GBM 
One-year survival 51.5% 29.3% 
Two-year survival 37.3% 8.7% 
Five-year survival 29.1% 3.3% 
Ten-year survival 25.3% 2.3% 
Table 6.2. Observed average relative survival rates for patients diagnosed over the period 1973-2002 with 
a primary malignant brain/CNS tumours vs. glioblastoma multiforme. Adapted from Accelerate Brain 
Cancer Cure website135 
• Anaplastic Astrocytoma (WHO Grade III) ICD-0 9401/3 
Anaplastic astrocytoma is a diffusely infiltrating malignant brain tumour that primarily affects 
adults. It mostly arises from the cerebral hemispheres, either from diffuse astrocytoma WHO 
grade II or de novo (i.e. without a recognizable precursor lesion). These tumours have an 
inherent tendency to progress to glioblastoma multiforme. The rate of progression is variable, 
but some studies suggest a mean time interval of two years.1 6 
• Diffuse Astrocytoma (WHO Grade II) ICD-0 9400/3 
Diffuse astrocytoma is a diffusely infiltrating astrocytoma typically affecting young adults and 
characterized by a high degree of cellular differentiation and slow growth. Depending on the 
predominant cellular composition of the tumour, it may be further classified into fibrillary 
(ICD-0 9420/3), gemistocytic (ICD-0 9411/3), and protoplasmic (ICD-O 9410/3) types. 
Diffuse astrocytoma represents 10-15% of all astrocytic brain tumours with mean survival time 
after surgical resection ranging from 6-8 years.81 Gemistocytic astrocytoma is more prone to 
malignant transformation to anaplastic astrocytoma and glioblastoma multiforme, 1 3 7 , 1 3 8 but the 
WHO Working Groups did not recommend assigning it a WHO grade III as for anaplastic 
81 137 astrocytoma. ' 
• Oligodendroglioma (WHO Grade II) ICD-O 9450/3 
These tumours are diffusely infiltrating, well-differentiated glioma of adults, and appear on light 
microscopy as round cells with perinuclear halos (termed the "fried egg" appearance) and an 
acutely branching (chicken-wire) capillary pattern. Oligodendroglioma accounts for 
approximately 2.5% of all primary brain tumours and 5-6% of all gliomas. 8" 1 0 , 1 3 9 
• Anaplastic Oligodendroglioma (WHO Grade III) ICD-O 9382/3 
Anaplastic oligodendroglioma is a malignant brain tumour of oligodendrocytic cells that has 
diffuse histological features and less favourable prognosis than oligodendroglioma. This type of 
tumour makes up approximately 1.2% of all primary brain tumours predominantly affecting 
adults, with a peak incidence between ages 45 and 50 . 9 , 1 0 ' 1 3 9 Manifestation of anaplastic 
oligodendroglioma is thus 7-8 years later on average than WHO Grade II oligodendroglioma.9, 
io, 139 R e c e n t a ( j v a n c e s in the treatment of oligodendroglioma and anaplastic oligodendroglioma 
through the use of chemotherapy-radiotherapy combination have lead to improved survival rates 
from 3.5 years 1 3 9 to 4-5 years. 1 4 0" 1 4 3 These rates are further improved in patients whose tumours 
have lost the lp and 19q allele. 1 4 0 ' 1 1 
These advances are important to the current study because they introduce a potential bias to the 
incidence rates through increased genetic testing (lp/19q deletions), and thus diagnosis of 
oligodendrogliomas. It has further been suggested that less stringent diagnostic criteria triggered 
by a desire not to impede any patient from gaining benefit from chemotherapy has accounted for 
an increased incidence. 8" 1 0 , 1 3 9 A recent study using both CBTRUS and SEER data showed an 
inverse trend between the incidence of oligodendroglioma and astrocytoma over the period 
1973-2004. In the recent years a levelling off of the observed rapid increased oligodendroglioma 
incidence was suggested by the authors as a return to the true incidence that was previously 
caused by misclassification and a desire not to deprive patients of a chance for cure. 1 8 
• Medulloblastoma (WHO Grade IV) ICD-0 9470/3 
Medulloblastoma is a malignant embryonal tumour of the cerebellum found predominantly in 
children. It is invasive in nature with an inherent tendency to metastasize to other sites via 
cerebrospinal fluid pathways. A number of types exist, including desmoplastic/nodular 
medulloblastoma (ICD-0 9471/3), medulloblastoma with extensive nodularity (ICD-0 9471/3), 
anaplastic medulloblastoma (ICD-0 9474/3), and large cell medulloblastoma (ICD-0 9474/3). 
Annual incidence has been estimated at 0.5 per 100 000 children less than 15 years of age, 8 " 1 0 , 1 4 4 
with a peak age at 7 years and a male predominance of 65%. Seventy percent of 
medulloblastomas occur in patients less than 16 years 1 4 5 , 1 4 6 and rarely occur beyond the fifth 
decade of life. A recent study highlighted the seasonal variation in incidence of paediatric 
medulloblastoma in the US over the period 1995-2001. 1 4 7 
6.1.2 Tumours of Cranial Nerves 
• Vestibular Schwannoma (WHO Grade I) ICD-O 9560/0 
A Schwannoma is a benign nerve sheath tumour that is typically encapsulated and well-
differentiated. These can occur in any nerve sheath. Multiple Schwannomas are associated with 
neurofibromatosis type 2 or Schwannomatosis. The vast majority of Schwannomas occur 
outside the central nervous system, but we have limited our focus only to intra-cranial 
Schwannomas. They represent 8% of intra-cranial tumours and 85% of cerebellopontine angle 
tumours. 8 1 When Schwannomas occur in the eighth cranial nerve they are termed vestibular 
Schwannoma or acoustic neuroma and typically present asymptomatically or with hearing loss. 
These tumours have recently become the focus of extensive research to determine whether a 
positive link exists between mobile phone usage and development of the tumour. Some authors 
report positive assoc ia t ions , 4 3 ' 5 5 ' 5 6 , 5 8 ' 6 8 , 1 4 8 , 1 4 9 while others refute the association. 7 1 , 7 3 
6.1.3 Tumours of the Meninges 
• Meningioma (WHO Grade I-III) ICD-0 9530/0 
Most meningiomas are benign and correspond to WHO Grade I (Table 6.3). They are 
neoplasms of the meningothelial (arachnoidal) cells that form the covering of the brain 
substance (dura). They account for 24-40% of all primary intra-cranial tumours, 1 0 ' 1 5 0 although 
many are found incidentally and patients may remain asymptomatic without a resection for 
many years. 
Meningioma with low risk of recurrence and aggressive growth 
ICD-O code 
Meningioma Who Grade I 9530/0 
Meningothelial meningioma Who Grade I 9531/0 
Fibrous (fibroblastic) meningioma Who Grade I 9532/0 
Transitional (mixed) meningioma Who Grade I 9537/0 
Psammomatous meningioma Who Grade I 9533/0 
Angiomatous meningioma Who Grade I 9534/0 
Microcystic meningioma Who Grade I 9530/0 
Secretory meningioma Who Grade I 9530/0 
Lymphoplasmacyte-rich meningioma Who Grade I 9530/0 
Metaplastic meningioma Who Grade I 9530/0 
Meningioma with greater likelihood of recurrence and/or aggressive growth 
Clear cell meningioma Who Grade II 9538/1 
Chordoid meningioma Who Grade II 9538/1 
Atypical meningioma Who Grade II 9539/1 
Papillary meningioma Who Grade III 9538/3 
Rhabdoid meningioma Who Grade III 9538/3 
Anaplastic (malignant) meningioma Who Grade III 9530/3 
Table 6.3. Meningiomas grouped by likelihood of recurrence and grade. Adapted from the latest WHO 
Classification of Tumours of the Central Nervous System. 
These tumours have also recently become the focus of extensive research to determine whether 
a positive link exists between mobile phone usage and development of the tumour,5 7 and genetic 
associations for targeted therapeutic options. 1 5 0 Despite the vast majority of these tumours being 
slow-growing, they are nonetheless clinically significant and can cause obstruction of normal 
fluid flows through the brain, leading to seizures, coma and death. Meningiomas are mandated 
by law in the US for reporting to Cancer Registries, but this is not the case in Australia. As 
such, we have a limited view of the incidence of these tumours. 
6.1.4 Tumours of the Sellar Region 
• Pituitary Adenoma (WHO Grade I) ICD-0 8140/0 
By far the most common tumour of the pituitary gland is the pituitary adenoma, comprising 
about 12% of all intra-cranial neoplasms. Because this tumour arises from hormone secreting 
cells of the pituitary, it mostly affects the endocrine system, but it can have devastating effects 
on the central nervous system through mass effect (compression of surrounding structures such 
as nerves that control vision). 
6.1.5 Other Neoplasms 
A number of tumours not considered in the current study include subtypes of lymphomas and 
haematopoietic neoplasms, germ cell tumours and metastatic tumours. With the exception of 
certain tumours (e.g. primary central nervous system lymphoma, haemangioma, 
haemangiopericytoma), this group is not considered as originating from the brain parenchyma 
(i.e. primary) or evolve from embryological origins. 
I l l 
6.2 Migration Data Table (Australian Hospital Statistics) 
Table 6.4 below shows separation statistics for all Australian states and territories. This data is 
compiled by the AIHW and refers to the number of patients receiving treatment in a state or 
territory separate to their residential address. This data was used to determine a weighting factor 
of 3.21% in the current study. 
~~~ ~ ~~ ~~~ ~ separations 
Stat* or territory of hospitalisation ^ 1 ^ 
State or territory of usual residence NSW V k CHd W A SA Taa ACT NT Total population
1" 
Public hospitals 
New South Wales 1.426.157 18.897 9.120 583 1.659 247 18.075 345 1,475.083 207.8 
Victoria 5.868 1.285.853 1.825 522 2.204 260 275 316 1,297.123 243.5 
Queensland 12,387 1,365 768.237 443 365 193 194 367 783.551 189.9 
Western Australia 456 430 394 447,508 264 78 46 1.647 450.843 218.4 
South Australia 575 1.559 407 214 363.409 59 53 2 5 5 0 368.826 231.6 
Tasmania 338 1.415 229 70 81 96.199 19 27 98.378 191.0 
Australian Capital Territory 2,998 224 156 52 45 12 57.056 34 60.577 195.1 
Northern Territory 218 314 370 231 2.044 9 12 80.527 83.725 466.4 
Other Australian territories*'1 n.p 0 4 158 0 0 1 0 ftp. np i 
Not elsewhere classified*31 n p 4.185 3.291 1,115 65 99 36 0 ftp. n.p. 
Not reported 0 0 597 0 491 0 0 0 1.088 
Total 1.462.129 1314,242 784.630 450.896 360.M7 97.156 75767 85.813 4,861.280 218J 
Private hospitals 
New South Wales 790.009 6,902 25.239 204 1.390 np. np. n-p- 831.135 116.0 
Victoria 6.523 750,610 1.535 136 1.249 ftp. n p n p . 760.258 141.1 
Queensland 3.446 960 712,860 163 213 np. n p n.p. 717.753 172.1 
Western Australia 355 286 227 288.186 98 n p . np. n.p. 289.225 138.4 
South Australia 193 403 291 57 224.718 np. n.p n-P- 225.716 130.3 
Tasmania 273 1,120 270 30 55 np. np . n.p. 60.837 115.5 
Australian Capital Territoiy 1.996 181 150 15 56 ftp. n.p. n.p. 29.475 92.0 
Northern Territory 199 364 499 179 1.247 ftp. npL n-P- 13,528 13.4 
Other Australian territories''' 0 83 36 0 np. n.p. n-P- ftp. np i 
Not elsewhere classified"31 n p 601 837 157 26 np. np i n p . ftp. np i 
Not reported 0 0 3 0 272 np. npL n p . 275 
Total 808,378 761.417 742.614 288.163 229.324 up. n p . 2.941.637 136.3 
(a) Separations for ^ tch the care type was reported as Newborn win no quail ed days. and records for Hospital boarders and Pafiumoui organ procurement nave Been excluded. 
(b) Rales per 1.000 popuiaton were d<recty a^e-standardised as delated m Append* 1. 
(c) Includes Cocoa <Kee4rg) Islands. Cmtstmas Island. Jenns Bay Terrtory. Records win a Stare of usual residence of Other Australian temtones in New Soutn Wales are currenty under review. 
(d) Includes resdent overseas, at sea, no fixed address. Record) wan a Sfae of usual residence of Notelsenhere classified n New Soutn Wales are currenty under revew. 
Table 6.4: Separations, by state or territory of usual residence and hospital sector, states and territories, 
2006-07. pl55 Australian Hospital Statistics 2006-7, AIHW 2008.91 
Calculation of weighting factor; 
Public Hospitals 
1. The number of NSW residents using public hospitals in NSW minus NSW residences 
using public hospitals in other Australian states, minus ACT residents using NSW 
public hospitals equalled 30,851 persons (1,475,083 - 1,426,157 - 18,075). 
2. 30,851 + number of ACT residents going to other states for public health care (224 + 
156 + 52 + 45 + 12) equals 31,340. 
3. Given a total residence of ACT and NSW is 1,483,223. 
4. A migration rate of 0.02113 (31,340/1,483,223) is calculated 
Private Hospitals 
1. The number of NSW residents using private hospitals in NSW minus NSW residences 
using private hospitals in other Australian states, minus ACT residents using NSW 
private hospitals equalled 41,127 persons (831,136 - 790,009). 
2. 41,127 + number of ACT residents going to other states for public health care (181 + 
150+ 15+ 56) equals 41,529. 
3. Given a total residence of NSW is 790,009. 
4. A migration rate of 0.052568 (41,529/790,009) is calculated 
Combined totals equalled 2,273,232 (1,483,223 + 790,009) with migration of 72,869 (31,340 + 
41,529) people giving a final rate of 0.032055 (72,869/2,273,232). 
6.3 Standard Population Tables 
Age group Australian Standard 2001 2000 U.S. Standard WHO World standard 2000-2025 
0-4 1282357.00 18986520.00 886000.00 
5-9 1351664.00 19919840.00 869000.00 
10-14 1353177.00 20056779.00 860000.00 
15-19 1352745.00 19819518.00 847000.00 
20-24 1302412.00 18257225.00 822000.00 
25-29 1407081.00 17722067.00 793000.00 
30-34 1466615.00 19511370.00 761000.00 
35-39 1492204.00 22179956.00 715000.00 
40-44 1479257.00 22479229.00 659000.00 
45-49 1358594.00 19805793.00 604000.00 
50-54 1300777.00 17224359.00 537000.00 
55-59 1008799.00 13307234.00 455000.00 
60-64 822024.00 10654272.00 372000.00 
65-69 682513.00 9409940.00 296000.00 
70-74 638380.00 8725574.00 221000.00 
75-79 519356.00 7414559.00 152000.00 
80-84 330050.00 4900234.00 91000.00 
85+ 265235.00 4259173.00 63500.00 
Table 6.5. Standard population tables by five year age groups for 2001 Australian Standard Population, 
2000 US standard Population, and WHO World Standard Population 2000-2025. 
6.4 CBTRUS Data and Morphology Code Comparison 
Mstotogy 
TOTAL 
N 
% of All 
Reported A trusted 
Brain Tumors Rait 95% Ci. 
Tumors of Neuroepithelial Tissue 54,341 343 848 (641-6.52) 
PtocyHc astrocytoma 2,625 17 033 (0.31-0.34) 
Protoplasmic & flbriary astrocytoma 854 05 010 (0.104.11) 
Anaplastic astrocytoma 3,365 2.1 0.40 (0.39-0.42) 
Unique astrocytoma variants 753 05 0.09 (0.06-0 10) 
Astrocytoma, NOS 3,695 23 0.44 (0.43-0 46) 
CMMIFIFFLFT 27,040 17.1 617 (3.13421) 
OSgodendrogloma 2,269 1.4 027 (020029) 
Anaplastic olgodendrogioma 1,031 07 012 (0.12-0.13) 
Ependymoma/anaplastic ependymoma 2,147 1.4 0.26 (025-027) 
Ependymoma variants 798 05 010 (0 09410) 
Mixed gKoma 1,573 10 019 (016-020) 
Gioma malignant, NOS 3,518 22 0.43 (0.41-0 44) 
Oorold plexus 351 02 0.04 (0 04-005) 
Meuroefithefal 171 0.1 0.02 (0 02-002) 
Non-maignant and malgnant neuronaVgial 2250 14 027 (028429) 
Pineal parenchymal 279 02 003 (0 034 04) 
ErrhrycriaVpdmittve/medulotolastoma 1364 1.0 019 (0l18420) 
Tumors of Cranial and Soinal Nerves 13,735 87 141 (1.59-1.64) 
Nerve sheath, n on-malignant and malignant 13,733 67 1.81 (159-164) 
Tumors of Meninges 5M32 35.1 a 52 (847-857) 
Meningioma 53,455 338 6l29 (623-6 34) 
Other mesenchymal, non-malignant and malignant 631 04 0.08 (0.074.08) 
Hem an g iohia stoma 1,346 OS 018 (0.154.17) 
Lvmohomas and Hematoooletic Neodasms 3,355 24 048 (044447) 
Lymphoma 3,855 24 0.46 (0.444.47) 
Germ Call Tumors and Cysts 642 04 0.08 (0 074 09) 
Germ cell tuners, cysts and heterotopias 642 04 0.08 (0.074.09) 
Tumors of Seltar Region 21,287 135 254 (250457) 
Pituitary 20,131 127 240 (236-2 43) 
Craniopharyngioma 1,156 07 0.14 (0.134.15) 
Local Ertanstons from Regional Tumors 156 0.1 0.02 (0.02-0.02) 
Chordoma/chondrosarcoma 156 0.1 002 (0.024.02) 
Unclassified Tumors 8,680 55 1.02 (1.00-1.05) 
Hemangioma 1,161 07 014 (0.134.15) 
Neoplasm, unspecified 7,443 4.7 0.88 (0.864.90) 
Al other 76 00 001 (0.014 01) 
TOTAL' • 158,088 1004 18.71 (18.82-1680) 
Mt*M»lttrlOOjO(Bfieat>nyetn 
'/Mbtt to bmtn toman IhduMng MMqgUM ntt fntenttd In MtoM». 
AMmMtNu: CBTRUS. CMM Bato Timor «r mo Uilloit Slam* NIK^ CDC't Niton* Pnagwn of Ctnatr RtgiMa: 
SEBl NCTt SumnMtimi. EfUmlobgy ant 6M HntuMt program. Ct coitdtnca IMtnal; HQS, net omerutm tp/rMed 
Table 6.6. Distribution and incidence rates of primary (malignant and non-malignant) brain and central 
nervous system tumours by major histology groupings and histology, age-adjusted to the 2000 U.S. 
standard population; CBTRUS statistical report: NPCR and SEER, 2004-2006. 1 0 
CBTRUS Groupings" Morphology codes in CBTRUS but not in the current study Morphology codes common to both 
Pilocytic astrocytoma 
Protoplasmic & fibrillary astrocytoma 
Anaplastic astrocytoma 
Unique astrocytoma variants 
Astrocytoma, NOS 
Glioblastoma 
Oligodendroglioma 
Anaplastic oligodendroglioma 
Ependymoma/anaplastic ependymoma 
Ependymoma variants 
Mixed glioma 
Glioma malignant, NOS 
Choroid plexus 
Neuroepithelial 
Non-malignant and malignant neuronal/glial, neuronal and mixed 
Pineal parenchymal 
Embryonal/primitive/medulloblastoma 
Nerve sheath, non-malignant and malignant 
Other tumours of cranial and spinal nerves 
Meningioma 
Other mesenchymal, non-malignant and malignant 
Haemangioblastoma 
Lymphoma 
Germ cell tumours, cysts and heterotopias 
Pituitary 
Craniopharyngioma 
Choidoma/chondrosarcoma 
Haemangioma 
Neoplasm, unspecified 
All other 
M 9423 
M 8680 M 8681 M 8682 M 8690 M 8693 M 9442/le M 9491 
M 9360 
M 8963 M 9363 M 9472 M 9502 M 9503 M 9508 
M 9541 M 9561 M 9570 
M 9562 
M 8324 M 8728 M 8770 M 8800 M 8801 M 8802 M 8803 M 8804 M 8805 M 8806 M 8810 M 
8815 M 8824 M 8825 M 8830 M 8831 M 8850 M 8851 M 8857 M 8861 M 8890 M 8897 M 
8900 M 8910 M 8920 M 8990 M 9040 M 9180 M 9210 M 9241 M 9260 M 9480 
M 9535 
M 9590 M 9591 M 9596 M 9650 M 9651 M 9652 M 9653 M 9654 M 9655 M 9659 M 9661 M 
9662 M 9663 M 9664 M 9665 M 9667 M 9670 M 9671 M 9673 M 9675 M 9680 M 9684 M 
9687 M 9690 M 9691 M 9695 M 9698 M 9699 M 9701 M 9702 M 9705 M 9714 M 9719 M 
9727 M 9728 M 9729 M 9731 M 9733 M 9734 M 9740 M 9741 M 9750 M 9755 M 9756 M 
9757 M 9758 M 9766 M 9827 M 9861 M 9930 M 9970 
M 8020 M 9060 M 9061 M 9064 M 9065 M 9070 M 9071 M 9072 M 9080 M 9081 M 9082 M 
9083 M 9084 M 9085 M 9100 
M 8022 M 8040 M 8146 M 8190c M 8246 M 8260 M 8270 M 8271 M 8280 M 8281 M 8290 M 
8300 M 8310 M 8320c M 8323 M 8333 M 8334 M 8341c 
M 9220 M 9231 M 9240 M 9370 M 9371 M 9372 M 9373 
M 9121 M 9122 M 9123 M 9125 M 9130 M 9131M 9140 
M 8000 M 8001 M 8002 M 8003 M 8004 M 8005 M 8010 M 8013 M 8021 
M 8683c M 8720 M 8811c M 8840c M 8860c M 8896c M 8980c M 9173 M 9580 M 9751 M 
9752c M 9753c M 9754 M 9823c M 9837c M 9866c 
M 9421 
M 9410 M 9420 
M 9401 M 9411 
M 9383 M 9384 M 9424 M 9425 
M 9400 
M 9440 M 9441 M 9442 
M 9450 
M 9451 
M 9391 M 9392 M 9393 
M 9382 
M 9380 
M 9390 
M 9381 M 9430 M 9431 M 9444 
M 9412 M 9413 M 9490 M 9493 M 9500 M 9505 M 9506 M 9509 
M 9361 M 9362 
M 9470 M 9471 M 9472 M 9473 M 9474 
M 9540 M 9560 
M 9530 M 9531 M 9532 M 9533 M 9534 M 9537 M 9538 M 9539 
M 9150 
M 9161 
M 8140 M 8272 M 9582 
M 9350 M 9351 M 9352 
Table 6.7. Comparison of ICD-O-3/SNOMED morphology codes from CBTRUS and the current study. Highlighted codes are new entities included in the latest WHO Classification of 
Tumours of the Central Nervous System. 
6.5 Incidence tables from the current study 
US Std Incidence (+/- CI) by Year 
TOTAL 2000 2001 2002 
TUMOURS OF NEUROEPITHELIAL TISSUE 5.39 (±0.17) 5.86 (±0.18) 6.01 (±0.18) 
Pilocytic astrocytoma 0.22 (±0.04) 0.39 (±0.05) 0.32 (±0.04) 
Protoplasmic & fibrillary astrocytoma 0.03 (±0.01) 0.04 (±0.02) 0.10 (±0.02) 
Anaplastic astrocytoma 0.49 (±0.05) 0.54 (±0.05) 0.45 (±0.05) 
Unique astrocytoma variants 0.08 (±0.02) 0.00 (±0.00) 0.04 (±0.02) 
Astrocytoma, NOS 0.32 (±0.04) 0.29 (±0.04) 0.48 (±0.05) 
Glioblastoma 3.13 (±0.13) 3.34 (±0.14) 3.01 (±0.13) 
Oligodendroglioma 0.18 (±0.03) 0.33 (±0.04) 0.50 (±0.05) 
Anaplastic oligodendroglioma 0.26 (±0.04) 0.26 (±0.04) 0.27 (±0.04) 
Ependymoma/anaplastic ependymoma 0.16 (±0.03) 0.14 (±0.03) 0.15 (±0.03) 
Ependymoma variants 0.00 (±0.00) 0.00 (±0.00) 0.00 (±0.00) 
Mixed glioma 0.04 (±0.02) 0.01 (±0.01) 0.13 (±0.03) 
Glioma malignant, NOS 0.02 (±0.01) 0.02 (±0.01) 0.13 (±0.03) 
Choroid plexus n<16 
Neuroepithelial n<16 
Non-malignant and malignant neuronal/glial, 
neuronal and mixed 0.19 (±0.03) 0.17 (±0.03) 0.20 (±0.03) 
Pineal parenchymal n<16 
Embryonal/primitive/medulloblastoma 0.25 (±0.04) 0.26 (±0.04) 0.19 (±0.03) 
TUMOURS OF CRANIAL AND SPINAL 
NERVES 0.69 (±0.06) 0.97 (±0.07) 0.77 (±0.07) 
Schwannoma 0.69 (±0.06) 0.97 (±0.07) 0.77 (±0.07) 
TUMOURS OF MENINGES 2.18 (±0.11) 3.06 (±0.13) 2.88 (±0.13) 
Meningioma 2.05 (±0.11) 2.82 (±0.13) 2.70 (±0.12) 
Other mesenchymal, non-malignant and malignant n<16 
Haemangioblastoma 0.11 (±0.02) 0.18 (±0.03) 0.15 (±0.03) 
LYMPHOMAS AND HEMOPOIETIC n<16 NEOPLASMS 
Lymphoma n<16 
TUMOURS OF SELLAR REGION 1.52 (±0.09) 1.60 (±0.09) 1.46 (±0.09) 
Pituitary 1.43 (±0.09) 1.48 (±0.09) 1.39 (±0.09) 
Craniopharyngioma 0.09 (±0.02) 0.12 (±0.03) 0.07 (±0.02) 
UNCLASSIFIED TUMOURS 0.12 (±0.03) 0.15 (±0.03) 0.16 (±0.03) 
Haemangioma 0.12 (±0.03) 0.15 (±0.03) 0.16 (±0.03) 
2003 2004 2005 
6.50 (±0.19) 5.82 (±0.18) 5.89 (±0.18) 
0.48 (±0.05) 0.30 (±0.04) 0.16 (±0.03) 
0.04 (±0.02) 0.06 (±0.02) 0.06 (±0.02) 
0.60 (±0.06) 0.46 (±0.05) 0.45 (±0.05) 
0.11 (±0.02) 0.03 (±0.01) 0.11 (±0.03) 
0.40 (±0.05) 0.29 (±0.04) 0.23 (±0.04) 
3.33 (±0.14) 2.95 (±0.13) 3.52 (±0.14) 
0.45 (±0.05) 0.56 (±0.06) 0.26 (±0.04) 
0.26 (±0.04) 0.46 (±0.05) 0.27 (±0.04) 
0.16 (±0.03) 0.11 (±0.02) 0.10 (±0.02) 
0.00 (±0.00) 0.00 (±0.00) 0.00 (±0.00) 
0.15 (±0.03) 0.18 (±0.03) 0.11 (±0.03) 
0.10 (±0.02) 0.06 (±0.02) 0.13 (±0.03) 
0.12 (±0.03) 0.06 (±0.02) 0.21 (±0.03) 
0.22 (±0.04) 0.19 (±0.03) 0.23 (±0.04) 
0.79 (±0.07) 0.78 (±0.07) 0.79 (±0.07) 
0.79 (±0.07) 0.78 (±0.07) 0.79 (±0.07) 
3.27 (±0.14) 3.16 (±0.13) 2.92 (±0.13) 
3.02 (±0.13) 3.03 (±0.13) 2.82 (±0.13) 
0.19 (±0.03) 0.12 (±0.03) 0.04 (±0.02) 
1.76 (±0.10) 1.77 (±0.10) 1.28 (±0.08) 
1.59 (±0.09) 1.68 (±0.10) 1.17 (±0.08) 
0.17 (±0.03) 0.09 (±0.02) 0.12 (±0.03) 
0.11 (±0.02) 0.21 (±0.03) 0.14 (±0.03) 
0.11 (±0.02) 0.21 (±0.03) 0.14 (±0.03) 
2006 2007 2008 
6.01 (±0.18) 6.69 (±0.19) 6.70 (±0.19) 
0.29 (±0.04) 0.25 (±0.04) 0.32 (±0.04) 
0.03 (±0.01) 0.01 (±0.01) 0.04 (±0.02) 
0.47 (±0.05) 0.49 (±0.05) 0.60 (±0.06) 
0.03 (±0.01) 0.04 (±0.02) 0.06 (±0.02) 
0.35 (±0.04) 0.49 (±0.05) 0.37 (±0.05) 
3.33 (±0.14) 3.75 (±0.14) 3.86 (±0.15) 
0.35 (±0.04) 0.33 (±0.04) 0.16 (±0.03) 
0.33 (±0.04) 0.21 (±0.03) 0.24 (±0.04) 
0.15 (±0.03) 0.10 (±0.02) 0.14 (±0.03) 
0.00 (±0.00) 0.00 (±0.00) 0.00 (±0.00) 
0.04 (±0.02) 0.16 (±0.03) 0.19 (±0.03) 
0.13 (±0.03) 0.21 (±0.03) 0.22 (±0.04) 
0.23 (±0.04) 0.27 (±0.04) 0.25 (±0.04) 
0.20 (±0.03) 0.25 (±0.04) 0.09 (±0.02) 
0.61 (±0.06) 0.64 (±0.06) 0.65 (±0.06) 
0.61 (±0.06) 0.64 (±0.06) 0.65 (±0.06) 
3.37 (±0.14) 2.90 (±0.13) 2.96 (±0.13) 
3.20 (±0.13) 2.71 (±0.12) 2.78 (±0.12) 
0.15 (±0.03) 0.17 (±0.03) 0.16 (±0.03) 
1.80 (±0.10) 1.50 (±0.09) 1.38 (±0.09) 
1.66 (±0.10) 1.36 (±0.09) 1.26 (±0.08) 
0.15 (±0.03) 0.14 (±0.03) 0.12 (±0.03) 
0.18 (±0.03) 0.06 (±0.02) 0.22 (±0.03) 
0.18 (±0.03) 0.06 (±0.02) 0.22 (±0.03) 
Total per Year 9.95 (±0.24) 11.66 (±0.26) 11.28 (±0.25) 
US Std Incidence (+/- CI) by Year 
MALE 2000 2001 2002 
TUMOURS OF NEUROEPITHELIAL TISSUE 6.49 (±0.19) 7.07 (±0.20) 7.25 (±0.20) 
Pilocytic astrocytoma 0.16 (±0.03) 0.52 (±0.05) 0.34 (±0.04) 
Protoplasmic & fibrillary astrocytoma 0.06 (±0.02) 0.03 (±0.01) 0.12 (±0.03) 
Anaplastic astrocytoma 0.61 (±0.06) 0.67 (±0.06) 0.39 (±0.05) 
Unique astrocytoma variants 0.06 (±0.02) 0.00 (±0.00) 0.09 (±0.02) 
Astrocytoma, NOS 0.38 (±0.05) 0.41 (±0.05) 0.65 (±0.06) 
Glioblastoma 4.03 (±0.15) 4.04 (±0.15) 3.97 (±0.15) 
Oligodendroglioma 0.22 (±0.04) 0.34 (±0.04) 0.43 (±0.05) 
Anaplastic oligodendroglioma 0.34 (±0.04) 0.28 (±0.04) 0.32 (±0.04) 
Ependymoma/anaplastic ependymoma 0.07 (±0.02) 0.15 (±0.03) 0.12 (±0.03) 
Ependymoma variants 0.00 (±0.00) 0.00 (±0.00) 0.00 (±0.00) 
Mixed glioma 0.03 (±0.01) 0.03 (±0.01) 0.17 (±0.03) 
Glioma malignant, NOS 0.03 (±0.01) 0.00 (±0.00) 0.15 (±0.03) 
Choroid plexus n<16 
Neuroepithelial n<16 
Non-malignant and malignant neuronal/glial, 
neuronal and mixed 0.12 (±0.03) 0.21 (±0.03) 0.25 (±0.04) 
Pineal parenchymal n<16 
Embryonal/primitive/medulloblastoma 0.37 (±0.05) 0.34 (±0.04) 0.25 (±0.04) 
TUMOURS OF CRANIAL AND SPINAL 0.54 (±0.06) 0.89 (±0.07) NERVES 0.72 (±0.06) 
Schwannoma 0.54 (±0.06) 0.89 (±0.07) 0.72 (±0.06) 
TUMOURS OF MENINGES 1.17 (±0.08) 1.60 (±0.09) 1.65 (±0.10) 
Meningioma 1.14 (±0.08) 1.42 (±0.09) 1.36 (±0.09) 
Other mesenchymal, non-malignant and malignant n<16 
Haemangioblastoma 0.03 (±0.01) 0.15 (±0.03) 0.27 (±0.04) 
LYMPHOMAS AND HEMOPOIETIC n<16 NEOPLASMS 
Lymphoma n<16 
TUMOURS OF SELLAR REGION 1.51 (±0.09) 1.72 (±0.10) 2.07 (±0.11) 
Pituitary 1.42 (±0.09) 1.59 (±0.09) 1.99 (±0.11) 
Craniopharyngioma 0.09 (±0.02) 0.13 (±0.03) 0.08 (±0.02) 
UNCLASSIFIED TUMOURS 0.18 (±0.03) 0.14 (±0.03) 0.15 (±0.03) 
Haemangioma 0.18 (±0.03) 0.14 (±0.03) 0.15 (±0.03) 
Total per Year 9.96 (±0.24) 11.42 (±0.25) 11.85 (±0.26) 
12.47 (±0.26) 11.75 (±0.26) 11.06 (±0.25) 11.99 (±0.26) 11.78 (±0.26) 11.94 (±0.26) 
2003 2004 2005 2006 2007 2008 
7.59 (±0.21) 7.07 (±0.20) 7.63 (±0.21) 6.56 (±0.19) 8.09 (±0.21) 7.97 (±0.21) 
0.49 (±0.05) 0.28 (±0.04) 0.16 (±0.03) 0.23 (±0.04) 0.18 (±0.03) 0.31 (±0.04) 
0.02 (±0.01) 0.10 (±0.02) 0.06 (±0.02) 0.00 (±0.00) 0.00 (±0.00) 0.03 (±0.01) 
0.79 (±0.07) 0.60 (±0.06) 0.43 (±0.05) 0.64 (±0.06) 0.58 (±0.06) 0.79 (±0.07) 
0.14 (±0.03) 0.06 (±0.02) 0.20 (±0.03) 0.02 (±0.01) 0.03 (±0.01) 0.03 (±0.01) 
0.34 (±0.04) 0.35 (±0.04) 0.33 (±0.04) 0.28 (±0.04) 0.64 (±0.06) 0.47 (±0.05) 
4.05 (±0.15) 4.02 (±0.15) 4.70 (±0.16) 3.68 (±0.14) 4.90 (±0.17) 4.97 (±0.17) 
0.60 (±0.06) 0.56 (±0.06) 0.45 (±0.05) 0.29 (±0.04) 0.49 (±0.05) 0.15 (±0.03) 
0.23 (±0.04) 0.41 (±0.05) 0.37 (±0.05) 0.49 (±0.05) 0.24 (±0.04) 0.29 (±0.04) 
0.14 (±0.03) 0.03 (±0.01) 0.14 (±0.03) 0.21 (±0.03) 0.08 (±0.02) 0.19 (±0.03) 
0.00 (±0.00) 0.00 (±0.00) 0.00 (±0.00) 0.00 (±0.00) 0.00 (±0.00) 0.00 (±0.00) 
0.17 (±0.03) 0.24 (±0.04) 0.14 (±0.03) 0.03 (±0.01) 0.16 (±0.03) 0.26 (±0.04) 
0.09 (±0.02) 0.03 (±0.01) 0.16 (±0.03) 0.12 (±0.03) 0.16 (±0.03) 0.15 (±0.03) 
0.18 (±0.03) 0.09 (±0.02) 0.28 (±0.04) 0.20 (±0.03) 0.24 (±0.04) 0.11 (±0.02) 
0.28 (±0.04) 0.15 (±0.03) 0.21 (±0.03) 0.33 (±0.04) 0.28 (±0.04) 0.12 (±0.03) 
0.68 (±0.06) 0.73 (±0.06) 1.04 (±0.08) 0.62 (±0.06) 0.65 (±0.06) 0.58 (±0.06) 
0.68 (±0.06) 0.73 (±0.06) 1.04 (±0.08) 0.62 (±0.06) 0.65 (±0.06) 0.58 (±0.06) 
1.83 (±0.10) 1.98 (±0.11) 1.90 (±0.10) 1.96 (±0.10) 2.06 (±0.11) 2.02 (±0.11) 
1.55 (±0.09) 1.81 (±0.10) 1.81 (±0.10) 1.73 (±0.10) 1.85 (±0.10) 1.78 (±0.10) 
0.19 (±0.03) 0.14 (±0.03) 0.06 (±0.02) 0.21 (±0.03) 0.21 (±0.03) 0.21 (±0.03) 
1.69 (±0.10) 1.97 (±0.11) 130 (±0.09) 1.93 (±0.10) 1.78 (±0.10) 1.60 (±0.09) 
1.60 (±0.09) 1.91 (±0.10) 1.15 (±0.08) 1.79 (±0.10) 1.70 (±0.10) 1.50 (±0.09) 
0.09 (±0.02) 0.06 (±0.02) 0.15 (±0.03) 0.14 (±0.03) 0.08 (±0.02) 0.10 (±0.02) 
0.14 (±0.03) 0.21 (±0.03) 0.18 (±0.03) 0.12 (±0.03) 0.00 (±0.00) 0.17 (±0.03) 
0.14 (±0.03) 0.21 (±0.03) 0.18 (±0.03) 0.12 (±0.03) 0.00 (±0.00) 0.17 (±0.03) 
11.96 (±0.26) 11.96 (±0.26) 12.08 (±0.26) 11.21 (±0.25) 12.59 (±0.27) 12.34 (±0.26) 
US Std Incidence (+/- CI) by Year 
FEMALE 2000 2001 2002 
TUMOURS OF NEUROEPITHELIAL TISSUE 4.34 (±0.17) 4.71 (±0.18) 4.91 (±0.18) 
Pilocytic astrocytoma 0.29 (±0.04) 0.25 (±0.05) 0.29 (±0.04) 
Protoplasmic & fibrillary astrocytoma 0.00 (±0.01) 0.06 (±0.02) 0.09 (±0.02) 
Anaplastic astrocytoma 0.36 (±0.05) 0.41 (±0.05) 0.49 (±0.05) 
Unique astrocytoma variants 0.10 (±0.02) 0.00 (±0.00) 0.00 (±0.02) 
Astrocytoma, NOS 0.26 (±0.04) 0.17 (±0.04) 0.30 (±0.05) 
Glioblastoma 2.27 (±0.13) 2.72 (±0.14) 2.18 (±0.13) 
Oligodendroglioma 0.13 (±0.03) 0.33 (±0.04) 0.58 (±0.05) 
Anaplastic oligodendroglioma 0.18 (±0.04) 0.24 (±0.04) 0.23 (±0.04) 
Ependymoma/anaplastic ependymoma 0.25 (±0.03) 0.13 (±0.03) 0.19 (±0.03) 
Ependymoma variants 0.00 (±0.00) 0.00 (±0.00) 0.00 (±0.00) 
Mixed glioma 0.06 (±0.02) 0.00 (±0.01) 0.09 (±0.03) 
Glioma malignant, NOS 0.00 (±0.01) 0.03 (±0.01) 0.11 (±0.03) 
Choroid plexus n<16 
Neuroepithelial n<16 
Non-malignant and malignant neuronal/glial, 
neuronal and mixed 0.26 (±0.03) 0.12 (±0.03) 0.16 (±0.03) 
Pineal parenchymal n<16 
Embryonal/primitive/medulloblastoma 0.12 (±0.04) 0.18 (±0.04) 0.13 (±0.03) 
TUMOURS OF CRANIAL AND SPINAL 0.81 (±0.06) 1.05 (±0.07) 0.82 (±0.07) NERVES 
Schwannoma 0.81 (±0.06) 1.05 (±0.07) 0.82 (±0.07) 
TUMOURS OF MENINGES 3.18 (±0.11) 4.48 (±0.13) 4.10 (±0.13) 
Meningioma 2.94 (±0.11) 4.18 (±0.13) 4.05 (±0.12) 
Other mesenchymal, non-malignant and malignant n<16 
Haemangioblastoma 0.18 (±0.02) 0.21 (±0.03) 0.02 (±0.03) 
LYMPHOMAS AND HEMOPOIETIC n<16 NEOPLASMS 
Lymphoma n<16 
TUMOURS OF SELLAR REGION 1.55 (±0.09) 1.51 (±0.09) 0.93 (±0.09) 
Pituitary 1.45 (±0.09) 1.39 (±0.09) 0.87 (±0.09) 
Craniopharyngioma 0.09 (±0.02) 0.12 (±0.03) 0.06 (±0.02) 
UNCLASSIFIED TUMOURS 0.06 (±0.03) 0.16 (±0.03) 0.18 (±0.03) 
Haemangioma 0.06 (±0.03) 0.16 (±0.03) 0.18 (±0.03) 
Total per Year 9.98 (±0.24) 11.93 (±0.26) 10.93 (±0.25) 
2003 2004 2005 
5.49 (±0.19) 4.74 (±0.18) 4.22 (±0.18) 
0.48 (±0.05) 0.33 (±0.04) 0.16 (±0.03) 
0.05 (±0.02) 0.03 (±0.02) 0.07 (±0.02) 
0.40 (±0.06) 0.35 (±0.05) 0.48 (±0.05) 
0.08 (±0.02) 0.00 (±0.01) 0.02 (±0.03) 
0.45 (±0.05) 0.24 (±0.04) 0.12 (±0.04) 
2.67 (±0.14) 2.02 (±0.13) 2.40 (±0.14) 
0.31 (±0.05) 0.55 (±0.06) 0.08 (±0.04) 
0.29 (±0.04) 0.51 (±0.05) 0.16 (±0.04) 
0.19 (±0.03) 0.18 (±0.02) 0.05 (±0.02) 
0.00 (±0.00) 0.00 (±0.00) 0.00 (±0.00) 
0.14 (±0.03) 0.12 (±0.03) 0.08 (±0.03) 
0.11 (±0.02) 0.09 (±0.02) 0.09 (±0.03) 
2006 2007 2008 
5.46 (±0.18) 5.37 (±0.19) 5.47 (±0.19) 
0.36 (±0.04) 0.32 (±0.04) 0.33 (±0.04) 
0.07 (±0.01) 0.03 (±0.01) 0.06 (±0.02) 
0.29 (±0.05) 0.39 (±0.05) 0.41 (±0.06) 
0.03 (±0.01) 0.06 (±0.02) 0.09 (±0.02) 
0.41 (±0.04) 0.33 (±0.05) 0.27 (±0.05) 
2.98 (±0.14) 2.71 (±0.14) 2.79 (±0.15) 
0.40 (±0.04) 0.18 (±0.04) 0.17 (±0.03) 
0.17 (±0.04) 0.18 (±0.03) 0.19 (±0.04) 
0.09 (±0.03) 0.11 (±0.02) 0.09 (±0.03) 
0.00 (±0.00) 0.00 (±0.00) 0.00 (±0.00) 
0.06 (±0.02) 0.17 (±0.03) 0.14 (±0.03) 
0.13 (±0.03) 0.25 (±0.03) 0.29 (±0.04) 
0.07 (±0.03) 
0.16 (±0.04) 
0.91 (±0.07) 
0.91 (±0.07) 
4.69 (±0.14) 
4.47 (±0.13) 
0.20 (±0.03) 
0.03 (±0.02) 
0.23 (±0.03) 
0.82 (±0.07) 
0.82 (±0.07) 
4.30 (±0.13) 
4.22 (±0.13) 
0.08 (±0.03) 
0.15 (±0.03) 
0.25 (±0.04) 
0.55 (±0.07) 
0.55 (±0.07) 
3.93 (±0.13) 
3.82 (±0.13) 
0.03 (±0.02) 
0.25 (±0.04) 
0.07 (±0.03) 
0.60 (±0.06) 
0.60 (±0.06) 
4.75 (±0.14) 
4.63 (±0.13) 
0.09 (±0.03) 
0.28 (±0.04) 
0.20 (±0.04) 
0.62 (±0.06) 
0.62 (±0.06) 
3.74 (±0.13) 
3.58 (±0.12) 
0.13 (±0.03) 
0.39 (±0.04) 
0.06 (±0.02) 
0.71 (±0.06) 
0.71 (±0.06) 
3.88 (±0.13) 
3.75 (±0.12) 
0.11 (±0.03) 
1.83 (±0.10) 
1.59 (±0.09) 
0.24 (±0.03) 
0.08 (±0.02) 
0.08 (±0.02) 
13.02 (±0.27) 
1.58 (±0.10) 
I.47 (±0.10) 
0.11 (±0.02) 
0.21 (±0.03) 
0.21 (±0.03) 
II.67 (±0.26) 
1.26 (±0.08) 
1.17 (±0.08) 
0.09 (±0.03) 
0.09 (±0.03) 
0.09 (±0.03) 
10.10 (±0.24) 
1.68 (±0.10) 
1.53 (±0.10) 
0.15 (±0.03) 
0.25 (±0.03) 
0.25 (±0.03) 
12.74 (±0.27) 
1.25 (±0.09) 
I.05 (±0.09) 
0.21 (±0.03) 
0.11 (±0.02) 
0.11 (±0.02) 
II.10 (±0.25) 
1.17 (±0.09) 
I.03 (±0.08) 
0.14 (±0.03) 
0.26 (±0.03) 
0.26 (±0.03) 
II.58 (±0.25) 
6.6 Case number tables from the current study 
TOTAL 2000 2001 2002 
TUMOURS OF NEUROEPITHELIAL TISSUE 372.75 412.65 426.3 
Pilocytic astrocytoma 14.7 26.25 21 
Protoplasmic & fibrillary astrocytoma 2.1 3.15 7.35 
Anaplastic astrocytoma 33.6 37.8 31.5 
Unique astrocytoma variants 5.25 0 3.15 
Astrocytoma, NOS 22.05 21 33.6 
Glioblastoma 219.45 238.35 217.35 
Oligodendroglioma 11.55 23.1 34.65 
Anaplastic oligodendroglioma 17.85 17.85 19.95 
Ependymoma/anaplastic ependymoma 10.5 9.45 10.5 
Ependymoma variants 0 0 0 
Mixed glioma 3.15 1.05 9.45 
Glioma malignant, NOS 1.05 1.05 9.45 
Choroid plexus 1.05 2.1 0 
Neuroepithelial 1.05 0 0 
Non-malignant and malignant neuronal/glial, neuronal and mixed 12.6 11.55 13.65 
Pineal parenchymal 0 2.1 2.1 
Embryonal/primitive/medulloblastoma 16.8 17.85 12.6 
TUMOURS OF CRANIAL AND SPINAL NERVES 47.25 69.3 55.65 
Schwannoma 47.25 69.3 55.65 
TUMOURS OF MENINGES 151.2 217.35 207.9 
Meningioma 141.75 200.55 195.3 
Other mesenchymal, non-malignant and malignant 2.1 4.2 2.1 
Haemangioblastoma 7.35 12.6 10.5 
LYMPHOMAS AND HEMOPOIETIC NEOPLASMS 3.15 1.05 0 
Lymphoma 3.15 1.05 0 
TUMOURS OF SELLAR REGION 105 113.4 105 
Pituitary 98.7 105 99.75 
Craniopharyngioma 6.3 8.4 5.25 
UNCLASSIFIED TUMOURS 8.4 10.5 11.55 
Haemangioma 8.4 10.5 11.55 
Total per Year 687.75 824.25 806.4 
2003 2004 2005 2006 2007 2008 Total % Total 
469.35 424.2 437.85 452.55 506.1 521.85 4023.6 52.7 
32.55 19.95 10.5 19.95 16.8 22.05 183.75 2.4 
3.15 4.2 4.2 2.1 1.05 3.15 30.45 0.4 
44.1 34.65 32.55 34.65 40.95 47.25 337.05 4.4 
8.4 2.1 8.4 2.1 3.15 4.2 36.75 0.5 
28.35 21 16.8 25.2 35.7 29.4 233.1 3.1 
244.65 222.6 267.75 259.35 294 311.85 2275.35 29.8 
31.5 38.85 18.9 25.2 23.1 11.55 218.4 2.9 
18.9 33.6 19.95 24.15 15.75 17.85 185.85 2.4 
11.55 7.35 7.35 10.5 7.35 10.5 85.05 1.1 
0 0 0 0 0 0 0.0 
11.55 12.6 8.4 3.15 11.55 14.7 75.6 1.0 
7.35 4.2 9.45 9.45 15.75 16.8 74.55 1.0 
2.1 3.15 1.05 1.05 0 5.25 15.75 0.2 
2.1 0 2.1 1.05 4.2 1.05 11.55 0.2 
8.4 4.2 14.7 15.75 18.9 18.9 118.65 1.6 
0 3.15 0 5.25 1.05 1.05 14.7 0.2 
14.7 12.6 15.75 13.65 16.8 6.3 127.05 1.7 
57.75 56.7 59.85 45.15 49.35 51.45 492.45 6.4 
57.75 56.7 59.85 45.15 49.35 51.45 492.45 6.4 
2373 232.05 218.4 257.25 223.65 233.1 1978.2 25.9 
219.45 222.6 211.05 244.65 210 219.45 1864.8 24.4 
4.2 1.05 4.2 2.1 1.05 2.1 23.1 0.3 
13.65 8.4 3.15 10.5 12.6 11.55 90.3 1.2 
2.1 1.05 2.1 1.05 0 3.15 13.65 0.2 
2.1 1.05 2.1 1.05 0 3.15 13.65 0.2 
128.1 1323 94.5 134.4 114.45 109.2 1036.35 13.6 
116.55 126 86.1 123.9 103.95 99.75 959.7 12.6 
11.55 6.3 8.4 10.5 10.5 9.45 76.65 1.0 
8.4 14.7 9.45 13.65 4.2 15.75 96.6 1 3 
8.4 14.7 9.45 13.65 4.2 15.75 96.6 1 3 
903 861 822.15 904.05 897.75 934.5 7640.85 100.0 
MALE 2000 2001 2002 
TUMOURS OF NEUROEPITHELIAL TISSUE 220.5 242.55 249.9 
Pilocytic astrocytoma 5.25 17.85 11.55 
Protoplasmic & fibrillary astrocytoma 2.1 1.05 4.2 
Anaplastic astrocytoma 21 23.1 13.65 
Unique astrocytoma variants 2.1 0 3.15 
Astrocytoma, NOS 12.6 14.7 23.1 
Glioblastoma 137.55 137.55 135.45 
Oligodendroglioma 7.35 11.55 14.7 
Anaplastic oligodendroglioma 11.55 9.45 11.55 
Ependymoma/anaplastic ependymoma 2.1 5.25 4.2 
Ependymoma variants 0 0 0 
Mixed glioma 1.05 1.05 6.3 
Glioma malignant, NOS 1.05 0 5.25 
Choroid plexus 0 2.1 0 
Neuroepithelial 0 0 0 
Non-malignant and malignant neuronal/glial, neuronal and mixed 4.2 7.35 8.4 
Pineal parenchymal 0 0 0 
Embryonal/primitive/medulloblastoma 12.6 11.55 8.4 
TUMOURS OF CRANIAL AND SPINAL NERVES 18.9 31.5 25.2 
Schwannoma 18.9 31.5 25.2 
TUMOURS OF MENINGES 38.85 54.6 57.75 
Meningioma 37.8 48.3 47.25 
Other mesenchymal, non—malignant and malignant 0 1.05 1.05 
Haemangioblastoma 1.05 5.25 9.45 
LYMPHOMAS AND HEMOPOIETIC NEOPLASMS 2.1 0 0 
Lymphoma 2.1 0 0 
TUMOURS OF SELLAR REGION 51.45 59.85 70.35 
Pituitary 48.3 55.65 67.2 
Craniopharyngioma 3.15 4.2 3.15 
UNCLASSIFIED TUMOURS 6.3 5.25 5.25 
Haemangioma 6.3 5.25 5.25 
Total per Year 338.1 393.75 408.45 
2003 2004 2005 2006 2007 2008 Total % Total 
268.8 252 280.35 241.5 300.3 306.6 2362.5 62.4 
16.8 9.45 5.25 8.4 6.3 10.5 91.35 2.4 
1.05 3.15 2.1 0 3.15 2.1 18.9 0.5 
28.35 21 15.75 23.1 24.15 30.45 200.55 5.3 
5.25 2.1 7.35 1.05 1.05 1.05 23.1 0.6 
12.6 12.6 12.6 10.5 23.1 18.9 140.7 3.7 
142.8 144.9 174.3 137.55 184.8 195.3 1390.2 36.7 
21 19.95 15.75 10.5 16.8 5.25 122.85 3.2 
8.4 14.7 13.65 17.85 8.4 10.5 106.05 2.8 
5.25 1.05 5.25 7.35 3.15 7.35 40.95 1.1 
0 0 0 0 0 0 0 0.0 
6.3 8.4 5.25 1.05 5.25 9.45 44.1 1.2 
3.15 1.05 6.3 4.2 5.25 5.25 31.5 0.8 
1.05 3.15 0 0 0 0 6.3 0.2 
1.05 0 0 0 1.05 1.05 3.15 0.1 
6.3 3.15 9.45 7.35 8.4 4.2 58.8 1.6 
0 2.1 0 1.05 0 1.05 4.2 0.1 
9.45 5.25 7.35 11.55 9.45 4.2 79.8 2.1 
24.15 26.25 37.8 22.05 25.2 22.05 233.1 6.2 
24.15 26.25 37.8 22.05 25.2 22.05 233.1 6.2 
61.95 69.3 68.25 72.45 75.6 76.65 575.4 15.2 
52.5 63 65.1 64.05 68.25 68.25 514.5 13.6 
3.15 1.05 1.05 1.05 0 1.05 9.45 0.2 
6.3 5.25 2.1 7.35 7.35 7.35 51.45 1.4 
1.05 0 1.05 1.05 0 0 5.25 0.1 
1.05 0 1.05 1.05 0 0 5.25 0.1 
60.9 72.45 47.25 70.35 66.15 61.95 560.7 14.8 
57.75 70.35 42 65.1 63 57.75 527.1 13.9 
3.15 2.1 5.25 5.25 3.15 4.2 33.6 0.9 
5.25 7.35 6.3 4.2 0 6.3 46.2 1.2 
5.25 7.35 6.3 4.2 0 6.3 46.2 1.2 
422.1 427.35 441 411.6 467.25 473.55 3783.15 100.0 
FEMALE 2000 2001 2002 
TUMOURS OF NEUROEPITHELIAL TISSUE 152.25 170.1 176.4 
Pilocytic astrocytoma 9.45 8.4 9.45 
Protoplasmic & fibrillary astrocytoma 0 2.1 3.15 
Anaplastic astrocytoma 12.6 14.7 17.85 
Unique astrocytoma variants 3.15 0 
Astrocytoma, NOS 9.45 6.3 10.5 
Glioblastoma 81.9 100.8 81.9 
Oligodendroglioma 4.2 11.55 19.95 
Anaplastic oligodendroglioma 6.3 8.4 8.4 
Ependymoma/anaplastic ependymoma 8.4 4.2 6.3 
Ependymoma variants 0 0 0 
Mixed glioma 2.1 0 3.15 
Glioma malignant, NOS 0 1.05 4.2 
Choroid plexus 1.05 0 0 
Neuroepithelial 1.05 0 0 
Non-malignant and malignant neuronal/glial, neuronal and mixed 8.4 4.2 5.25 
Pineal parenchymal 0 2.1 2.1 
Embryonal/primitive/medulloblastoma 4.2 6.3 4.2 
TUMOURS OF CRANIAL AND SPINAL NERVES 28.35 37.8 30.45 
Schwannoma 28.35 37.8 30.45 
TUMOURS OF MENINGES 112.35 162.75 150.15 
Meningioma 103.95 152.25 148.05 
Other mesenchymal, non-malignant and malignant 2.1 3.15 1.05 
Haemangioblastoma 6.3 7.35 1.05 
LYMPHOMAS AND HEMOPOIETIC NEOPLASMS 1.05 1.05 0 
Lymphoma 1.05 1.05 0 
TUMOURS OF SELLAR REGION 53.55 53.55 34.65 
Pituitary 50.4 49.35 32.55 
Craniopharyngioma 3.15 4.2 2.1 
UNCLASSIFIED TUMOURS 2.1 5.25 6.3 
Haemangioma 2.1 5.25 6.3 
Total per Year 349.65 430.5 397.95 
2003 2004 2005 2006 2007 2008 Total % Total 
200.55 172.2 157.5 211.05 208.95 216.3 1665.3 43.1 
15.75 10.5 5.25 11.55 10.5 11.55 92.4 2.4 
2.1 1.05 2.1 2.1 1.05 2.1 15.75 0.4 
15.75 13.65 16.8 11.55 16.8 16.8 136.5 3.5 
3.15 1.05 1.05 2.1 3.15 13.65 0.4 
15.75 8.4 4.2 14.7 12.6 10.5 92.4 2.4 
101.85 77.7 93.45 121.8 109.2 116.55 885.15 22.9 
10.5 18.9 3.15 14.7 6.3 6.3 95.55 2.5 
10.5 18.9 6.3 6.3 7.35 7.35 79.8 2.1 
6.3 6.3 2.1 3.15 4.2 3.15 44.1 1.1 
0 0 0 0 •\JsfV 0 0 0.0 
5.25 4.2 3.15 2.1 6.3 5.25 31.5 0.8 
4.2 3.15 3.15 5.25 10.5 11.55 43.05 1.1 
1.05 0 1.05 1.05 0 5.25 9.45 0.2 
1.05 0 2.1 1.05 3.15 0 8.4 0.2 
2.1 1.05 5.25 8.4 10.5 14.7 59.85 1.5 
0 1.05 0 4.2 1.05 0 10.5 0.3 
5.25 7.35 8.4 2.1 7.35 2.1 47.25 1.2 
33.6 30.45 22.05 23.1 24.15 29.4 259.35 6.7 
33.6 30.45 22.05 23.1 24.15 29.4 259.35 6.7 
175.35 162.75 150.15 184.8 148.05 156.45 1402.8 36.3 
166.95 159.6 145.95 180.6 141.75 151.2 1350.3 35.0 
1.05 0 3.15 1.05 1.05 1.05 13.65 0.4 
7.35 3.15 1.05 3.15 5.25 4.2 38.85 1.0 
1.05 1.05 1.05 0 0 3.15 8.4 0.2 
1.05 1.05 1.05 0 0 3.15 8.4 0.2 
67.2 59.85 47.25 64.05 48.3 47.25 475.65 12.3 
58.8 55.65 44.1 58.8 40.95 42 432.6 11.2 
8.4 4.2 3.15 5.25 7.35 5.25 43.05 1.1 
3.15 7.35 3.15 9.45 4.2 9.45 50.4 1.3 
3.15 7.35 3.15 9.45 4.2 9.45 50.4 1.3 
480.9 433.65 381.15 492.45 433.65 462 3861.9 100.0 
6.7 Histological Subtype Graphs - Incidence by Age Groupings 
Only tumours with number >300 over the years 2000-2008 are included in the figures below. 
An example of crunching numbers until significance is found. All male benign tumours are analysed in Figure 6.2 below using one joinpoint and exponential regression 
analysis assuming a Poisson distribution. When no joinpoints are used, no significant trend is identified, but given the low data point in the year 2000, analysis with an 
additional joinpoint given two significant trends. This type of analysis was avoided and the current analysis concentrated only on major histological subgroups to reduce the 
amount of erroneous conclusion through small sample size. 
All: 1 Joinpoint 
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Figure 6.2. Joinpoint analysis of all male benign brain tumours showing significant trends when analysed using one joinpoint. When no joinpoint is used, the trend demonstrates no significant 
trend up or down, highlighting the issue of significance hunting. 
6.7.1 All tumours 
General 
Age-standardised incidence rates for all 
tumours by gender over the years 2000-2008. 
95% confidence intervals are displayed. Rates 
are standardised to the 2000 US Standard 
Population. 1 a 8 R 
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Joinpoint Regression Analysis 
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95% CI 
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Male 1.7* 0.1,3.3 
0-19 - -
20-64 - -
65+ - -
Female 0.7 -2.3,3.7 
0-19 - -
20-64 -
65+ - -
*denotes significance. APC is statistically 
significant from zero. All models are 
Poisson regression. APC, annual 
percentage change; CI, confidence 
intervals. 
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6.7.2 Malignant Tumours 
General 
Age-standardised incidence rates for 
malignant tumours by gender over the years 
2000-2008. 95% confidence intervals are 
displayed. Rates are standardised to the 2000 
US Standard Population. 
& s % 
S A 1 4 i a 
4 i. Male age std_USstd Female age std_US std 
Total age std_US std 
Crude Rate (total) 
2004 
Year 
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2000 2001 2002 2003 2004 2005 2006 2007 2008 
Year 
Total age-specific incidence rates for malignant tumours by 
age group 
£ i o 
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Year 
Male age-specific incidence rates for malignant tumours by 
age group 
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Joinpoint Regression Analysis 
Subgroup APC 95% CI 
(%) for APCs 
Total 3.9* 2.4,5.4 
0-19 - -
20-64 - » 
65+ 1.5* 0.1, 3.0 
Male 2.3* 0.4,4.2 
0-19 - -
20-64 - -
65+ 0.6 -2.1,3.4 
Female 2.3* 0.3,4.3 
0-19 - -
20-64 - -
65+ 2.6 -2.7, 8.2 
*denotes significance. APC is statistically 
significant from zero. All models are 
Poisson regression. APC, annual 
percentage change; CI, confidence 
intervals. 
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6.7.3 Benign Tumours 
General 
Age-standardised incidence rates for benign 
tumours by gender over the years 2000-2008. 
95% confidence intervals are displayed. Rates 
are standardised to the 2000 US Standard 
Population. 
I « 
t 8 § 5 
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-Male age std_US ltd 
— Female age std_US ltd 
-Total age std_U5 std 
-Crude Rale (total) 
2004 
Year 
Joinpoint Regression Analysis 
Subgroup APC 
(%) 
95% CI 
for APCs 
Total 1.7 -1.4,4.9 
0-19 - -
20-64 - -
65+ - -
Male 1.1 -2.3,4.7 
0-19 - -
20-64 - -
65+ - -
Female -0.2 -3.9,3.6 
0-19 - -
20-64 - -
65+ - -
*denotes significance. APC is statistically 
significant from zero. All models are 
Poisson regression. APC, annual 
percentage change; CI, confidence 
intervals. 
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6.7.4 Glioblastoma 
General 
Glioblastoma includes all cases of 
glioblastoma multiforme, 
gliosarcoma, and giant cell 
glioblastoma (codes M 9440 M 9441 
M 9442). 
Age-standardised incidence rates for GBM by 
gender over the years 2000-2008. 95% 
confidence intervals are displayed. Rates are 
standardised to the 2000 US Standard 
Population. - M a l e aee std_US std 
—Female age std_US std 
-Total age std_US std 
-C rude Rate (total) 
2004 
Year 
Joinpoint Regression Analysis 
Subgroup APC 95% CI 
(%) for APCs 
Total 2.5* 0.4,4.6 
0-19 - -
20-64 2.8 -0.7, 6.4 
65+ 3.0* 0.5, 5.6 
Male 2.6 -0.1,5.4 
0-19 -
20-64 3.1 -0.9, 7.3 
65+ 2.9* 0.1,5.8 
Female 2.2 -1.5,6.0 
0-19 - -
20-64 2.2 -2.2, 6.8 
65+ 3.2 -2.9, 9.6 
•denotes significance. APC is statistically 
significant from zero. All models are 
Poisson regression. APC, annual 
percentage change; CI, confidence 
intervals. 
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6.7.5 Meningioma 
General 
Age-standardised incidence rates for 
meningioma by gender over the years 2000-
2008. 95% confidence intervals are 
displayed. Rates are standardised to the 2000 
US Standard Population. 
-Maleage std_us std 
- Female age rtd_US std 
-Total ace std_us std 
-Crude Rate (total) 
2007 2008 
Joinpoint Regression Analysis 
Subgroup APC 95% CI 
(%) for APCs Total 1.9 -1.6,5.5 
0-19 - -
20-64 1.9 -0.9,4.9 
65+ 2.9 -3.6, 9.8 
Male 5.3* 2.6,8.1 
0-19 - •"-A1 
20-64 6.3* 3.8, 8.8 
65+ 5.0 -1.4, 12.0 
Female 0.6 -3.6,5.0 
0-19 - -
20-64 0.5 -3.2, 4.4 
65+ 1.9 -5.8, 10.1 
*denotes significance. APC is statistically 
significant from zero. All models are 
Poisson regression. APC, annual 
percentage change; CI, confidence 
intervals. 
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6.7.6 Pituitary Adenoma 
Total age-specific incidence rates for pituitary adenoma by 
age group 
Male age-specific incidence rates for pituitary adenoma by 
age group 
Female age-specific incidence rates for pituitary adenoma by 
age group 
General 
Age-standardised incidence rates for pituitary 
adenoma by gender over the years 2000-2008. 
95% confidence intervals are displayed. Rates 
are standardised to the 2000 US Standard 
Population. 
- M i l e a g e std_US std 
—Ferrule age std_US std 
-Total age strJ US std 
Joinpoint Regression Analysis 
Subgroup APC 95% CI 
(%) for APCs Total -1.0 -5.1,3.2 
0-19 -
20-64 -0.8 -6.1,4.7 
65+ -0.8 -5.5,4.2 
Male -0.5 -5.5,4.8 
0-19 - -
20-64 -0.9 -7.1,5.7 
65+ 0.4 -0.8, 9.6 
Female -2.1 -8.3,4.5 
0-19 - -
20-64 -0.9 -6.7, 5.3 
65+ -4.2 -13.3,5.9 
*denotes significance. APC is statistically 
significant from zero. All models are 
Poisson regression. APC, annual 
percentage change; CI, confidence 
intervals. 
6.7.7 Schwannoma 
General 
Age-standardised incidence rates for 
Schwannoma by gender over the years 2000-
2008. 95% confidence intervals are displayed. 
Rates are standardised to the 2000 US 
Standard Population. 
Male age «td_US std 
Female age std_US std 
Total age std_US std 
Crude Rate (total) 
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Joinpoint Regression Analysis 
Subgroup APC 95% CI 
(%) for APCs 
Total -3.5 -7.2,0.5 
0-19 - -
20-64 -3.0 -8.4, 2.6 
65+ -2.9 -10.7,5.7 
Male -1.0 -7.9,6.3 
0-19 -
20-64 0.3 -8.1,9.6 
65+ -4.2 -14.3,7.1 
Female -5.3* -9.9, -0.5 
0-19 
20-64 -5.8 -11.6,0.3 
65+ -1.8 -10.9, 8.3 
•denotes significance. APC is statistically 
significant from zero. All models are 
Poisson regression. APC, annual 
percentage change; CI, confidence 
intervals. 
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6.7.8 Anaplastic Astrocytoma 
General 
Age-standardised incidence rates for 
anaplastic astrocytoma by gender over the 
years 2000-2008. 95% confidence intervals 
are displayed. Rates are standardised to the 
2000 US Standard Population. 
*denotes significance. APC is statistically 
significant from zero. All models are 
Poisson regression. APC, annual 
percentage change; CI, confidence 
intervals. 
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6.8 Additional Results (not included in Chapters 2 and 3) 
Results not presented in the papers above are offered here as well as in Appendix 6.7.1 have 
included these results for completeness but continual searching for significance through subtype 
analysis was not extensively performed. The reason for this is that the chance of random 
significance increases with continual analysis, particularly in view of small numbers inherent to 
brain tumour data. An example was provided above (Appendix 6.7) where Joinpoint analysis of 
benign tumours in males only using multiple points of analysis yielded significant trends. In 
addition, this study may be viewed as a pilot study, and given the limitations on data quality 
imposed by methodology and ethical constraints; significance hunting was treated with caution. 
Descriptive Statistics 
Weighted totals of all tumours according to WHO Grade are presented in Table 6.8 below, with 
malignant tumours defined as WHO Grade III and IV, and benign (non-malignant) tumours 
being WHO Grade I and II. 
Malignant Benign Total 
John Hunter Hospital 300.3 406.35 706.65 
Westmead Pub_Priv Hospitals 329.7 254.1 583.8 
The Children's Hospital at Westmead 49.35 127.05 176.4 
Sydney Adventist Hospital 2.1 3.15 5.25 
Dalcross Private Hospital 0 1.05 1.05 
The Canberra Hospital 205.8 262.5 468.3 
RNS, Dalx & NSP 653.1 623.7 1276.8 
The Mater Hospital 1.05 0 1.05 
Prince of Wales Pub_Priv Hospitals_STG Pub_SCH 624.75 510.3 1135.05 
St George Priv Hospital 92.4 157.5 249.9 
Wollongong Hospital 84 85.05 169.05 
St Vincent's Pub_Priv Hospitals 202.65 658.35 861 
Concord Repatriation General Hospital 75.6 76.65 152.25 
Liverpool Hospital 112.35 273 385.35 
Royal Prince Alfred Hospital 364.35 662.55 1026.9 
Nepean Hospital 103.95 132.3 236.25 
POW Cancer Centre 0 205.8 205.8 
Total 3201.45 4439.4 7640.85 
Table 6.8. Weighted totals of tumours sourced from each pathology collection site by WHO Grade. 
Figures 6.3,6.4 and 6.5 demonstrate the proportion of total, benign and malignant tumours 
received from each participating centre. Data were complete from the Prince of Wales Hospital 
(POW) site only from mid-1999, and hence our full analysis was limited to the years 2000-
2008, despite other centres having more complete data prior to this date. It was thought that 
analysis without the POW data prior to the year 2000 would introduce an insurmountable 
degree of sampling error. 
The largest load of tumours was sourced from the databases at Royal North Shore Hospital 
(17%), Prince of Wales Hospital (15%) and Royal Prince Alfred Hospital (13%) (which in fact 
includes Liverpool (5%) and Concord Repatriation General (2%) Hospitals pathological data) 
(Figure 6.3). 
Proportion of total tumours by collection site 
_ POW Cancer Centre 
Nepean Hospital 
Concord Repatriation General _ 
Hospital 
Wolongong Hospital 
a 
St George Priv Hospital 
The Children's Hospital at 
Sydney Adventist Hospital 
Oakross Private Hospital 
The Mater Hospital 
Figure 6.3. Proportion of total tumours by collection site. Percentages are displayed. 
Abbreviations: POW - Prince of Wales, Pub - public, Priv - private, STG - St George Hospital, SCH -
Sydney Childrens Hospital, RNS - Royal North Shore, Dalx - Dalcross Private Hospital, NSP - North 
Shore Private Hospital. 
The majority of malignant tumours were also collected from the three centres named above with 
approximately 60% of all malignant tumours in the study originating from these sources in 
relatively equal proportions (Figure 6.4). 
NepeanHospital P O W C a n i Centre 
Liverpool Hospital 4% 
Concord Repatriation General 
Hospital 2* 
St George Prlv Hospital 3% 
The Mater Hospital 
OK 
Figure 6.4. Proportion of malignant tumours by collection site. Percentages are displayed. 
Benign tumours were collected mostly from the Royal Prince Alfred collection site (~23%), St 
Vincent's Public and Private Hospitals (15%) and Royal North Shore Hospital collection site 
(14%) (Figure 6.5). 
The Prince of Wales Cancer Centre data has also been included here to demonstrate the 
proportion of non-histologically confirmed tumours contributed by this centre (5%). The POW 
Cancer Centre is the largest stereotactic radiosurgical centre in the ACT/NSW region and treats 
tumours generally not amenable to surgical excision due to either size or location within the 
brain. Analysis of this data is referred to only passingly in the current study but included for 
completeness. 
Proportion of benign tumours by collection site 
P O W Cancer Centre 
Nepean Hospital 5 . * 
3 % 
West mead Pub_Priv Hospitals 
^ ^ The Children's Hospital 
at Westmead 
g s j k Sydney Adventist Hospital 
Royal Prince Alfred Hospital 
1 5 * 
The Canberra Hospital 
H ^ r 6% 
S-Dakross Private Hospital 
0 % 
Liverpool Hospital 
6 % nl 
Concord Repatriation 
General Hospital ti^H 
2 % St Vincent's Pub PrW Hospitals 
1 
RNS,Dsfca NSP 
M X 
1 Prince of Wales P u b P r i v 
1 Hospitak_STG Pufc.SCH Mrfer HospHal 
" * W 0 % 
Wollongong Hospital 
2 % St George Priv Hospital 
4 % 
Figure 6.5. Proportion of benign tumours by collection site. Percentages are displayed. 
Figures 6.6,6.7 and 6.8 present US-standardised incidence rates for all primary brain tumours 
by 10 year age groups and gender in the period 2000 - 2008 as well as comparison between 
earlier (2000, 2001) and later (2007, 2008) years of study. Peak incidence is found in older 
patients (aged 65 - 74 years) with average incidence rates of 32.72 (total), 34.08 (male), 31.45 
(female) cases per 100,000 person-years across the years of study. Slightly higher incidence 
rates are seen in later years of study in patients aged 75-84 years for total population (Figure 
6.6b)). 
Total Age Specific Incidence Rates all Primary Brain Tumours 
M M M M M I M M M M I M S M M MKT M M 
Age Specific Total Tumour Incidence by Year and Age Group 
Figure 6.6. a) Age specific incidence rates for total population for all primary brain tumours by year, b) Age 
specific incidence rates for total population for all primary brain tumours with comparison of years 2001, 2002, 
2007, 2008. 
Agt specific incidence rates for total population foe ail benign tumours 2000-2008 
Figure 6.6. c) Age specific incidence rates for total population for all benign tumours, 2000-2008. d) 
Age specific incidence rates for total population for all malignant tumours, 2000-2008. 
Male incidence rates are slightly higher than female incidence rates in the older populations, 
particularly persons aged 74 - 84 years. 
Male Age Specific Incidence Rates all Primary Brain Tumours Age Specific Male Tumour Incidence by Year and Age Group 
Figure 6.7. a) Age specific incidence rates for male population for all primary brain tumours by year, b) Age 
specific incidence rates for male population for all primary brain tumours with comparison of years 2001, 
2002, 2007, 2008. 
Figure 6.7. c) Age specific incidence rates for male population for all benign tumours, 2000-2008. d) 
Age specific incidence rates for male population for all malignant tumours, 2000-2008. 
While incidence rates are similar in younger age groups for both males and females. 
Female Age Specific Incidence Rates all Primary Brain Tumours 
2000-2008 
Age Specific Female Tumour Incidence by Year and Age Group 
Figure 6.8. a) Age specific incidence rates for female population for all primary brain tumours by year, b) Age 
specific incidence rates for female population for all primary brain tumours with comparison of years 2001, 
2002, 2007, 2008. 
Age specific Incidence rates for female population for all maignant tumours 
2000-2008 
Figure 6.8. c) Age specific incidence rates for female population for all benign tumours, 2000-2008. d) 
Age specific incidence rates for female population for all malignant tumours, 2000-2008. 
Additional Subtype Statistics 
The majority of primary brain tumours observed in the current study were Tumours of 
Neuroepithelial Tissue (53%, n = 4024), followed by Tumours of Meninges (26%, n = 1978) 
and Tumours of the Sellar Region (14%, n = 1036) (Figure 6.9). 
53% 
• TUMORSOF NEUROEPITHELIAL 
TISSUE 
• TUMORS OF CRANIAL AND 
SPINAL NERVES 
• TUMORS OF MENINGES 
• LYMPHOMAS AND 
26% HEMOPOIETIC NEOPLASMS 
• TUMORS OF SELLAR REGION 
I UNCLASSIFIED TUMORS 
14% 
Figure 6.9. Distribution of histological subtype according to WHO Classification of the Nervous System. 
Percentages are displayed. 
Note, although Figure 6.9 is labelled according to WHO subgroups, no spinal nerve tumours were 
included in the study as implied by the title 'Tumours of Cranial and Spinal nerves". 
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